



Date: 03.09.2026

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 538837)

Dear Sirs,

Sub: Submission of 28th AGM Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR) Regulation 2015.

Unit: Jeevan Scientific Technology Limited

In Compliance with Regulation 34 of SEBI (LODR) Regulations, 2015, we are herewith submitting the 28th Annual Report for the Financial Year 2025-26 of the Company, which is dispatched to our shareholders on 03rd September, 2026. The Annual General Meeting of the Company is scheduled to be held on Friday, 25th day of September, 2026 at 10:00 A.M. through Video Conference "VC" / Other Audio-Visual Means.

Further, pursuant to Regulation 36(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a letter providing the web-link of the Annual Report, being sent to those members who have not registered their e-mail address, is available on the Company's website at <https://www.jeevanscientific.com/>

This is for the information and records of the exchange, please.

Thanking You.

**Yours faithfully,
For Jeevan Scientific Technology Limited**

**KODATI KRISHNA
SAI NADH**

Digitally signed by KODATI
KRISHNA SAI NADH
Date: 2026.09.03 17:55:11 +05'30'

**Krishna Sainadh Kodati
Company Secretary & Compliance Officer**

28th

ANNUAL REPORT

2025 -2026

**We assure Quality, Integrity and
Safety at every step with Values**

**Your Trusted Partner for Complete
Clinical Research
Solutions**



Values

Quality, Team work, Accountability, Innovation, Initiative and Integrity



Mission

To deliver value added, reliable and cost effective services to our customers



Vision

To be an integrated CRO with global distinction aiming for long-term partnership with our customers based on shared beliefs and goals for synergistic growth



Quality Policy

To ensure our services adhere to the highest standards which are at par with global quality standards and setting new global benchmarks





TABLE OF CONTENTS

-  Board of Directors
 -  Message
 -  About JSTL
 -  About Nayas Labs
 -  Notice of AGM
 -  Directors' Report
 -  Corporate Governance
 -  Auditor's Report
 -  Financials for FY 2024-25
- 

BOARD OF DIRECTORS



Divakar Atluri
Chairman & Non-Executive Director



Krishna Kishore Kuchipudi
Managing Director



Snigdha Mothukuri
Executive Director



Jeevan Krishna Kuchipudi
Non Executive Director



Y. Nageswara Rao
Executive Director



Gollapinwi Mallikarjuna
Independent Director



Kolli Srinivas Rao
Independent Director



Dr. G. Venkata Subbarao
Independent Director



B. Suryaprakasa Rao
Independent Director

Divakar Atluri

Chairman & Non-Executive Director DIN: 08934860

Mr. Divakar Atluri, Chartered Accountant, Commerce Graduate is a fellow member of the Institute of Chartered Accountants of India (ICAI) having experience of 42 years in the field of Auditing, Taxation and Other Laws, Fund Management, Corporate Laws and Others.

Snigdha Mothukuri

Executive Director DIN: 08934860

Ms. Snigdha Mothukuri is an enthusiastic honors graduate from the finest educational institutions across the globe. She pursued two master's degrees, one in the field of Management Science from a leading Ivy Leagues School - Columbia University in New York and the other in the field of Technology from the prestigious Indian Institute of Technology (IIT) Madras. She completed her Bachelor of Technology from IIT Madras.

During her tenure with JSTL she played a key role in the overall organizational growth including Strategy Deployment, Operations & Project Management.

Prior to JSTL, she worked with reputed organizations like Lansum Estates LLP (India), Louis Vuitton (USA), Fresh Direct (USA), University of British Columbia (Canada) and Aarvee Associates (India).

Y. Nageswara Rao

Executive Director DIN: 00293474

Nageswara Rao is an experienced professional in the areas of Management, Operations, Finance Marketing and Administration. Currently a Director of Sri Surya Wheels Private Limited, he has an overall experience of over 33 years successfully managing multiple organisations - Sri Surya Automobiles, Sri Surya Transport Corporation, Sri Surya Wheels Private Limited, Sri Surya Electronics and Home Appliances. He has gained multiple awards in the field of marketing and has rich experience in managing multiple teams across various levels and locations.

B. Suryaprakasa Rao

Independent Director DIN: 08089189

B. Suryaprakasa Rao is Chartered Accountant by profession. He is a partner in M/s. Pundarikashyam and Associates. Expertise in specific functional areas specialize in Audit, Accounts, and Finance and in Banking, Tax Planning, Stock Audit, Credit Audit and Concurrent Audit of Banks.

Krishna Kishore Kuchipudi

Managing Director DIN: 00876539

Mr. Kishore, a Postgraduate from Andhra University, he is the Chief architect of Jeevan Mitra Chit Fund Private Limited. Under his aegis and stewardship as Chairman and Managing Director, the Company has grown impressively in size and stature to become a leading chit fund concern in the State of Andhra Pradesh.

Jeevan Krishna Kuchipudi

Non Executive Director DIN: 08207809

Mr. Jeevan is a passionate entrepreneur with diverse global experience, exceptionally in Healthcare, Pharma, Information Technology (IT) and Finance. Currently serving as the Non Executive Director of JSTL, Jeevan leads the organisation in the strategic execution and is the key member in the growth of the organization.

Prior to JSTL, he was the CEO & Executive Director of Enhops Solutions Private Limited & Enhops Inc wherein he played a major role in building Enhops, an independent software testing services organization.

Jeevan holds an MBA in Finance from San Diego State University. He embraced progressive skills in various segments which include Software Development, Quality Assurance, Financial Analysis, Business Analysis, Strategy Planning and Project Management. He played active roles in finance, credit, insurance, technology and healthcare domains while working for giants like Core Logic Credco, Boingo Wireless, Humana, Tata Consultancy Services and Jeevan Sotiech Limited.

Kolli Srinivas Rao

Independent Director DIN: 07980993

CA. Kolli Srinivas Rao is a Bachelor of Commerce (B.Com), Fellow Chartered Accountant (F.CA) and Bachelor of Laws (LL.B.) with over 22 years of experience in the profession, having been in practice as a Chartered Accountant since 2003. He is a Qualified Social Auditor, certified by the National Institute of Securities Markets (NISM), SEBI. He is also the Proprietor of K S Rao & Associates, Chartered Accountants.

Gollapinwi Mallikarjuna

Independent Director

DIN: 11189083

Mr. Mr. Gollapinni Mallikarjuna is former Principal Commissioner of Income Tax with over three decades of distinguished service in the Indian Revenue Service (IRS), Ministry of Finance, Government of India. Proven expertise in taxation, corporate dispute resolution, investigation, policy formulation, administration, and governance. Recognized

for leadership in managing large teams, overseeing complex tax operations, and coordinating with government and corporate stakeholders for sustainable economic development.

Currently leveraging strategic leadership skills as CEO of SNR eDatas and serving as an advisor/consultant to leading infrastructure and biotechnology companies. Known for excellence in revenue collection, corporate taxation, dispute resolution, and national policy execution.

Dr. G. Venkata Subbarao

Independent Director

DIN: 01900749

Dr. G. Venkata Subbarao is Founder Director of Spansules Pharma Group. A Technocrat with 3 Decades of Techno-commercial experience in Pharmaceutical Sciences and Technology, working with several leading pharmaceutical companies in India and Abroad. He has expertise in Research and Development of complex generics products from lab scale to commercial scale. He has experience in Designing and execution of specialty projects for pharmaceutical Industry. With his Business Development acumen and experience of more than 31 years he is responsible for the Vision and growth strategy of Spansules Pharma Group Companies.



MESSAGE

Dear Shareholders,

I am pleased to address you following a highly successful Financial Year 2025-26 for our company. It is with great pride that I share the achievements and milestones we have reached together over the past year.

First and foremost, I am delighted to report that our company has delivered enhanced financial results. This accomplishment is a testament to the dedication and hard work of our talented team, whose commitment to excellence has been exemplary. Furthermore, our commitment to compliance remains the top priority and we have strengthened our internal quality management systems and started expanding to more regulatory authorities around the globe. We have continued to invest in facility / capability expansion wherein we have increased our capacities at clinical as well as bioanalytical front and executed challenging studies. These enhancements have not only driven revenue growth but have also reinforced our reputation as a leader in our industry.

In closing, I extend my heartfelt gratitude to our shareholders, customers and employees for their invaluable contributions and dedication. Together, we have achieved remarkable results, and I am confident that we are well-positioned for continued success in the future.

Thank you for your continued support and trust in our company.

Warm regards,

Managing Director.



ABOUT US

Jeevan Scientific is an Independent Clinical Contract Research Organization, offering reliable, cost-effective and technology-driven clinical research solutions to various Clients across the globe.

Highlights & Milestones of JSTL

- 1999** Incorporated as Jeevan Softech Pvt. Ltd.
- 2001** Became a public limited company
- 2011** Started Medical Writing Services
- 2014** Expanded to full CRO with a portfolio of BA/BE, PV and CT services;
- 2014** Listed in Bombay Stock Exchange (BSE)
- 2015** Bioanalytical facility approved by CDSCO
- 2016** Clinical Facility Approved by CDSCO
- 2017** Successfully completed first USFDA inspection of our Bioanalytical facility
- 2018** Successfully completed first USFDA inspection of our Clinical facility
- 2019** Successfully completed first WHO inspection of both our facilities
- 2020** Successfully completed first Phase I study (Glucose clamp technique) and established large molecule bioanalysis capabilities
- 2021** Received NABL accreditation to our Clinical path lab
- 2021** Successfully completed first patient based BA/BE clinical study and initiated first Phase III clinical trial
- 2021** Successfully completed first UK MHRA inspection of both our facilities
- 2024** JSTL marked successful completion of 25 years as an organization on 02 Feb 2024. Added new capability to the B.A. Lab Unit with the addition of two new highly sensitive instruments (LC-MS/MS) (Sciex 6500+) for the analysis of hormones, monoclonal antibodies, and biosimilars.
- 2025** Successfully received approval from CDSCO for both sites for BA/BE studies and clinical trials, increased client base by about 50% with clients from different geographical areas, and initiated the expansion of regulatory landscape to include ANVISA (Brazil), GCC (Middle East), and NPRA (Malaysia). Current scoreboard: Successfully closed 23 regulatory audits including USFDA (8), WHO (32), UKMHRA (1), CDSCO (7) and NABL (4); Oman (1); And conducted about 784 Clinical studies.
- 2026** FY 2025-26: Strengthening Capacity, Expanding Reach, Delivering Excellence: Jeevan Scientific added 6 LC-MS/MS systems, taking the total to 17, successfully completed a USFDA inspection of its Clinical Facility, and expanded its client base through new business engagements. With 900+ bioequivalence studies conducted, the Company has strengthened its foundation for sustainable growth and future expansion.

CLINICAL TRIAL SERVICES

We specialize in the conduct of Clinical Trials through excellence in strategic developmental planning, management, execution and analysis of clinical trial ranging from small to complex studies.

We are an integrated CRO always aiming for long term partnership and collaboration with Pharmaceutical, Biotechnology & Medical Device Industries. We strive for becoming integrated clinical development partner.

-  Patient PK trials
-  Pharmacodynamic endpoint studies
-  Early & late phase clinical trials
-  Postmarketing surveillance studies
-  Investigator initiated and real world evidence studies
-  Clinical Trials Support for Complex Generics & Biosimilars

BIOANALYTICAL

- MD/MV and subject sample analysis
- Statistical Analysis and Data Management
- SAS and WinNonlin
- CDISC
- Experience in developing the bioanalytical methods for NCE molecule



CLINICAL

- Healthy and Patient based BA/BE studies
- Food effect, Age Effect, Gender effect studies
- Studies in both male and female subjects (Pre and Post menopausal women)
- PK/PD end point studies
- Single ascending dose (SAD) and Multiple ascending dose (MAD) studies
- 505(b)2 studies
- Clinical study execution on niche formulations

PHARMACOVIGILANCE SERVICES

- JSTL offers end to end PV solutions across the globe including data migration, setup and maintenance of PV activities, database management, literature search services and regulatory inspection/audit support.
- As a strategic partner, JSTL offers PV solutions to ensure regulatory compliance.
- JSTL works on partnership model/form an alliances to reduce client's overheads, infrastructure & operational cost.
- JSTL PV services are provided by medical and pharma professionals from rich pharma domain knowledge.



PV

ICSR Management

Aggregate Safety reporting

Risk Management Plan

Signal Detection

Medical Information Call Centre (MICC)

BIOAVAILABILITY & BIOEQUIVALENCE SERVICES

BA/BE studies are one of our Key services, we offer end-to-end solutions in this arena. Our cross-functional team has extensive experience in executing and managing Bioequivalence studies covering various therapeutic areas and complex studies.



Independent Facility spread over 20,000 Sq.ft.



Qualified Scientists for analysis of molecules



12 LC-MS/MS



Temperature Monitoring System (21 CFR compliant data logger)



cold walk-in chamber & Freezers -70°C, -20°C



Facility was inspected by USFDA, MHRA, WHO & CDSCO



CLINICAL PHARMACOLOGY UNIT



Independent Facility Spread over 20,000 sq.ft.



NABL Accredited in house clinical path lab



Facility was inspected by USFDA, MHRA, WHO & CDSCO



BEDs spread over 4 wards



Automated volunteer management process



Pharmacy Walk-in chamber



Dedicated ambulance & Tie up with tertiary care hospitals



Glucose clamp Phase I unit (4+4 beds), 3 YSI glucose analyzers



Biomedical Freezers -70°C and -25 °C



2 Special Care Units 3 Beds each



CLINICAL TRIAL SERVICES

We are committed to data quality, timely delivery on budget and always ensure trial subject rights, safety and data integrity

Our Clinical Trial Operations team has got vast experience in conducting Phase I to Phase IV clinical trials of diversified therapeutic areas across the globe. Fast turn around time in completion of patient recruitment and subsequent final clinical study report is the major advantage when working with JSTL, which will ease the process of market entry of new drugs or generic drugs for its clientele.



PHARMACOVIGILANCE SERVICES

JSTL Pharmacovigilance services include handling ICSRs (Clinical Trial, Literature, Post Marketing, Health Authority, License Partner and other), Literature screening and all aggregate reports such as PADER/ PSUR/ PBRER, Signal Detection activity (SD), Risk Management Plan, Pharmacovigilance System Master File (PSMF) globally for all regulatory agencies.

JSTL has a fully established Medical Information Call Centre (MICC) service line with automated databases such as Ozonetel and Aavaz which help in providing 24x7 call center services to all our clients across the globe.

*"Our commitment towards **Quality** helps in ensuring **timely service deliverables** with **100% regulatory compliance**"*



Nayas Laboratories Private Limited is a Subsidiary Company of
Jeevan Scientific Technology Limited

www.nayaslabs.com



Nayas Laboratories Private Limited

- India's First of a kind Contract Research Organization specializing in Advanced Drug Delivery Technology Platforms and In-house, Novel, Innovative, Patentable Biomedical Polymers
- One of the most promising Quality and Technology Driven Independent Formulation Research and Development Organization with primary focus on Drug Delivery Technology, Complex Generics, 505 (b)(2) & Para IV developments
- Fully equipped with state-of-the-art facilities and robust technologies to develop high quality niche formulations/ globally accepted dossiers of various dosage forms and high-end cutting-edge polymers.
- Conceptualization to Commercialization
- Offerings include:
 - o Novel & Patentable Biomedical Polymers
 - o Drug Delivery Technology Platforms
 - o Formulation & Analytical Development
 - o Quality and Regulatory Services



- 5-35/178, Plot No. 26, Prashanthi Nagar, I.E. Kukatpally, Hyderabad - 500072, Telangana, India.
- +91 40 46144544
- info@nayaslabs.com

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. Divakar Atluri	-	Chairman – Non-Executive Director (DIN: 00033386)
Mr. K. Krishna Kishore	-	Managing Director (DIN: 00876539)
Ms. Snigdha Mothukuri	-	Whole-time Director (DIN: 08934860)
Mr. K. Jeevan Krishna	-	Non- Executive Director (DIN: 08207809)
Mr. Y. Nageswar Rao	-	Whole-time Director (DIN: 00293474)
Mr. G. Venkata Subba Rao	-	Independent Director (DIN: 01900749)
Mr. B. Suryaprakasa Rao	-	Independent Director (DIN: 08089189)
Mr. Gollapinni Mallikarjuna	-	Independent Director (DIN: 11189083)
*Mr. Kolli Srinivas Rao	-	Additional Director (Independent) (DIN: 07980993)

*Appointed w.e.f., 13.08.2026

CHIEF EXECUTIVE OFFICER

Mr. Srinivas Reddy Maram

CHIEF FINANCIAL OFFICER

Mr. Venkateswara Rao Ravipati

COMPANY SECRETARY

Mr. Krishna Sainadh Kodati

REGISTERED OFFICE

Plot No. 1 & 2,
Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Golconda Post,
Hyderabad, Telangana -500008.
Ph No 040-67364700.

PHARMACOLOGY UNIT

B-17, TIE, Phase II, Balanagar,
Hyderabad, Telangana - 500037.
Ph. No: 040-23721008

STATUTORY AUDITORS

M/s. Pavuluri & Co
Chartered Accountants
Plot No. 48, Flat No. 301,
Sucasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033

INTERNAL AUDITORS

M/s. K P & Associates
Chartered Accountants
Hyderabad

BANKERS

Karur Vysya Bank Ltd.
Punjab National Bank,
Union Bank of India.

SECRETARIAL AUDITORS

M/s. Aakanksha Dubey & Co.
Practicing Company Secretary
Secunderabad, Telangana – 500061

AUDIT COMMITTEE

Mr. Suryaprakasa Rao Bommiseti	-	Chairman
Mr. Venkata Subba Rao Guttikonda	-	Member
Mr. Divakar Atluri	-	Member
Mr. Gollapinwi Mallikarjuna	-	Member

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

NOMINATION & REMUNERATION COMMITTEE

Mr. Suryaprakasa Rao Bommiseti	-	Chairman
Mr. Venkata Subba Rao Guttikonda	-	Member
Mr. Divakar Atluri	-	Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

Mr. Gollapinwi Mallikarjuna	-	Chairman
Mr. Suryaprakasa Rao Bommiseti	-	Member
Mr. Krishna Kishore Kuchipudi	-	Member
Mr. Divakar Atluri	-	Member

REGISTRAR & SHARE TRANSFER AGENTS

M/s. CIL Securities Limited,
214, Raghavaratna Towers,
Chirag Ali Lane, Hyderabad -500001
Phone Number: 91 - 040 – 69011111

CORPORATE IDENTITY NUMBER

L72200TG1999PLC031016

LISTED AT	:	BSE Limited
ISIN	:	INE237B01018
WEBSITE	:	www.jeevanscientific.com
INVESTOR E-MAIL ID	:	shareholders@jeevanscientific.com

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

NOTICE

Notice is hereby given that the 28th (Twenty Eighth) Annual General Meeting of the Shareholders of Jeevan Scientific Technology Limited will be held on Friday, the 25th day of September, 2026 at 10:00 A.M. through video conferencing and other audio-visual means, to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider, approve and adopt the Standalone and Consolidated Audited Balance Sheet as at 31st March 2026, the Statement of Profit & Loss and Cash Flow Statement for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.
2. To appoint a director in place of Mr. Krishna Kishore Kuchipudi (DIN: 00876539) who retires by rotation and being eligible, offered himself for re-appointment.
3. To appoint a director in place of Mrs. Snigdha Mothukuri (DIN: 08934860) who retires by rotation and being eligible, offered herself for re-appointment.

SPECIAL BUSINESS:

4. **RE-APPOINTMENT OF MRS. SNIGDHA MOTHUKURI (DIN: 08934860) AS WHOLE TIME DIRECTOR OF THE COMPANY**

To consider and if thought fit, to pass with or without modification(s), the following resolution, as a Special Resolution: -

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("Act"), read with Schedule V thereto and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors, consent of the Members be and is hereby accorded for the re-appointment of Mrs. Snigdha Mothukuri (DIN: 08934860) as Whole Time Director of the Company for a further term of three (3) years with effect from 02.11. 2026, on the existing terms and conditions of appointment, including salary, perquisites and allowances, as set out in the Explanatory Statement annexed to the Notice convening this Meeting, with liberty to the Board of Directors (including the Nomination and Remuneration Committee) to alter, revise or vary the remuneration and other terms and conditions of appointment from time to time, within the limits prescribed under the Companies Act, 2013, Schedule V thereto, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws."

"RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during her tenure, the Company shall pay to Mrs. Snigdha Mothukuri (DIN: 08934860), the same remuneration by way of salary, perquisites and allowances, as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government of India from time to time."

"RESOLVED FURTHER THAT the Board be and is hereby authorized to take all such steps as may be necessary, desirable, proper or expedient and file necessary e-forms with the Registrar of Companies, Telangana to give effect to this resolution."

5. **TO CONSIDER AND APPROVE THE CONTINUATION OF MR. NAGESWAR RAO YARLLAGADDA (DIN: 00293474) AS WHOLE TIME DIRECTOR OF THE COMPANY BEYOND THE AGE OF 70 YEARS.**

To consider and if, thought fit to pass with or without modification(s), the following resolution as a Special Resolution: -

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("Act"), read with Schedule V thereto and the Rules made thereunder, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and Regulation 17(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and pursuant to the recommendation of the Nomination and Remuneration Committee and the approval of the Board of Directors, approval of the Members be and

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

is hereby accorded for the continuation of Mr. Nageswar Rao Yarllagadda (DIN: 00293474) as the Whole Time Director of the Company, notwithstanding that he shall attain the age of 70 (Seventy) years on October 01, 2026, for the balance period of his existing term of office up to June 23, 2027, and for his subsequent reappointments, if any, as may be approved by the Board and the Members from time to time in accordance with the provisions of the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, on such terms and conditions, including remuneration, as may be approved from time to time."

"RESOLVED FURTHER THAT the Members hereby note and approve the opinion of the Board of Directors that, considering the rich experience, proven leadership, domain knowledge, strategic guidance and valuable contribution of Mr. Nageswar Rao Yarllagadda to the growth and operations of the Company, his continuation as Whole Time Director beyond the age of 70 years is desirable and in the best interests of the Company and its stakeholders."

"RESOLVED FURTHER THAT Mr. Nageswar Rao Yarllagadda shall continue to discharge the duties and responsibilities of Whole Time Director on the existing terms and conditions of his appointment, including remuneration, as approved by the Members and/or the Board of Directors from time to time, subject to such modifications as may be approved by the Board within the limits prescribed under the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws."

"RESOLVED FURTHER THAT any Director of the Company and the Company Secretary be and are hereby severally authorised to do all such acts, deeds, matters and things, execute all such documents, forms and writings and take all such steps as may be considered necessary, proper or expedient to give effect to this Resolution, including filing of necessary forms and disclosures with the Registrar of Companies, Stock Exchanges and such other authorities as may be required under applicable laws."

6. RE-APPOINTMENT OF MR. NAGESWAR RAO YARLLAGADDA (DIN: 00293474) AS WHOLE TIME DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass with or without modification(s), the following resolution, as a Special Resolution: -

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("Act"), read with Schedule V thereto and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and Regulation 17(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors, consent of the Members be and is hereby accorded for the re-appointment of Mr. Nageswar Rao Yarllagadda (DIN: 00293474) as Whole Time Director of the Company for a further term of three (3) years commencing from June 23, 2027, notwithstanding that he has attained the age of 70 (Seventy) years, on the existing terms and conditions of appointment, including salary, perquisites and allowances, as set out in the Explanatory Statement annexed to the Notice convening this Meeting, with liberty to the Board of Directors (including the Nomination and Remuneration Committee) to revise, modify or vary the remuneration and other terms and conditions of appointment from time to time, within the limits prescribed under the Companies Act, 2013, Schedule V thereto, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws."

"RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during her tenure, the Company shall pay to Mr. Nageswar Rao Yarllagadda (DIN: 00293474), the same remuneration by way of salary, perquisites and allowances, as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government of India from time to time."

"RESOLVED FURTHER THAT the Board be and is hereby authorized to take all such steps as may be necessary, desirable, proper or expedient and file necessary e-forms with the Registrar of Companies, Telangana to give effect to this resolution."

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

7. TO RE-APPOINT MR. SURYAPRAKASA RAO BOMMISETTI (DIN: 08089189) AS INDEPENDENT DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and other applicable provisions, if any, of the Companies Act, 2013 ("Act"), read with Schedule IV thereto and the Companies (Appointment and Qualifications of Directors) Rules, 2014, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, Regulation 17, Regulation 25 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, the Nomination and Remuneration Policy of the Company, and pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors, Mr. Suryaprakasa Rao Bommiseti (DIN: 08089189), who was appointed as an Independent Director of the Company for a first term of five (5) consecutive years commencing from March 25, 2022 to March 24, 2027 (both days inclusive) and who is eligible for re-appointment, and in respect of whom the Company has received his consent to act as a Director, a declaration confirming that he meets the criteria of independence as prescribed under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations, and whose performance has been evaluated by the Board of Directors, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from March 25, 2027 to March 24, 2032 (both days inclusive)."

"RESOLVED FURTHER THAT any Director or Company Secretary of the Company be and are hereby severally authorized to do all the acts, deeds and things which are necessary for the re-appointment of Mr. Suryaprakasa Rao Bommiseti as an Independent Director of the Company, including filing of the necessary forms with the Registrar of Companies."

8. APPOINTMENT OF MR. KOLLI SRINIVAS RAO (DIN: 07980993) AS INDEPENDENT DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

"RESOLVED THAT, pursuant to the provisions of Sections 149 and 152 read with Schedule IV, Section 161 and other applicable provisions, if any, of the Companies Act, 2013 along with the rules made thereunder, including, the Companies (Appointment and Qualification of Directors) Rules, 2014, each as amended ("Companies Act"), Regulation 17 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (including any amendments, modification(s) or re-enactment(s) thereof, for the time being in force) ("SEBI Listing Regulations"), and other applicable provisions thereof, if any, and pursuant to the provisions of the articles of association of the Company, Mr. Kolli Srinivas Rao (DIN: 07980993) who has provided his consent in writing to act as an independent director of the Company and possesses relevant expertise and experience and has submitted a declaration in writing that he meets the criteria for appointment as an independent director under the Companies Act, be and is hereby appointed as an independent director on the board of directors of the Company (the "Board"), who shall hold office for a term of five years commencing on 13.08.2026 and shall not be liable to retire by rotation."

"RESOLVED FURTHER THAT any Director of the Company be and is hereby authorized to do all the acts, deeds, matters and things which are necessary to the appointment of Mr. Kolli Srinivas Rao as an independent director of the Company, including filing of the necessary forms with the Registrar of Companies, Telangana at Hyderabad and things as may be required to be done to give effect to the abovementioned resolutions and to settle any question or difficulty that may arise with regard to the aforesaid purpose and which it may deem fit in the interest of the Company."

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

**Sd/-
Krishna Kishore Kuchipudi
Managing Director
(DIN: 00876539)**

**Place: Hyderabad
Date: 13-08-2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

EXPLANATORY STATEMENT

[Pursuant to Section 102 of the Companies Act, 2013]

ITEM NO.4: RE-APPOINTMENT OF MS. SNIGDHA MOTHUKURI (DIN: 08934860) AS WHOLE TIME DIRECTOR OF THE COMPANY

Pursuant to the provisions of Sections 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and Rules framed thereunder, the applicable provisions of the SEBI (LODR) (including any statutory modification(s) or re-enactment thereof for the time being in force), Ms. Snigdha Mothukuri (DIN: 08934860) was appointed earlier as Whole Time Director of the Company w.e.f., 02.11.2026 for a period of 3 (Three) years i.e., up to 01.11.2029.

Pursuant to the evolution of performance made by the Board, recommendation of the Nomination and Remuneration Committee, and approval of the Board of Directors in their respective meetings held on 13.08.2026 and pursuant to the provisions of Sections 196, 197 and 203 read with Schedule V and any other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the SEBI (LODR) (including any statutory modification(s) or re-enactment thereof for the time being in force), the consent and approval of the Members of the Company by way special resolution is sought for re-appointment of Ms. Snigdha Mothukuri as Whole Time Director of the Company for a further term of 3 (Three) consecutive years w.e.f. 02nd November, 2026 with the following terms and conditions of appointment, including salary, perquisites and allowances:

- a) Period of Appointment: Three Years with effect from 02.11.2026.
- b) Remuneration: In terms of Schedule V of the Companies Act, 2013 read together with Section 196, 197, 203 and any other applicable provisions of the Companies Act, 2013, the Whole Time Director shall be paid Rs. 48,00,000/- p.a. towards salary as decided by the Nomination remuneration committee from time to time She shall also be allowed the following perquisites and allowances in addition to afore mentioned salary:
- c) Encashment of Leave: as per the rules of the Company.
- d) Provident fund, superannuation benefits and gratuity as per the rules of the Company subject to the ceilings as per the applicable provisions of Law in force from time to time.
- e) Any other allowance as may be permitted under the provisions of the Companies Act read with Schedule V of the Companies Act.

Except Ms. Snigdha Mothukuri, Whole- Time Director, Mr. Krishna Kishore Kuchipudi, Managing Director and Mr. Jeevan Krishna Kuchipudi, Director being related to the Whole Time Director, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, directly or indirectly, financially or otherwise, in the resolution as set out at Item No. 4.

The Board of Directors recommends the passing of the above resolution as a Special Resolution as set out in the item no.4 of the Notice.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Information in accordance with Schedule V of Companies Act, 2013

I. GENERAL INFORMATION

1	Nature of Industry: Clinical Research		
2	Date or expected date of commencement of commercial: The Company started its commercial operations on 02.02.1999.		
3	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable		
4	Financial performance based on given indications		
	Particulars	2025-26 (Rs. in Lakhs)	2024-25 (Rs. in Lakhs)
	Turnover	5511.91	4423.90
	Net profit after Tax	182.83	72.20
	Net Profit under Sec 198 of the Companies Act, 2013	165.01	73.57
5	Foreign investments or collaborations, if any: Not Applicable		

II. INFORMATION ABOUT THE APPOINTEE

1.	Background Details: Ms. Snigdha Mothukuri is a Hons. graduate from the finest educational institutions across the globe. She pursued two master's degrees, one in the field of Management Science from a leading Ivy Leagues School - Columbia University in New York and the other in the field of Technology from the prestigious Indian Institute of Technology (IIT) Madras. She completed her Bachelor of Technology from IIT Madras. She was a part of reputed organizations like Lansum Estates LLP, Louis Vuitton, University of British Columbia, Aarvee Associates and Visakhapatnam Steel Plant. She worked with global teams in highly distributed environments and gained industry experience in various domains ranging from Civil Engineering, Transportation, Supply Chain to Operations and Finance.
2.	Past Remuneration: Rs. 4,00,000 P.M. in capacity of Whole Time Director till 01.11.2026
3.	Recognition or awards: Not Applicable
4.	Job Profile and suitability: Based on her work experience and suitability it was proposed to re-appoint Ms. Snigdha Mothukuri as Whole Time Director of the Company.
5.	Remuneration proposed: There is no change in the present remuneration being drawn by Ms. Snigdha Mothukuri, Whole Time Director.
6.	Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin): Taking into consideration of the size of the Company, the profile of Ms. Snigdha Mothukuri and the responsibilities shouldered by her, the aforesaid remuneration package is comparable to the remuneration package paid to managerial personal prevailing in other companies.
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any: Besides the remuneration proposed, she is holding 78,500 Equity Shares of Rs. 10/- each of the Company (0.39% of the paid-up equity share capital).

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

III. OTHER INFORMATION:

1.	Reasons for inadequate Profits: NotApplicable
2.	Steps taken or proposed to be taken for improvement: Necessary and proactive efforts are being made to increase the operational efficiency by setting up of proper and strong systems in place including enhancement of human resources which in turn will effect the growth of the business positively.
3.	Expected increase in productivity and profit in measurable terms: The Company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the Company will improve considerably in the coming years.

ITEM NO.5: TO CONSIDER AND APPROVE THE CONTINUATION OF MR. NAGESWAR RAO YARLLAGADDA (DIN: 00293474) AS WHOLE TIME DIRECTOR OF THE COMPANY BEYOND THE AGE OF 70 YEARS

Pursuant to the provisions of Section 196(3)(a) of the Companies Act, 2013, no Company shall continue the employment of a person as Managing Director, Whole-time Director or Manager who has attained the age of 70 years unless such continuation is approved by the Members by way of a Special Resolution.

Pursuant to the provisions of Sections 196, 197 and 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and Rules framed thereunder, Mr. Nageswar Rao Yarllagadda (DIN: 00293474) was re-appointed earlier as a Whole Time Director of the Company at the 26th Annual General Meeting held on 09th August, 2024 for a period of 3 (Three) consecutive years starting from 23th June, 2024.

Mr. Nageswar Rao Yarllagadda is serving as a whole time Director of the Company and has been instrumental in the growth and development of the Company's business. Under his leadership, the Company has achieved significant operational and financial milestones and continues to benefit from his extensive industry knowledge, strategic vision and managerial expertise.

Considering his rich experience, leadership capabilities and valuable contribution towards the Company's growth, the Board of Directors, upon the recommendations of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on 13.08.2026, the approval of the Members of the Company be and is hereby sought for continuation of Mr. Nageswar Rao Yarllagadda (DIN: 00293474) as a Whole Time Director of the Company who will be attaining age of 70 years on 01.10.2026.

Save and except Mr. Nageswar Rao Yarllagadda (DIN: 00293474) Whole Time Director none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 5.

The Board of Directors recommends the passing of the above resolution as a Special Resolution set out in the item no.5

ITEM NO. 6: RE-APPOINTMENT OF MR. NAGESWAR RAO YARLLAGADDA (DIN: 00293474) AS WHOLE TIME DIRECTOR OF THE COMPANY

Pursuant to the provisions of Sections 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and Rules framed thereunder, the applicable provisions of the SEBI (LODR) (including any statutory modification(s) or re-enactment thereof for the time being in force), Mr. Nageswar Rao Yarllagadda (DIN: 00293474) was appointed earlier as Whole Time Director of the Company w.e.f., 23rd June, 2024 for a period of 3 (Three) years i.e., upto 22nd June, 2027.

Pursuant to the evolution of performance made by the Board, recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on 13.08.2026 and pursuant to the provisions of Sections 196, 197and 203 read with Schedule V and any other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the SEBI (LODR) (including any statutory modification(s) or re-enactment thereof for the time being in force), the consent and approval of the Members of the Company by way special resolution is sought for re-appointment of Mr. Nageswar Rao Yarllagadda (DIN: 00293474) as

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Whole Time Director of the Company for a further term of 3 (Three) consecutive years w.e.f. 23rd June, 2027 with the following terms and conditions of appointment, including salary, perquisites and allowances:

- f) Period of Appointment: Three Years with effect from 23.06.2027.
- g) Remuneration: In terms of Schedule V of the Companies Act, 2013 read together with Section 196, 197, 203 and any other applicable provisions of the Companies Act, 2013, the Whole Time Director shall be paid Rs. 15,00,000/- p.a. towards salary as decided by the Nomination remuneration committee from time to time. She shall also be allowed the following perquisites and allowances in addition to afore mentioned salary:
- h) Encashment of Leave: as per the rules of the Company.
- i) Provident fund, superannuation benefits and gratuity as per the rules of the Company subject to the ceilings as per the applicable provisions of Law in force from time to time.
- j) Any other allowance as may be permitted under the provisions of the Companies Act read with Schedule V of the Companies Act.

Except Mr. Nageswar Rao Yarlagadda, Whole- Time Director, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, directly or indirectly, financially or otherwise, in the resolution as set out at Item No. 6.

The Board of Directors recommends the passing of the above resolution as a Special Resolution as set out in the item no.6 of the Notice.

Information in accordance with Schedule V of Companies Act, 2013:

I. GENERAL INFORMATION

1	Nature of Industry: Clinical Research		
2	Date or expected date of commencement of commercial: The Company started its commercial operations on 02.02.1999.		
3	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable		
4	Financial performance based on given indications		
	Particulars	2025-26 (Rs. in Lakhs)	2024-25 (Rs. in Lakhs)
	Turnover	5511.91	4423.90
	Net profit after Tax	182.83	72.20
	Net Profit under Sec 198 of the Companies Act, 2013	165.01	73.57
			2023-24 (Rs. in Lakhs)
			3919.17
			(102.87)
			(104.96)
5	Foreign investments or collaborations, if any: Not Applicable		

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

II. INFORMATION ABOUT THE APPOINTEE

1.	Background Details: Mr. Nageswara Rao is an experienced professional in the areas of Management, Operations, Finance Marketing and Administration. Currently, he is a Director of Sri Surya Wheels Private Limited and has an overall experience of over 30 years successfully managing multiple organisations like Sri Surya Automobiles, Sri Surya Transport Corporation, Sri Surya Wheels Private Limited, Sri Surya Electronics and Home Appliances. He has gained multiple awards in the field of marketing and has rich experience in managing multiple teams across various levels and locations
2.	Past Remuneration: Rs. 15,00,000 p.a. in capacity of Whole Time Director
3.	Recognition or awards: Not Applicable
4.	Job Profile and suitability: Based on his work experience and suitability it was proposed to re-appoint Mr. Nageswar Rao Yarlagadda as Whole Time Director of the Company
5.	Remuneration proposed: There is no change in the present remuneration being drawn by Mr. Nageswar Rao Yarlagadda, Whole Time Director.
6.	Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin): Taking into consideration of the size of the Company, the profile of Mr. Nageswar Rao Yarlagadda and the responsibilities shouldered by him, the aforesaid remuneration package is comparable to the remuneration package paid to managerial personal prevailing in other companies.
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any: Besides the remuneration, he is holding 1,08,900 Equity Shares of Rs.10/- each of the Company (0.55% of the paid-up equity share capital).

III. OTHER INFORMATION:

1.	Reasons for inadequate Profits: Not Applicable
2.	Steps taken or proposed to be taken for improvement: Necessary and proactive efforts are being made to increase the operational efficiency by setting up of proper and strong systems in place including enhancement of human resources which in turn will effect the growth of the business positively.
3.	Expected increase in productivity and profit in measurable terms: The Company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the Company will improve considerably in the coming years.

ITEM NO.7: TO RE-APPOINT MR. SURYAPRAKASA RAO BOMMISETTI (DIN: 08089189) AS INDEPENDENT DIRECTOR OF THE COMPANY

Mr. Suryaprakasa Rao Bommiseti (DIN: 08089189) is currently an Independent Director and Chairman of the Audit Committee and Nomination and Remuneration Committee and Member of Stake Holders and Relationship Committee.

Mr. Suryaprakasa Rao Bommiseti was appointed as an Independent Director of the Company by the Members at the Extra Ordinary General Meeting of the Company held on 25.04.2022 for a period of 5 (Five) consecutive years commencing from March 25, 2022 to March 24, 2027 (both days inclusive) and is eligible for re-appointment for a second term on the Board of the Company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Based on the recommendation of the Nomination & Remuneration Committee ('NRC'), the Board of Directors at its meeting held on August 13, 2026, proposed the re-appointment of Mr. Suryaprakasa Rao Bommiseti as an Independent Director of the Company for a second term of 5 (Five) consecutive years commencing from March 25, 2027 up to March 24, 2032 (both days inclusive), not liable to retire by rotation, recommended for the approval of the Members by way of a Special Resolution.

Mr. Suryaprakasa Rao Bommiseti is Chartered Accountant by profession. He is a partner in M/s. Pundarikashyam & Associates. He is having over 29 years of experience in Audit, Accounts, and Finance and in Banking. At present, he is a Practicing Chartered Accountant dealing in all Financial Matters i.e. Finance, Accounting, Audit, Tax Planning, including providing Advisory & Financial Consultancy Services to various clients at large and carrying out of Stock Audit, Credit Audit and Concurrent Audit of Banks.

The NRC taking into consideration the skills, expertise and competencies required for the Board in the context of the business and sectors of the Company and based on the performance evaluation, concluded and recommended to the Board that Mr. Suryaprakasa Rao Bommiseti qualifications and the rich experience in the above-mentioned areas meets the skills and capabilities required for the role of Independent Director of the Company. The Board is of the opinion that Mr. Suryaprakasa Rao Bommiseti continues to possess the identified core skills, expertise and competencies fundamental for effective functioning in his role as an Independent Director of the Company and his continued association would be of immense benefit to the Company.

The Company has received a declaration from Mr. Suryaprakasa Rao Bommiseti confirming that he continues to meet the criteria of independence as prescribed under Section 149(6) of the Act, read with the rules framed thereunder and Regulation 16(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). In terms of Regulation 25(8) of the SEBI Listing Regulations, Mr. Suryaprakasa Rao Bommiseti has confirmed that he is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact his ability to discharge his duties. Mr. Suryaprakasa Rao Bommiseti has also confirmed that he is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority pursuant to circulars dated June 20, 2018 issued by BSE Limited and the National Stock Exchange of India Limited pertaining to enforcement of SEBI Orders regarding appointment of Directors by the listed companies.

Further, Mr. Suryaprakasa Rao Bommiseti has confirmed that he is not disqualified from being appointed as Director in terms of Section 164 of the Act and has given his consent to act as Director in terms of Section 152 of the Act, subject to re-appointment by the Members. Mr. Suryaprakasa Rao Bommiseti has also confirmed that he is in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualifications of Directors) Rules, 2014, with respect to his registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs ('IICA').

In the opinion of the Board, Mr. Suryaprakasa Rao Bommiseti fulfils the conditions specified in the Act, rules thereunder and the SEBI Listing Regulations for re-appointment as an Independent Director and that he is independent of the Management. The terms and conditions of the appointment of Independent Directors is uploaded on the website of the Company at <https://www.jeevanscientific.com/>.

In compliance with the provisions of Section 149 read with Schedule IV to the Act, Regulation 17 of the SEBI Listing Regulations and other applicable provisions of the Act and SEBI Listing Regulations, the re-appointment of Mr. Suryaprakasa Rao Bommiseti as an Independent Director is now placed for the approval of the Members by a Special Resolution.

Pursuant to Regulation 25 (2A) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), the appointment, re-appointment or removal of an independent director of a listed entity, shall be subject to the approval of shareholders by way of a special resolution. Provided that where a special resolution for the appointment of an independent director fails to get the requisite majority of votes but the votes cast in favour of the resolution exceed the votes cast against the resolution and the votes cast by the public shareholders in favour of the resolution exceed the votes cast against the resolution, then the appointment of such an independent director shall be deemed to have been made under sub-regulation (2A).

As per performance evaluation report made by the Board earlier, Mr. Suryaprakasa Rao Bommiseti has been accredited with maximum points.

The Board commends the Special Resolution set out in Item No. 7 of the accompanying Notice for approval of the Members.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Except Mr. Suryaprakasa Rao Bommisetti, Independent Director, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, directly or indirectly, financially or otherwise, in the resolution as set out at Item No. 7.

Disclosures as required under Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard-2 on General Meetings issued by the Institute of Company Secretaries of India are annexed to this Notice.

ITEM NO.8: TO APPOINT MR. KOLLI SRINIVAS RAO (DIN: 07980993) AS INDEPENDENT DIRECTOR OF THE COMPANY

Mr. Kolli Srinivas Rao was appointed as an Additional Director in the Independent category of the Company pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, with effect from 13.08.2026, for a term of 5 (five) consecutive years, i.e., up to 12.08.2031 (both days inclusive), subject to the approval of the shareholders of the Company.

The appointment of Mr. Kolli Srinivas Rao as an Independent Director is proposed in accordance with the applicable provisions of the Companies Act, 2013 ("Act"), including Sections 149 and 152 read with Schedule IV, Section 161 and other applicable provisions, if any, of the Act, together with the rules made thereunder, including the Companies (Appointment and Qualification of Directors) Rules, 2014, as amended from time to time, and Regulation 17 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended from time to time, and other applicable provisions thereof, and pursuant to the Articles of Association of the Company.

The Board of Directors is of the opinion that Mr. Kolli Srinivas Rao fulfils the criteria of independence as prescribed under the Act, the rules made thereunder and the SEBI Listing Regulations. The Board is also of the opinion that he is independent of the management of the Company.

Mr. Kolli Srinivas Rao has submitted a declaration confirming that he meets the criteria for independence as prescribed under the Act and the SEBI Listing Regulations. The Company has also received his consent in writing to act as a Director in Form DIR-2 and his declaration in Form DIR-8 confirming that he is not disqualified from being appointed as a Director under the provisions of the Act. Further, the Company has received the certificate issued by the Indian Institute of Corporate Affairs in compliance with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014.

The Board, based on the recommendation of the Nomination and Remuneration Committee, has recommended the appointment of Mr. Kolli Srinivas Rao as an Independent Director of the Company for a term of 5 (five) consecutive years, commencing from 13.08.2026 and ending on 12.08.2031 (both days inclusive), subject to his continuing to satisfy the criteria of independence as prescribed under the Act, the rules made thereunder and the SEBI Listing Regulations. In accordance with the provisions of Section 149(13) of the Act, he shall not be liable to retire by rotation during his tenure as an Independent Director.

Except Mr. Kolli Srinivas Rao, none of the Directors, Key Managerial Personnel ("KMP"), Senior Management Personnel ("SMP") of the Company, or their respective relatives, is concerned or interested, financially or otherwise, in the proposed resolution, except to the extent of their respective shareholding, if any, in the Company.

The Board of Directors recommends the passing of the proposed resolution as a Special Resolution as set out at Item No. 8 of the Notice for approval of the Members.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

ANNEXURE-A: ITEM. 2,3,4,6,7 and 8 OF THE NOTICE.

Details of Directors seeking appointment and re-appointment at the forthcoming Annual General Meeting [Pursuant to Regulation 36(3) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 and Secretarial Standard 2 on General Meetings]

Name of the Director	Krishna Kishore Kuchipudi	Snigdha Mothukuri	Nageswar Rao Yarlagadda	Suryaprakasa Rao Bommiseti	Kolli Srinivas Rao
DIN	00876539	08934860	00293474	08089189	07980993
Date of Birth	29.07.1960	09.09.1992	01.10.1956	14.07.1968	01.06.1966
Date of first appointment	02.02.1999	02.11.2020	23.06.2021	25.03.2022	13.08.2026
Board Meetings attended during the year	06	06	06	06	Not Applicable
Brief Resume, Qualification and Experience	Mr. K. Krishna Kishore is the Promoter and Managing Director of the Company. He is a Postgraduate from Andhra University. Under his aegis and stewardship as Vice-Chairman and Managing Director, the Company has grown impressively in size and has built its brand in India and abroad. He has played multiple roles throughout his career including but not limited to mentor, advisor, investor, entrepreneur, board member helping visionary leaders realize their dreams.	Ms. Snigdha Mothukuri is a Hons. graduate from the finest educational institutions across the globe. She pursued two master's degrees, one in the field of Management Science from a leading Ivy Leagues School - Columbia University in New York and the other in the field of Technology from the prestigious Indian Institute of Technology (IIT) Madras. She completed her Bachelor of Technology from IIT Madras. She was a part of reputed organizations like Lansum Estates LLP, Louis Vuitton, University of British Columbia, Aarvee Associates and Visakhapatnam Steel Plant worked with global teams in highly distributed environments and gained industry experience in various domains ranging from Civil Engineering, Transportation, Supply Chain to Operations and Finance.	Nageswara Rao is an experienced professional in the areas of Management, Operations, Finance Marketing and Administration. Currently, he is a Director of Sri Surya Wheels Private Limited and has an overall experience of over 30 years successfully managing multiple organisations like Sri Surya Automobiles, Sri Surya Transport Corporation, Sri Surya Wheels Private Limited, Sri Surya Electronics and Home Appliances. He has gained multiple awards in the field of marketing and has rich experience in managing multiple teams across various levels and locations	Mr. B. Suryaprakasa Rao is Chartered Accountant by profession. He is a partner in M/s. Pundarikashyam & Associates. He is having over 24 years of experience in Audit, Accounts, and Finance and in Banking. At present, he is a Practicing Chartered Accountant dealing in all Financial Matters i.e. Finance, Accounting, Audit, Tax Planning, including providing Advisory & Financial Consultancy Services to various clients at large and carrying out of Stock Audit, Credit Audit and Concurrent Audit of Banks.	CA. Kolli Srinivas Rao is a Bachelor of Commerce (B.Com), Fellow Chartered Accountant (F.CA) and Bachelor of Laws (LL.B.) with over 22 years of experience in the profession, having been in practice as a Chartered Accountant since 2003. He is a Qualified Social Auditor, certified by the National Institute of Securities Markets (NISM), SEBI. He is also the Proprietor of K. S Rao & Associates, Chartered Accountants.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Expertise in specific functional area	Expertise in pharma industry	Expertise in various domains ranging from Civil Engineering, Transportation, Supply Chain to Operations and Finance.	Expertise in field of marketing and has rich experience in managing multiple teams across various levels and locations.	Expertise in finance, accounting, auditing, tax planning, and financial consultancy.	Expertise in finance, accounting, auditing, tax planning, and financial consultancy.
Terms and conditions of appointment	Liable to Retirement by rotation, eligible for reappointment.	Liable to Retirement by rotation, eligible for reappointment. Re Appointment as Whole Time Director of the Company for a term of 3 years w.e.f. 02.11.2026.	Re Appointment as Executive Director of the Company for a term of 3 years w.e.f. 23.06.2027.	Re Appointment as Independent Director of the Company for a term of 5 years w.e.f. 24.03.2027.	Appointment as Independent Director w.e.f. 13.08.2026 for a period of 5 years
Remuneration drawn, if any	Rs.1,08,00,00 0/- p.a. in capacity of Managing Director	Rs. 48,00,000/- p.a. in capacity of Whole Time Director.	Rs. 15,00,000 p.a. in capacity of Whole Time Director.	Not Applicable	Not Applicable
Relationships between Directors inter se	Mr. Jeevan Krishna Kuchipudi and Mrs. Snigdha Mothukuri are related to Mr. Krishna Kishore Kuchipudi	Mr. Jeevan Krishna Kuchipudi and Mr. Krishna Kishore Kuchipudi are related to Mrs. Snigdha Mothukuri.	Not Applicable	Not Applicable	Not Applicable
Name of the Listed entities in which the person also holds the directorship and the membership of the committees of the Board along with the Listed entities from which the person has resigned in the past three years*	NIL	NIL	NIL	1. Bandara m Pharma Packtech Limited 2. Samsrita Labs Limited	NIL

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Other Directorships, Membership/ Chairmanship of Committees of other Boards	1. Naya s Laboratories Private Limited 2. JSTL Pharmaceuti cal Private Limited 3. Naya Pharma Private Limited 4. SM Therapeutics Private Limited	1. Naya Pharma Private Limited	1. Sri Surya Wheels Private Limited	NIL	NIL
Number of shares held in the Company	19,35,113 shares (9.71%)	78,500 Shares (0.39%)	80,000 Shares (0.52%)	NIL	NIL

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

Sd/-

**Krishna Kishore Kuchipudi
Managing Director
(DIN: 00876539)**

**Place: Hyderabad
Date: 13-08-2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Notes:

1. The Government of India, Ministry of Corporate Affairs has allowed conducting Annual General Meeting through Video Conferencing (VC) or Other Audio Visual Means (OAVM) and dispensed the personal presence of the members at the meeting. Accordingly, in compliance with the General Circular No. 03/2025 dated September 22, 2025 issued by Ministry of Corporate Affairs ("MCA") read with other relevant circulars issued in the past by MCA in this regard (collectively referred to as "MCA Circulars"), read also with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations 2025 (the "SEBI Listing Amendment Regulations") dated December 12, 2024, amending the related provisions by insertion of the same under regulation 44(4) of the SEBI Listing Amendment Regulations, which was made effective from December 30, 2024, this Notice convening Annual General Meeting of the Company ("Notice") is being sent by email only, to the members whose e-mail addresses are registered with the Company/ Depository Participants ("DP") / Depository/ Registrar & Share Transfer Agent of the Company. In terms of the MCA Circulars and the SEBI Listing Amendment Regulations, the 28th Annual General Meeting ("AGM") of the Members will be held through VC/OAVM. Hence, Members can attend and participate in the AGM through VC/ OAVM only.
2. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the quorum of the AGM under Section 103 of the Act.
3. Explanatory Statement pursuant to Section 102 of the Companies Act, 2013, in respect of the Ordinary/Special Business to be transacted at the Annual General Meeting as set out in the Notice is annexed hereto.
4. In pursuance of Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings, details in respect of the Directors seeking appointment/re-appointment at the AGM, form part of this Annual Report.
5. Pursuant to Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books of the Company will remain closed from 19.09.2026 to 25.09.2026 (Both days inclusive).
6. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020, May 05, 2020 and May 13, 2022 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
7. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
8. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
9. Pursuant to MCA Circular No. 14/2020 dated April 08, 2020, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, in pursuance of Section 112 and Section 113 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the AGM through VC/OAVM and cast their votes through e-voting.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

10. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.jeevanscientific.com. The Notice can also be accessed from the website of the Stock Exchange i.e., BSE Limited at www.bseindia.com. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e., www.evotingindia.com.
11. The AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 8, 2020 and MCA Circular No. 17/2020 dated April 13, 2020 and MCA Circular No. 20/2020 dated May 05, 2020, May 13, 2022.
12. The company has appointed M/s. Aakanksha Dubey & Co., representing by Mrs. Aakanksha Sachin Dubey, Practicing Company Secretary, as scrutinizer of the company to scrutinize the voting process.

THE INTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:

- (i) The voting period begins on 22.09.2026 at 09:00 A.M and ends on 24.09.2026 at 05:00 P.M. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of 18.09.2026 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

- (iv) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in Demat mode is given below:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders holding securities in demat mode with NSDL	1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

	available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting
Individual Shareholders (holding securities in demat mode) login through their Depository Participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note:

Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

(v) Login method for e-Voting and joining virtual meeting for shareholders other than individual shareholders holding in Demat form & physical shareholders.

- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
- 2) Click on "Shareholders" module.
- 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	For Shareholders holding shares in Demat Form and other than individual and Physical Form
PAN	Enter your 10-digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.

- (vi) After entering these details appropriately, click on "SUBMIT" tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant <Jeevan Scientific Technology Limited> on which you choose to vote.
- (x) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- (xiii) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvi) Shareholders can also cast their vote using CDSL's mobile app "m-Voting". The m-Voting app can be downloaded from respective Store. Please follow the instructions as prompted by the mobile app while Remote Voting on your mobile.
- (xvii) Facility for Non – Individual Shareholders and Custodians –Remote Voting
 - Non-Individual shareholders (i.e., other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; shareholders@jeevanscientific.com (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for Remote e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 3 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at info@jeevanscientific.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 3 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at info@jeevanscientific.com. These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022-23058738 and 022-23058542/43.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futorex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

**Sd/-
Krishna Kishore Kuchipudi
Managing Director
(DIN: 00876539)**

**Place: Hyderabad
Date: 13-08-2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

DIRECTORS' REPORT

**To the Members,
Jeevan Scientific Technology Limited
Hyderabad, Telangana, India**

The Board of Directors take pleasure in presenting the Twenty-Eighth (28th) Annual Report including inter-alia Directors' Report, its annexures and audited financial statements (including standalone and consolidated financial statements along with respective Auditors' Report thereon) for the year ended 31st March, 2026. The consolidated performance of the Company and its subsidiaries have been referred to wherever required. The Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are referred to as 'Act' and 'Listing Regulations' respectively.

1. FINANCIAL SUMMARY/HIGHLIGHTS:

The performance of the Company for the period ended 31st March, 2026 is as under:

(Rs. In Lakhs)

Particulars	Standalone		Consolidated	
	2025-26	2024-25	2025-26	2024-25
Revenue from Operations	5393.13	4360.99	6153.71	4684.36
Other Income	118.78	62.92	97.27	65.26
Profit/Loss before depreciation, finance costs, exceptional items and Tax expense	967.16	709.52	1078.92	806.32
Less: Depreciation/Amortisation	565.45	528.91	664.24	625.16
Profit/Loss before finance costs, exceptional items and Tax expense	401.71	180.61	414.68	181.16
Less: Finance Costs	137.77	103.56	203.94	176.09
Profit/Loss before Exceptional Items and Finance Costs	263.94	77.05	210.74	5.07
Add/(Less): Exceptional Items	--	--	(1.53)	--
Profit/Loss before Tax expense	263.94	77.05	209.21	5.07
(Less): Tax Expense (current & deferred)	98.93	3.48	105.87	(0.84)
Profit/(Loss) for the year (1)	165.01	73.57	103.34	5.90
Total Comprehensive Income/(Loss) (2)	17.82	(1.37)	17.82	(1.37)
Total (1+2)	182.83	72.20	121.16	4.53
Earnings per share	0.83	0.47	0.52	0.038
Balance of profit /loss for earlier years	3508.41	3332.13	3401.81	3294.82
Less: Transfer to Debenture Redemption Reserve	--	--	--	--
Less: Transfer to Reserves	1829.47	-176.28	1766.86	-108.62
Less: Dividend paid on Equity Shares	--	--	--	--
Less: Dividend Distribution Tax	--	--	--	--
Balance carried forward	5337.88	3508.41	5168.67	3401.81

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

2. OVERVIEW & STATE OF THE COMPANY'S AFFAIRS:

Revenues – Standalone

During the year under review, the Company on a Standalone basis has recorded an income of Rs. 5393.13 Lakhs and profit of Rs. 182.83 Lakhs as against the income of Rs. 4360.99 Lakhs and profit of Rs. 72.20 Lakhs respectively in the previous financial year ending 31.03.2025.

Revenues – Consolidated

During the year under review, the Company on a Consolidated basis has recorded an income of Rs. 6153.71 Lakhs and profit of Rs. 121.16 Lakhs as against the income of Rs. 4684.36 Lakhs and profit of Rs. 4.53 Lakhs respectively in the previous financial year ending 31.03.2025.

3. DIVIDEND:

No dividend is proposed for the year under review.

4. TRANSFER TO RESERVES:

Pursuant to provisions of Section 134 (3) (j) of the Companies Act, 2013, the Company has not transferred any amount to general reserves account of the Company during the year under review.

5. MATERIAL CHANGES & COMMITMENT AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There have been no material changes and commitments affecting the financial position of the Company which have occurred between the end of the Financial Year of the Company to which the financial statements relate and the date of the report.

6. SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS:

No significant or material orders have been passed against the Company by the Regulators, Courts or Tribunals, which impacts the going concern status and Company's operations in future.

7. REVISION OF FINANCIAL STATEMENTS:

There was no revision of the financial statements for the year under review.

8. CHANGE IN THE NATURE OF BUSINESS, IF ANY:

The Company has not undergone any change in the nature of business during the FY 2025-26.

9. DEPOSITS FROM PUBLIC:

The Company has not accepted any public deposits during the Financial Year ended March 31, 2026 and as such, no amount of principal or interest on public deposits was outstanding as on the date of the balance sheet and hence there has been no non-compliance with the requirements of the Act.

10. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES/ASSOCIATES:

The Company has one subsidiary namely Nayas Laboratories Private Limited situated in Hyderabad, Telangana. In accordance with Section 129(3) of the Companies Act, 2013, a statement containing salient features of the financial statements of the subsidiary company in Form AOC- 1 is attached as Annexure IX herewith forming part of the Annual Report. In accordance with the proviso to Section 136(1) of the Companies Act, 2013, the Annual Report of your Company, containing therein its audited standalone and the consolidated financial statements has been placed on the website of the Company at www.jeevanscientific.com.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

11. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR.

During the year under review, no company became or ceased to be a subsidiary, joint venture, or associate of the Company, except M/s. Naya Pharma Private Limited, which became an Associate of the Company during the year under review.

12. INDEPENDENT DIRECTOR'S FAMILIARIZATION PROGRAMMES:

Independent Directors are familiarized about the Company's operations, businesses, financial performance and significant development so as to enable them to take well-informed decisions in timely manner. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company are also made to the directors. Direct meetings with the Chairperson are further facilitated to familiarize the incumbent Director about the Company/its businesses and the group practices.

The details of familiarization programme held in FY 2025-26 are also disclosed on the Company's website: <https://www.jeevanscientific.com/>.

13. BOARD EVALUATION

Performance of the Board and Board Committees was evaluated on various parameters such as structure, composition, diversity, experience, corporate governance, competencies, performance of specific duties and obligations, quality of decision-making and overall Board effectiveness. Performance of individual Directors was evaluated on parameters such as meeting attendance, participation and contribution, engagement with colleagues on the Board, responsibility towards stakeholders and independent judgement.

All the Directors participated in the evaluation process conducted in February 2026. The Board discussed the performance evaluation reports of the Board, Board Committees, Individual Directors. The Board upon discussion noted the inputs of the Directors.

The detailed procedure followed for the performance evaluation of the Board, Committees and Individual Directors is enumerated in the Corporate Governance Report.

14. MEETINGS OF THE BOARD

The Board of Directors duly met 6 (Six) times on 30.05.2025, 14.08.2025, 15.10.2025, 12.11.2025, 02.01.2026 and 11.02.2026 in respect of which meetings, proper notices were given and the proceedings were properly recorded and signed in the Minutes Book maintained for the purpose.

15. COMMITTEES OF THE BOARD

There are various Board Committees as stipulated under the Act and Listing Regulations namely Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship and Corporate Social Responsibility Committee. Brief details pertaining to composition, terms of reference, meetings held and attendance thereof of these Committees during the year have been enumerated in Corporate Governance Report forming part of this Annual Report.

16. AUDIT COMMITTEE RECOMMENDATIONS:

During the year, all recommendations of Audit Committee were approved by the Board of Directors.

17. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/ CFO AND KEY MANAGERIAL PERSONNEL

As on date of this report, the Company has Nine Directors, out of which Four are Independent and Three are executive including one women director and Two non-executive Directors.

a) Appointment/Re-appointment/Resignation of Directors:KMP of the Company

- Re-Appointment of Mr. Krishna Kishore Kuchipudi as Managing Director of the Company with effect from 01st April, 2026

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- Appointment of Mr. Gollapinwi Mallikarjuna as Independent Director of the Company with effect from 14th August, 2025.
- Resignation of Mr. Thammareddy Ravi as Non-Executive Director of the Company with effect from 14th August, 2025.
- Retirement of Mr. Bhanu Prakash Gali as Independent Director of the Company upon completion of his second term (of 5 years) as an independent director with effect from 29th September, 2025.
- Appointment of Mr. Kolli Srinivas Rao as additional Director (Independent category) of the Company with effect from 13th August, 2026.

b) Key Managerial Personnel:

Key Managerial Personnel for the financial year 2025-26:

- Mr. Krishna Kishore Kuchipudi, Managing Director of the Company.
- Mrs. Snigdha Mothukuri, Whole Time Director of the Company.
- Mr. Nageswar Rao Yarlagadda, Whole Time Director of the Company.
- Dr. Srinivas Reddy Maram, Chief Executive Officer of the Company
- Mr. Venkateswara Rao Ravipati, Chief Financial officer of the Company
- Mr. Krishna Sainadh Kodati as Company Secretary and Compliance Officer of the company.

c) Information u/r 36(3) of SEBI (LODR), Regulations, 2015:

As required under regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointments are given as Annexure A to the notice of the AGM forming part of this Annual Report.

18. STATUTORY AUDIT AND AUDITORS REPORT:

The Members of the Company in accordance with Section 139 of the Companies Act, 2013 have passed a resolution for appointment of M/s. Pavuluri & Co., Chartered Accountants, Hyderabad (Firm Registration No. 012194S) as Statutory Auditors of the Company for a period of 5 years in the AGM held on 29.09.2022 to hold office up to the conclusion of 29th Annual General Meeting of the Company to be held for the financial year 2026-2027.

The notes of the financial statements referred to in the Auditors' Report issued by M/s. Pavuluri & Co., Chartered Accountants, Hyderabad for the financial year ended on 31st March, 2026 are self-explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation or adverse remark.

19. INTERNAL AUDITORS:

Pursuant to provisions of Section 138 read with Rule 13 of the Companies (Accounts) Rules, 2014 and Section 179 read with Rule 8(4) of the Companies (Meetings of Board and its Powers) Rules, 2014; during the year under review, the Internal Audit of the functions and activities of the Company was undertaken by M/s. K P & Associates the Internal Auditor of the Company.

Deviations are reviewed periodically and due compliance was ensured. Summary of Significant Audit Observations along with recommendations and its implementations are reviewed by the Audit Committee and concerns, if any, are reported to the Board. There were no adverse remarks or qualification on accounts of the Company from the Internal Auditor.

The internal audit is conducted at the Company and covered all key areas. All audit observations and follow up actions are discussed with the Management as also the Statutory Auditors and the Audit Committee review the same regularly.

The Board has re-appointed M/s. K P & Associates, Chartered Accountants, Hyderabad, as Internal Auditors for the Financial Year 2026-27.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

20. SECRETARIAL AUDITOR & AUDIT REPORT:

The Members of the Company, at their 27th Annual General Meeting held on 27th September, 2025, approved the appointment of M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, as the Secretarial Auditors of the Company for a period of 5 (five) consecutive years, commencing from the Financial Year 2025-26 to the Financial Year 2029-30.

M/s. Aakanksha Dubey & Co shall undertake the Secretarial Audit of the Company for the aforesaid period and issue the necessary Secretarial Audit Report in accordance with the provisions of Section 204 of the Companies Act, 2013, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

The Secretarial Audit Report for the FY 2025-26 confirms that the Company has complied with the provisions of the Act, Rules, Regulations and Guidelines and that there were no deviations or non-compliances except as stated below. The Secretarial Audit Report is provided as Annexure-I to this Report.

- a) The Secretarial Auditor has observed that there was a non-compliance with the applicable provisions relating to the composition of the Stakeholders' Relationship Committee ("SRC") for a period of 1 (one) day, for which a fine of ₹2,360/- (Rupees Two Thousand Three Hundred and Sixty Only), inclusive of GST, was levied by BSE Limited. The Management has clarified that the said fine has been duly paid and the non-compliance has been rectified by reconstituting the SRC in accordance with the applicable provisions. The requisite disclosure was also made and an appropriate reply was submitted to the Stock Exchange.
- b) The Secretarial Auditor has observed that the Company had not provided prior intimation to the Stock Exchanges regarding the Board Meeting held on 11.02.2026, at which the financial results of the Company were considered and approved. The Management has clarified that the prior intimation could not be submitted due to an inadvertent oversight and an internal communication gap at the compliance level. The outcome of the said Board Meeting, along with the approved financial results, was subsequently submitted to the Stock Exchanges within the prescribed timeline upon conclusion of the meeting.

21. ANNUAL SECRETARIAL COMPLIANCE REPORT:

SEBI vide its Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 read with Regulation 24(A) of the Listing Regulations, directed listed entities to conduct Annual Secretarial compliance audit from a Practicing Company Secretary of all applicable SEBI Regulations and circulars/guidelines issued thereunder. Further, Secretarial Compliance Report dated May 28, 2026, was given by M/s. Aakanksha Dubey & Co., Practicing Company Secretaries which was submitted to BSE Limited.

22. COST RECORDS AND COST AUDIT:

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148(1) of the Act, are not applicable for the business activities carried out by the Company.

23. NO FRAUDS REPORTED BY STATUTORY AUDITORS:

During the Financial Year 2025-26, the Auditors have not reported any matter under section 143(12) of the Companies Act, 2013, therefore no detail is required to be disclosed under section 134(3) (ca) of the Companies Act, 2013.

24. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The Company has, inter alia, received the following declarations from all the Independent Directors as prescribed under sub-section (6) of Section 149 of the Companies Act, 2013 and under Regulation 16(1)(b) read with Regulation 25 of the SEBI (LODR), Regulations, 2015 confirming that:

- a. they meet the criteria of independence as prescribed under the provisions of the Act, read with Schedule IV and Rules issued thereunder, and the Listing Regulations. There has been no change in the circumstances affecting their status as Independent Directors of the Company;
- b. they have complied with the Code for Independent Directors prescribed under Schedule IV to the Act; and

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- c. they have registered themselves with the Independent Director's Database maintained by the Indian Institute of Corporate Affairs and have qualified the online proficiency self-assessment test or are exempted from passing the test as required in terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.
- d. they had no pecuniary relationship or transactions with the Company, other than sitting fees, commission and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board of Directors and Committee(s).

The Board of Directors of the Company has taken on record the declaration and confirmation submitted by the Independent Directors after undertaking due assessment of the veracity of the same.

25. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:

The required information as per Sec.134 of the Companies Act 2013 is provided hereunder:

A. Conservation of Energy:

The Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Technology Absorption:

Research and Development (R&D): JSTL's Bioanalytical Research Laboratory is equipped with state-of-the-art analytical infrastructure comprising two processing laboratories and four LC-MS/MS laboratories. The facility currently accommodates seventeen (17) LC-MS/MS instruments and one ELISA reader. This infrastructure, together with a highly trained scientific workforce, provides JSTL with the capability to undertake sophisticated bioanalytical research and development activities.

During the year, the Company continued to adopt and implement new and technically challenging analytical approaches, enabling its scientific team to maximize the utilization of existing instrumentation and strengthen method-development capabilities. These efforts have supported the development and application of fit-for-purpose analytical methods for the assessment of critical and complex molecules, thereby enhancing the Company's scientific and technical capabilities.

JSTL fosters a culture of innovation, continuous learning and performance excellence across the organization. The Company remains committed to evaluating, adopting and upgrading technologies, analytical techniques and business processes wherever technically appropriate, operationally feasible and commercially justified. These initiatives are directed towards improving process efficiency, strengthening data quality and integrity, optimizing workflows and consistently delivering high-quality outcomes to customers.

The Company is also progressing towards greater automation and digitalization of its operational and quality processes. Increased adoption of paperless workflows, improved database management, streamlined workflow controls and enhanced data accessibility are expected to contribute to greater accuracy, improved operational visibility, reduced turnaround times and optimized operating costs, while maintaining strict adherence to applicable regulatory and quality requirements.

Technology Focus	Current Capability	Business / Quality Objective
Bioanalytical R&D	2 processing labs; 4 LC-MS/MS labs; 17 LC-MS/MS instruments; 1 ELISA reader	Support sophisticated analytical method development and assessment of complex molecules
Technology & Technique Adoption	Adoption of new and challenging analytical techniques	Maximize scientific capability and effective utilization of existing instrumentation
Automation & Digitalization	Increasingly paperless and digitally enabled workflows	Improve accuracy, workflow visibility, turnaround time and cost efficiency
Quality & Compliance	Technology and process upgrades aligned with applicable requirements	Maintain reliable, high-quality deliverables and regulatory compliance

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

C. Foreign Exchange Earnings and Out Go:

The foreign exchange earned in terms of actual inflows during the year and the foreign exchange outgo during the year in terms of actual outflow: Please refer notes to accounts attached to this report.

26. CORPORATE GOVERNANCE:

Your Company has taken adequate steps to ensure compliance with the provisions of Corporate Governance as prescribed under the Listing Regulations. A separate section on Corporate Governance, forming a part of this Report and the requisite certificate from the secretarial auditors confirming compliance with the conditions of Corporate Governance is attached to the report on Corporate Governance as Annexure-II.

27. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

Management discussion and analysis report for the year under review as stipulated under Regulation 34(2) (e) read with schedule V, Part B of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 with the stock exchange in India is annexed herewith as Annexure-III to this report.

28. RISK MANAGEMENT POLICY:

The Board of Directors had constituted Risk Management Committee to identify elements of risk in different areas of operations and to develop policy for actions associated to mitigate the risks. The Committee is responsible for reviewing the risk management plan and ensuring its effectiveness. The major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continual basis.

29. ANNUAL RETURN:

Pursuant to Sections 92 & 134(3) of the Act and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return in Form MGT-7 is also available on the Company's website: <https://www.jeevanscientific.com>.

30. AUTHORISED AND PAID-UP CAPITAL OF THE COMPANY:

The authorized capital of the Company at the beginning of Financial Year stands at Rs. 21,00,00,000/- divided into 2,10,00,000 equity shares of Rs.10/- each. During the year, in the extra-ordinary general meeting held on 12th November, 2025 the company has increased the authorized capital from Rs. 21,00,00,000/- divided into 2,10,00,000 (Two Crores Ten Lakhs) shares to Rs. 25,00,00,000/- divided into 2,50,00,000 (Two Crores Fifty Lakhs) shares.

The paid-up Share capital of the Company at the beginning of Financial Year stands at Rs.15,83,39,650/- divided into 1,58,33,965 equity shares of Rs.10/- each.

During the year, the company has allotted 40,85,000 equity shares of face value of Rs.10/- each as fully paid-up at an issue price of Rs.40/- per share, including a premium of Rs.30/- per share aggregating to Rs.16,34,00,000/- on preferential basis to the non-Promoters of the Company in the Board Meeting held on 02nd January, 2026.

The paid-up share capital as on 31st March, 2026 is Rs. 19,91,89,650 divided into 1,99,18,965 equity shares of Rs. 10/- each.

31. DECLARATION FROM DIRECTORS

None of the Directors of the Company are disqualified from being appointed as Directors as specified under Section 164(1) and 164(2) of the Act read with Rule 14(1) of the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) and/or re-enactment(s) thereof for the time being in force) or are debarred or disqualified by the Securities and Exchange Board of India ("SEBI"), Ministry of Corporate Affairs ("MCA") or any other such statutory authority.

All members of the Board and Senior Management have affirmed compliance with the Code of Conduct for Board and Senior Management for the financial year 2025-26. The Company had sought the following certificates from independent and reputed Practicing Company Secretaries confirming that:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- a. none of the Director on the Board of the Company has been debarred or disqualified from being appointed and/or continuing as Directors by the SEBI/MCA or any other such statutory authority.
- b. independence of the Directors of the Company in terms of the provisions of the Act, read with Schedule IV and Rules issued thereunder and the Listing Regulations.

32. DIRECTOR'S RESPONSIBILITY STATEMENT:

In pursuance of section 134 (5) of the Companies Act, 2013, the Directors hereby confirm that:

- a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The Directors had prepared the annual accounts on a going concern basis; and
- e) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

33. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

The Company has formulated a Vigil Mechanism / Whistle Blower Policy pursuant to Reg. 22 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 and Section 177(10) of the Companies Act 2013, enabling stakeholders to report any concern of unethical behaviour, suspected fraud or violation.

The said policy inter-alia provides safeguard against victimization of the Whistle Blower. Stakeholders including directors and employees have access to the Managing Director and Chairperson of the Audit Committee.

During the year under review, no stakeholder was denied access to the Chairperson of the Audit Committee.

The policy is available on the website of the Company at www.jeevanscientific.com.

34. EMPLOYEE STOCK OPTION SCHEME:

The Company adopted an Employee Stock Option (ESOP) scheme, namely "Employee Stock Option Scheme 2016-" ("JSTL- ESOP Scheme 2016) which helps the Company to retain and attract right talent. The Nomination and Remuneration Committee (NRC) administers the Company's ESOP scheme. There were no changes in the ESOP scheme during the financial year under review. The scheme is in compliance with the Securities and Exchange Board of India (Share-Based Employee Benefits and Sweat Equity) Regulations, 2021.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Following are the details of the ESOPs as on 31.03.2026:

Sl. No.	Details Related to ESOPS	JSTL ESOP Scheme 2016
1.	Description of each ESOP that existed at any times during the year, including the general terms and conditions of each ESOPS including:	
	a. Date of Shareholders Approval	30.09.2016
	b. Total no. of options approved under ESOPS	25,00,000
	c. Vesting Requirements	Vesting period shall not be less than one year and not more than 5 years from the date of grant of options.
	d. Exercise price or Pricing Formula	As decided by NRC
	e. Maximum term of options granted	5 years
	f. Source of shares (primary, secondary or combination)	Primary
	g. Variation in terms of options	--
2.	Method used to account for ESOPS	Black scholes
3.	Option movement during the year:	
aa.	Number of options outstanding at the beginning of the period	16,43,500
bb.	Adjustment on account of bonus issue (if any)	NA
cc.	No. of options granted during the year	3,00,000
dd.	No. of options forfeited-/ lapsed during the year	1,52,500
ee.	No. of options vested during the year	1,58,750
ff.	No. of options exercised during the year	--
gg.	No. of shares arising as a result of exercise of options	--
hh.	Money realized by exercise of options (INR), if scheme is implemented directly by the company	--
ii.	Loan repaid by the trust during the year from exercise price received	NA
jj.	No. of option outstanding at the end of the year (including the lapsed options being added back to pool account)	17,91,000
kk.	No. of options exercisable at the end of the year	NA
4.	Weighted average exercise prices and weighted average fair values of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock	NA

Disclosure in compliance with the Securities and Exchange Board of India (Share-Based Employee Benefits and Sweat Equity) Regulations, 2021 are available on the company website of the company at website: <https://www.jeevanscientific.com>.

Further, a certificate from Mrs. Aakanksha Sachin Dubey, Secretarial Auditor of the Company certifying that the ("JSTL- ESOP Scheme 2016) has been implemented in accordance with these regulations and in accordance with the resolution of the Company in the general meeting is enclosed as Annexure-IV.

35. CORPORATE SOCIAL RESPONSIBILITY (CSR, COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR POLICY)

Since the Company does not have the net worth of Rs. 500 Crore or more, or turnover of Rs. 1000 Crore or more, or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

36. SECRETARIAL STANDARDS:

The Company has devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India and such systems are adequate and operating effectively. During the year under review, the Company was in compliance with the Secretarial Standards (SS) i.e., SS-1 and SS- 2, relating to "Meetings of the Board of Directors" and "General Meetings", respectively.

37. INSURANCE:

The properties and assets of your Company are adequately insured.

38. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

During the financial year under review, the Company made an investment in M/s. Naya Pharma Private Limited on January 7, 2026, pursuant to the approval accorded by the Members of the Company at the Extraordinary General Meeting held on March 27, 2025. Consequent to the said investment, M/s. Naya Pharma Private Limited became an Associate Company of the Company.

39. INTERNAL FINANCIAL CONTROL SYSTEMS:

Your Company has well laid out policies on financial reporting, asset management, adherence to Management policies and also on promoting compliance of ethical and well-defined standards. The Company follows an exhaustive budgetary control and standard costing system. Moreover, the management team regularly meets to monitor goals and results and scrutinizes reasons for deviations in order to take necessary corrective steps. The Audit Committee which meets at regular intervals also reviews the internal control systems with the Management and the internal auditors.

The Company laid down internal financial controls and that such internal financial controls are adequate and were operating effectively.

40. RELATED PARTY TRANSACTIONS:

All related party transactions that were entered into during the financial year were on arm's length basis and in the ordinary course of business. The Form AOC-2 pursuant to Section 134(3)(h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014 is annexed herewith as Annexure-V to this report.

41. POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION:

In adherence to the provisions of Section 134(3)(e) and 178(1) & (3) of the Companies Act, 2013, the Board of Directors upon recommendation of the Nomination and Remuneration Committee approved a policy on Director's appointment and remuneration, including, criteria for determining qualifications, positive attributes, independence of a Director and other matters. The said Policy extract is covered in Corporate Governance Report which forms part of this Report and is also uploaded on the Company's website at www.jeevanscientific.com.

42. TRANSFER OF UN-CLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION:

Pursuant to the provisions of Section 124 of the Companies Act 2013, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

43. SHARES TRANSFERRED TO INVESTOR EDUCATION AND PROTECTION FUND:

No shares were transferred to the Investor Education and Protection Fund during the year under review.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

44. DETAILS OF NODAL OFFICER:

The Company has designated Mr. Krishna Sainadh Kodati as a Nodal Officer for the purpose of IEPF.

45. DETAILS OF UTILIZATION OF FUNDS:

During the year under review, the Company has raised funds through Preferential Allotment and no deviation were observed.

The Company has allotted 40,85,000 equity shares to non-Promoters and 35,00,000 convertible warrants to promoters and non-promoters of the Company in the Board Meeting held on 02nd January, 2026. Details of Amount allocated and Amount utilized is provided below:

(Rs. in lakhs)

S. No.	Objects of the Issue	Amount Allocated (in Rs.)	Amount Utilized as on 31.03.2026 (in Rs.)
1.	Capital Expenditure	500.00	365.73
2.	Working Capital Requirement	350.00	51.56
3.	Working Capital & Capital Expenditure for Subsidiary	500.00	177.67
4.	Acquisition of API/formulation unit(s)	1000.00	300.00
5.	General Corporate Purposes	724.00	189.04
	Total	3074.00	1084.00

46. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

A table containing the particulars in accordance with the provisions of Section 197(12) of the Act, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as **Annexure VI (a)** to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as **Annexure VI (b)**.

During the year, NONE of the employees (excluding Executive Directors) is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act, 2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

47. RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies (Appointment & Remuneration) Rules, 2014, the ratio of remuneration to median employees is as mentioned in **Annexure- VI (a)**.

48. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES:

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgement of the Board may affect the independence of the Directors except Mr. Jeevan Krishna Kuchipudi (Non- Executive Director) who is holding 9,17,772 Equity Shares and Mr. Diwakar Atturi (Non- Executive Director) who is holding 2,00,000 Equity Shares.

49. INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING THE COMPANY:

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures are not required.

50. FAILURE TO IMPLEMENT CORPORATE ACTIONS:

During the year under review, no corporate actions were done by the Company which were failed to be implemented.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

51. DETAILS OF APPLICATION MADE OR PROCEEDING PENDING UNDER INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the year under review, there were no applications made or proceedings pending in the name of the Company under Insolvency and Bankruptcy Code, 2016.

52. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS:

During the year under review, there has been no one time settlement of loans taken from banks and financial institutions.

53. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are posted on our website <https://www.jeevanscientific.com/>.

54. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

55. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, the Company has formulated a Code of Conduct for Prevention of Insider Trading ("Insider Trading Code") and a Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information ("UPSI").

The Code of Practices and Procedures for fair disclosure of UPSI is posted on the website of the Company at <https://www.jeevanscientific.com/>.

56. MD / CEO & CFO CERTIFICATION:

As required Regulation 17(8) read with Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the MD / CEO & CFO certification is attached with the annual report as Annexure VII.

57. PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- No. of complaints received: Nil
- No. of complaints disposed off: Nil
- No. of cases pending for more than ninety days: Nil

58. MATERNITY BENEFIT PROVIDED BY THE COMPANY UNDER MATERNITY BENEFIT ACT 1961.

The Company declares that it has duly complied with the provisions of the Maternity Benefit Act, 1961. All eligible women employees have been extended the statutory benefits prescribed under the Act, including paid maternity leave, continuity of salary and service during the leave period, and post-maternity support such as nursing breaks and flexible return-to-work options, as applicable. The Company remains committed to fostering an inclusive and supportive work environment that upholds the rights and welfare of its women employees in accordance with applicable laws.

59. EVENT BASED DISCLOSURES

During the year under review, the Company has not taken up any of the following activities:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- a. Issue of sweat equity share: NA
- b. Issue of shares with differential rights: NA
- c. Issue of shares under employee's stock option scheme: NA
- d. Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
- e. Buy back shares: NA
- f. Disclosure about revision: NA
- g. Preferential Allotment of Shares: The Board of Directors and members in its Meeting held on 15.10.2025 and 12.11.2025 respectively, approved the issue of up to 35,00,000 convertible warrants to promoters and non-promoters and up to 41,85,000 equity shares to non-promoters on preferential basis. Further, the Company has allotted 40,85,000 equity shares of face value of Rs.10/- each as fully paid-up at an issue price of Rs.40/- per share, including a premium of Rs.30/- per share aggregating to Rs.16,34,00,000/- on preferential basis to the non-Promoters of the Company in the Board Meeting held on 02nd January, 2026.

60. APPRECIATION & ACKNOWLEDGEMENT:

Your directors place on records their appreciation for the overwhelming co-operation and assistance received from the investors, customers, business associates, bankers, vendors, as well as regulatory and governmental authorities. Your directors also thank the employees at all levels, who through their dedication, co-operation, support and smart work have enabled the Company to sustain its operations and is determined to poise a rapid and remarkable growth in the years to come.

Your directors also wish to place on record their appreciation of all stakeholders including business constituents, banks and other "financial institutions and shareholders of the Company SEBI, BSE, NSDL, CDSL, Company's Bankers, etc. for their continued support for the growth of the Company.

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

Place: Hyderabad
Date: 13-08-2026

Sd/-
Krishna Kishore Kuchipudi
Managing Director
(DIN: 00876539)

Sd/-
Snigdha Mothukuri
Executive Director
(DIN: 08934860)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure-I

FORM MR-3 SECRETARIAL AUDIT REPORT

(Pursuant to section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2026

To
The Members of
M/s. Jeevan Scientific Technology Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Jeevan Scientific Technology Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2025 and ended 31st March, 2026, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s. Jeevan Scientific Technology Limited ("The Company") for the financial year ended on 31st March, 2026, according to the provisions of:
 - a. The Companies Act, 2013 (the Act) and the rules made there under;
 - b. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
 - c. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under.
 - d. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment (FDI) and Overseas Direct Investment and External Commercial Borrowings;
2. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') is furnished hereunder for the financial year 2025-26: -
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **including the provisions with regard to disclosures and maintenance of records required under the said Regulations;**
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e., www.jeevanscientific.com.**
 - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
 - d. Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- e. The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **Not Applicable as the Company has not issued any debt securities during the year under review.**
- f. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review.**
- g. Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
- h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018. **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**
- i. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- j. **Other applicable laws include the following:**
 1. Code on Wages,
 2. Industrial Relations Code,
 3. Code on Social Security, and
 4. Occupational Safety, Health and Working Conditions Code (OSHWC Code).

Environmental Laws

1. Water (Prevention and Control of Pollution) Cess Act, 1977;
2. Air (Prevention and Control of Pollution) Act, 1981;
3. Environment (Protection) Act, 1986;

We have also examined compliance with the applicable provisions / clauses of the following:

- a. Secretarial Standards issued by The Institute of Company Secretaries of India on Meetings of the Board of Directors and General Meetings.
- b. Securities and Exchange Board of India Act, 1992 & Circulars, Master Circulars and Regulations issued by SEBI and applicable to the Company.
- c. Listing Agreements entered into by the Company with BSE Limited.
3. We have not examined compliance by the Company with applicable financial laws, like direct and indirect tax laws, since the same have been subject to review by statutory financial auditor and other designated professionals.
4. We have relied on the representation made by the Company and its officers for systems and mechanisms formed by the Company for compliances under other applicable Acts, Laws and Regulations and it was noted that the Company has complied with the said Laws to the extent applicable.
5. During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, etc. including the following:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

During the year the Company has conducted 6 (Six) meetings of the Board of Directors, 6 (Six) Meetings of Audit Committee, 1 (One) Meeting of Nomination and Remuneration Committee, 1 (One) Meeting of Stakeholders and Relationship Committee and 1 (One) Meeting of Independent Directors Committee. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by the Institute of Company secretaries of India.

6. As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that:
 - i. The provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:
 - External Commercial Borrowings were not attracted to the Company under the financial year under report;
 - Foreign Direct Investment (FDI) was complied by the company under the financial year under report;
 - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.
7. As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, We report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that: -

- Dr. Srinivas Reddy Maram is the Chief Executive Officer of the Company and Mr. Venkateswara Rao Ravipati is the Chief Financial Officer of the Company while Mr. Krishna Sainadh Kodati as Company Secretary and Compliance officer of the Company as on the date of this report.
- The Company has M/s. Pavuluri & Co., Chartered Accountants, Hyderabad as the Statutory Auditors and M/s. KP & Associates, Chartered Accountants, Hyderabad as the Internal Auditors.
- The website of the Company contains policies as specified by SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and the provisions of Companies Act, 2013.
- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate notice of board meeting is given to all the directors along with agenda at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
- As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.
- The Company has not undertaken event/action having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc. other than those already disclosed to Stock Exchange i.e., BSE.
- There are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed in this audit since the same have been subject to review by statutory financial audit and other designated professionals.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Observations/ Non-Compliances/ Adverse Remarks/ Qualifications in respect of the Companies Act, 2013 and SEBI Act, Regulations, Rules, Guidelines, Notifications, Circulars made there under are as follows:

- c) Composition of Stakeholder Relationship Committee (SRC) was not constituted as per the applicable provisions for a period of 1 (One) day for which a fine of Rs. 2,360/- (Rupees Two Thousand Three Hundred and Sixty Only) (including GST) was levied by BSE Limited. The Company has paid the fine and complied by making the requisite disclosure and appropriate reply to the Exchange.
- d) The Company had not provided prior intimation to the Stock Exchanges regarding the Board Meeting held on 11.02.2026, at which the financial results were considered and approved. The Company has clarified that the delay/non-submission of the prior intimation was due to an inadvertent oversight and an internal communication gap at the compliance level. There was no mala fide intention to withhold any information from the Stock Exchanges or investors. The outcome of the said Board Meeting, along with the approved financial results, was subsequently submitted to the Stock Exchanges within the prescribed timeline following the conclusion of the meeting.

For Aakanksha Dubey & Co.

Sd/-

**Aakanksha Sachin Dubey
Practicing Company Secretary
C.P. No. 20064 & M. No. 49041
Peer Review Cer. No. 3363/2023
UDIN: A049041H001092921**

**Place: Hyderabad
Date: 12.08.2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure- A to Secretarial Audit Report

To
The Members of
M/s. Jeevan Scientific Technology Limited
Our report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices followed by us provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, We have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Aakanksha Dubey & Co.

Sd/-
Aakanksha Sachin Dubey
Practicing Company Secretary
C.P. No. 20064 & M. No. 49041
Peer Review Cer. No. 3363/2023
UDIN: A049041H001092921

Place: Hyderabad
Date: 12.08.2026

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CORPORATE GOVERNANCE

In accordance with Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the report containing the details of Corporate Governance systems and processes at Jeevan Scientific Technology Limited ("Jeevan") as follows:

1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:

Company's endeavor is to maximize shareholder value. Jeevan is committed to adopt best governance practices and its adherence in true spirit at all times. It has strong legacy of fair, transparent and ethical governance practices.

Company has adopted a code of conduct which is applicable to all employees and is posted on the website of the Company. The Company also has in place a code for preventing insider trading.

Company is fully compliant with the requirements of the listing regulations and applicable corporate governance norms and is committed to ensuring compliance with all modifications within the prescribed time.

BOARD DIVERSITY:

The Company recognizes and embraces the importance of a diverse Board in its success. We believe that a truly diverse Board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us, retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on our website, <https://www.jeevanscientific.com/>.

'JEEVAN' CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2015. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company. The policy has been formulated to regulate, monitor and ensure reporting of dealings by employees and to maintain the highest ethical standards of dealing in Company securities.

The Insider Trading Policy of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading, is available on our website <https://www.jeevanscientific.com/>.

DATE OF REPORT

The information provided in the Report on Corporate Governance for the purpose of unanimity is as on 31st March, 2026. The Report is updated as on the date of the report wherever applicable.

2. BOARD OF DIRECTORS

(a) COMPOSITION AND CATEGORY OF DIRECTORS:

The composition of the Board of Directors of the company is an appropriate combination of executive and non-executive Directors with right element of independence. As on March 31, 2026, the Company's Board comprises of Eight Directors. There are Three (3) Executive Directors including woman Director, 6 (Six) Non - Executive Directors including 4 (Four) Independent Directors. In terms of clause 17(1) (b) of SEBI (LODR) Regulations, 2015, the Company is required to have one third of total Directors as Independent Directors. The non-executive Directors are appointed or re-appointed based on the recommendation of the Nomination & Remuneration Committee which considers their overall experience, expertise and industry knowledge. One third of the Directors other than Independent Directors, are liable to retire by rotation every year and are eligible for reappointment, subject to approval by the shareholders.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(b) ATTENDANCE AND DIRECTORSHIPS HELD:

As mandated by the SEBI (LODR) Regulations, 2015, none of the Directors are members of more than ten Board-level committees nor are they chairman of more than five committees in which they are members. Further all the Directors have confirmed that they do not serve as an independent director in more than seven listed companies or where they are whole-time directors in any listed company, then they do not serve as independent director in more than three listed companies.

The names and categories of the Directors on the Board, their attendance at Board meeting during the year and at last Annual General Meeting, as also the number of Directorships and Committee memberships held by them in other companies are shown in Table 1.

(c) NO. OF MEETINGS OF THE BOARD OF DIRECTORS HELD AND DATES ON WHICH HELD:

Date of the Board Meetings: The Board of Directors duly met 6 (Five) times on 30.05.2025, 14.08.2025, 15.10.2025, 12.11.2025, 02.01.2026 and 11.02.2026:

Table-1								
Name of Director	Relationship with other Directors	Category	No. of Meetings Held	No. of Meetings Attended	Whether Attended Last AGM (27.09.2025)	No. of Outside Directorship	No. of Committee Memberships	No. of Committee Chairmanships
Mr. K. Krishna Kishore	Father of Jeevan Krishna Kuchipudi and Father in law of Mrs. Snigdha Mothukuri	P & ED	6	6	Yes	4	-	-
Mrs. Snigdha Mothukuri	wife of Mr. Jeevan Krishna Kuchipudi and Daughter in law of Mr. K. Krishna Kishore	P & ED	6	6	Yes	1	-	-
Mr. T. Ravi Babu	None	P&NED	6	1	No	-	-	-
Mr. G. Bhanu Prakash	None	ID	6	6	Yes	1	-	-
Mr. Jeevan Krishna Kuchipudi	Son of Krishna Kishore Kuchipudi and husband of Mrs. Snigdha Mothukuri	P & NED	6	6	Yes	1	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Mr. Y. Nageswar Rao	None	ED	6	6	No	1	-	-
Mr. B. Suryaprakasa Rao	None	ID	6	1	Yes	2	3	-
Mr. G. Venkata Subba Rao	None	ID	6	6	Yes	3	-	-
Mr. Divakar Atluri	None	NED	6	5	Yes	10	3	-
**Mr. Gollapinni Mallikarjuna	None	ID	6	4	Yes	1	-	-
# Mr. Kolli Srinivas Rao	None	ID	-	-	NA	-	-	-

*Resigned w.e.f.14.08.2025

**Retired w.e.f. 29.09.2025

**Appointed w.e.f.14.08.2025

#Appointed w.e.f. 13.08.2026

ID -Independent Director

P- Promoter

NED – Non- Executive Director

ED – Executive Director

MD – Managing Director

CEO-Chief Executive Officer

CFO-Chief Financial Officer

(d) THE NAME OF OTHER LISTED ENTITIES WHERE DIRECTORS OF THE COMPANY ARE DIRECTORS AND THE CATEGORY OF DIRECTORSHIP

Table-2		
Name of Director	Other Listed Entities in which concern Director is Director	Category of Directorship
Mr. K. Krishna Kishore	NIL	--
Mr. Y. Nageswar Rao	NIL	--
*Mr. T. Ravi Babu	NIL	--
**Mr. G. Bhanu Prakash	NIL	--
Ms. Snigdha Mothukuri	NIL	--
Mr. K. Jeevan Krishna	NIL	--
Mr. B. Suryaprakasa Rao	1. Samsrita Labs Limited 2. Bandaram Pharma Packtech Limited	Independent Director Independent Director
Mr. G. Venkata Subba Rao	NIL	--
Mr. Divakar Atluri	NIL	NIL
**Mr. Gollapinni Mallikarjuna	NIL	--
# Mr. Kolli Srinivas Rao	NIL	NIL

*Resigned w.e.f.14.08.2025

**Retired w.e.f. 29.09.2025

**Appointed w.e.f.14.08.2025

#Appointed w.e.f. 13.08.2026

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(e) SKILLS / EXPERTISE / COMPETENCIES OF THE BOARD OF DIRECTORS;

The following is the list of core skills / expertise / competencies identified by the Board of Directors as required in the context of the Company's business and that the said skills are available with the Board Members:

S. No.	Name of the Director	Skills / Expertise / Competence of the Board of Directors are required in the context of business of the Company
1.	Mr. K. Krishna Kishore	Management, Healthcare, Pharma, Finance and Operations
2.	Mr. Jeevan Krishna Kuchipudi	Operations, Finance, Health Care and Information Technology
3.	Mrs. Snigdha Mothukuri	Management, Healthcare, Pharma and Operations
4.	Mr. Y. Nageswar Rao	Management, Operations, Finance, Marketing and Administration
5.	Mr. Suryaprakasa Rao Bommiseti	Finance, Taxation and Accounts
6.	Dr. G.V. Subbarao	Technocrat in Pharmaceutical Sciences
7.	Mr. Divakar Atluri	Finance, Accounts and Taxation
8.	Mr. Gollapinni Mallikarjuna	Finance, Accounts and Taxation
9.	Mr. Kolli Srinivas Rao	Finance, Accounts and Taxation

(f) NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON- EXECUTIVE DIRECTORS:

Mr. Jeevan Krishna Kuchipudi, Non-Executive Director, has a pecuniary relationship with the Company by virtue of holding 9,17,772 equity shares and 6,00,000 convertible warrants, and Mr. Diwakar Atluri has a pecuniary relationship with the Company by virtue of holding 2,00,000 equity shares.

(g) FULL INFORMATION PROVIDED TO THE DIRECTORS TRANSPARENTLY FOR EFFICIENT DECISION MAKING:

The Board has complete access to all information of the Company and is regularly provided advanced detailed information as a part of the agenda papers or is tabled therein. In addition, detailed quarterly performance report by the CFO is presented in the quarterly Board meeting, encompassing all facets of the Company's operations during the quarter, including update of key projects, outlook and matters relating to environment, health & safety, corporate social responsibility etc. The following information is provided to the Board as a part of the agenda papers:

- Annual and Quarterly financial statements for the Company and the Accounting Policy
- Minutes of the meetings of the Audit Committee and other Committees of the Board
- Annual business plan
- Information on recruitment and remuneration of senior officers just below the level of Board, including the appointment or removal of Chief Financial Officer and Company Secretary, whenever required
- Expansion projects and its status monitoring
- Fatal or serious accidents, injuries or any material environmental problems, if any.
- Any material default in financial obligations to and by the Company, or substantial non-payment for goods sold by the Company, if any.
- Significant labour problems and their proposed solutions, whenever necessary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- Any significant development in human resources / industrial relations including long-term wage agreement, major voluntary retirement scheme, etc.
- Quarterly details of foreign exchange exposures and the steps taken by the management to limit the risks of adverse exchange rate movement, if material
- Quarterly disclosure of all the investments made
- Material non-compliance of any regulatory, statutory nature or listing requirements and shareholders service, such as non-payment of dividend, delay in share transfer and others, if any
- Quarterly review of compliance status under various laws applicable to the Company
- Substantial non-payment of goods sold by the Company except disputes
- Related Party Transactions, if they are not at arm's length and in the ordinary course of business
- Half-yearly summary of bank guarantees issued.
- All other matters required to be placed before the Board for its review / information / approval under the statutes, including SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(h) FAMILIARISATION PROGRAMME FOR INDEPENDENT DIRECTORS:

Independent Directors are familiarized about the Company's operations and businesses. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company are also made to the directors. Direct meetings with the Chairman is further facilitated to familiarize the incumbent Director about the Company/its businesses and the group practices.

The details of familiarisation programme held in FY 2025-26 are also disclosed on the Company's website i.e., <http://www.jeevanscientific.com>.

(i) DECLARATION BY INDEPENDENT DIRECTORS

All the Independent Directors have confirmed that they meet the criteria of independence as mentioned under Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements), 2015 read with Section 149(6) of the Act.

(j) DECLARATION BY BOARD:

The Board has confirmed that in its opinion, the independent directors fulfil the conditions specified in these regulations and are independent of the management.

(k) RESIGNATION OF INDEPENDENT DIRECTOR

During the financial year 2025-26, there has been no resignation of the Independent Director before the expiry of his/her tenure hence, there was no requirement of receiving the confirmation from the Independent Directors except for retirement of Mr. Bhanu Prakash Gali Independent Director of the Company upon completion of his second term (of 5 years) as an independent director with effect from 29th September, 2025

Performance Evaluation of Board, Committees and Directors:

Pursuant to provisions of Regulation 17(10) of the SEBI Listing Regulations and the provisions of the Act, an annual Board evaluation was conducted for FY 2025-26 on February 11, 2026, including the following:

- i. Evaluation of IDs by the entire Board was undertaken, based on their performance and fulfilment of the independence criteria prescribed under the Act and SEBI Listing Regulations; and
- ii. Evaluation of the Board of Directors, its committees and individual Directors, including the role of the Board Chairman.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

An IDs' meeting, in accordance with the provisions of Section 149(8) read with Schedule IV of the Act and Regulation 25(3) and 25(4) of the SEBI Listing Regulations, was convened on February 06, 2025, mainly to review the performance of Directors and the Chairman & Managing Director as also the Board as a whole. All IDs were present at the said meeting.

- (i) **Board:** Composition, responsibilities, stakeholder value and responsibility, Board development, diversity, governance, leadership, directions, strategic input, etc.
- (ii) **Executive Directors:** Skill, knowledge, performance, compliances, ethical standards, risk mitigation, sustainability, strategy formulation and execution, financial planning & performance, managing human relations, appropriate succession plan, external relations including CSR, community involvement and image building, etc.
- (iii) **Independent Directors:** Participation, managing relationship, ethics and integrity, Objectivity, brining independent judgement, time devotion, protecting interest of minority shareholders, domain knowledge contribution, etc.
- (iv) **Chairman:** Managing relationships, commitment, leadership effectiveness, promotion of training and development of directors etc.
- (v) **Committees:** Terms of reference, participation of members, responsibilities delegated, functions and duties, objectives alignment with company strategy, composition of committee, committee meetings and procedures, management relations.

Disclosures as prescribed under SEBI circular dated May 10, 2018 are given below:

Observations of Board evaluation carried out for the year	No observations.
Previous year's observations and actions taken	Since no observations were received, no actions were taken.
Proposed actions based on current year observations	Since no observations were received, no actions were taken.

COMMITTEES OF THE BOARD:

The Company has the following Five Board-level Committees:

- Audit Committee
- Stakeholder Relationship Committee
- Nomination & Remuneration Committee
- Corporate Social Responsibility Committee.
- Risk Management Committee

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of service for Committee members are taken by the Board of Directors. Details on the role and composition of these Committees, including the number of meetings held during the financial year and the related attendance are provided in this report below.

3. AUDIT COMMITTEE:

Terms of reference of Audit committee covers all the matters prescribed under Regulation 18 of the Listing Regulations and Section 177 of the Act, 2013.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The terms of reference of the Audit Committee encompasses the requirements of Section 177 of Companies Act, 2013 and as per Regulation 18 of SEBI (LODR) Regulations, 2015 and, inter alia, includes:

- i. Oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- ii. Recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;
- iii. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- iv. Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - a. Matters required to be included in the director's responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
 - b. Changes, if any, in accounting policies and practices and reasons for the same;
 - c. Major accounting entries involving estimates based on the exercise of judgment by management;
 - d. Significant adjustments made in the financial statements arising out of audit findings;
 - e. Compliance with listing and other legal requirements relating to financial statements;
 - f. Disclosure of any related party transactions;
 - g. Modified opinion(s) in the draft audit report;
- v. Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- vi. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public issue or rights issue or preferential issue or qualified institutions placement, and making appropriate recommendations to the board to take up steps in this matter;
- vii. Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;
- viii. Approval or any subsequent modification of transactions of the listed entity with related parties;
- ix. Scrutiny of inter-corporate loans and investments;
- x. Valuation of undertakings or assets of the listed entity, wherever it is necessary;
- xi. Evaluation of internal financial controls and risk management systems;
- xii. Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- xiii. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- xiv. Discussion with internal auditors of any significant findings and follow up there on;
- xv. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- xvi. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- xvii. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- xviii. To review the functioning of the whistle blower mechanism;
- xix. Approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of the candidate;
- xx. Carrying out any other function as is mentioned in the terms of reference of the audit committee.
- xxi. Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.
- xxii. Consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.
- xxiii. Carrying out any other function as may be referred to the Committee by the Board.
- xxiv. Authority to review / investigate into any matter covered by Section 177 of the Companies Act, 2013 and matters specified in Part C of Schedule II of the Listing Regulations.

B. THE AUDIT COMMITTEE SHALL MANDATORILY REVIEW THE FOLLOWING INFORMATION:

- i. Management discussion and analysis of financial condition and results of operations;
- ii. Management letters / letters of internal control weaknesses issued by the statutory auditors;
- iii. Internal audit reports relating to internal control weaknesses; and
- iv. The appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.
- v. Statement of deviations:
 - Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).
 - Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

C. COMPOSITION, MEETINGS & ATTENDANCE:

There were Six (6) Audit Committee Meetings held during the year on 30.05.2025, 14.08.2025, 15.10.2025, 12.11.2025, 02.01.2026 and 11.02.2026.

Name	Designation	Category	No of Meetings held during the tenure	No. of meeting attended
Mr. Suryaprakasa Rao Bommiseti	Chairman	ID	6	6
*Mr. G. Bhanu Prakash	Member	ID	2	1
Mr. G. V. Subbarao	Member	ID	6	6
Mr. Divakar Atturi	Member	NED	6	6
**Mr. Gollapinwi Mallikarjuna	Member	ID	3	3

*Retired w.e.f. 29.09.2025 ID: Independent Director

**Appointed w.e.f. 15.10.2025 NED : Non-Executive Director

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Previous Annual General Meeting of the Company was held on 27.09.2025 and Mr. Suryaprakasa Rao Bommiseti, Chairman of the Audit Committee attended previous AGM.

4. NOMINATION AND REMUNERATION COMMITTEE:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE

- i. Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
- ii. For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - a. use the services of an external agencies, if required;
 - b. consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - c. consider the time commitments of the candidates.
- iii. Formulation of criteria for evaluation of performance of independent directors and the board of directors;
- iv. Devising a policy on diversity of board of directors;
- v. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal.
- vi. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.
- vii. recommend to the board, all remuneration, in whatever form, payable to senior management.

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

There was one (1) Nomination and Remuneration Committee Meetings held during the financial year on 14.08.2025:

Name	Designation	Category	No of Meetings held during the tenure	No. of meeting attended
Mr. Suryaprakasa Rao Bommiseti	Chairman	ID	1	1
Mr. G. Venkata Subba Rao	Member	ID	1	1
Mr. Divakar Atluri	Member	NED	1	1

NED: Non-Executive Director

ID: Independent Director

C. PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

In terms of the requirements of the Act and the Listing Regulations, an annual performance evaluation of the Board is undertaken where the Board formally assesses its own performance with an aim to improve the effectiveness of the Board and its Committees.

The Company has a structured assessment process, wherein the NRC of the Company has laid down the process for the effective manner of performance evaluation of the Board, its Committees and the Directors, including the Chairperson.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The evaluations are carried out in a confidential manner and the Directors provide their feedback by rating based on various metrics.

The Independent Directors at their separate meeting reviewed the performance of Non-Independent Directors, the Board as a whole and the Chairman of the Company after considering the views of other Directors, succession planning, the quality, quantity and timeliness of flow of information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

The process of evaluations involved a questionnaire-based approach with all Board and committee members.

The Board evaluation process was completed for financial year 2025-26 to the satisfaction of the Board. The Board of Directors deliberated on the outcome and agreed to take necessary steps going forward.

D. POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE:

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

2.1 "Director" means a director appointed to the Board of a Company.

2.2 "Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2.3 "Independent Director" means a Director referred to in sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

3.1 Qualifications and criteria

3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.

3.1.2 In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:

- General understanding of the Company's business dynamics, global business and social perspective;
- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

3.1.3 The proposed appointee shall also fulfil the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall Endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- shall abide by the Code of Conduct established by the Company for Directors and senior Management personnel;
- shall disclose his concern or interest in any Company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as any prescribed, from time to time, under the Companies Act, 2013, Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the Company's business.

3.2 Criteria of Independence

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2.2 The criteria of independence shall be in accordance with the guidelines as laid down in Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

An independent Director in relation to a Company, means a director other than a Managing Director or a Whole-Time Director or a Nominee Director

- i. who, in the opinion of the board of directors, is a person of integrity and possesses relevant expertise and experience;
- ii. who is or was not a promoter of the listed entity or its holding, subsidiary or associate company [or member of the promoter group of the listed entity];
- iii. who is not related to promoters or directors in the listed entity, its holding, subsidiary or associate company;
- iv. who, apart from receiving director's remuneration, has or had no material pecuniary relationship with the listed entity, its holding, subsidiary or associate company, or their promoters, or directors, during the three immediately preceding financial years or during the current financial year;
- v. none of whose relatives—
 - a. is holding securities of or interest in the listed entity, its holding, subsidiary or associate company during the three immediately preceding financial years or during the current financial year of face value in excess of fifty lakh rupees or two percent of the paid-up capital of the listed entity, its holding, subsidiary or associate company, respectively, or such higher sum as may be specified;
 - b. is indebted to the listed entity, its holding, subsidiary or associate company or their promoters or directors, in excess of such amount as may be specified during the three immediately preceding financial years or during the current financial year;
 - c. has given a guarantee or provided any security in connection with the indebtedness of any third person to the listed entity, its holding, subsidiary or associate company or their promoters or directors, for such amount as may be specified during the three immediately preceding financial years or during the current financial year; or
 - d. has any other pecuniary transaction or relationship with the listed entity, its holding, subsidiary or associate company amounting to two percent or more of its gross turnover or total income: Provided that the pecuniary relationship or transaction with the listed entity, its holding, subsidiary or associate company or their promoters, or directors in relation to points (A) to (D) above shall not exceed two percent of its gross turnover or total income or fifty lakh rupees or such higher amount as may be specified from time to time, whichever is lower.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- vi. who, neither himself ["/herself], nor whose relative(s) —
 - a. holds or has held the position of key managerial personnel or is or has been an employee of the listed entity or its holding, subsidiary or associate company [or any company belonging to the promoter group of the listed entity.] in any of the three financial years immediately preceding the financial year in which he is proposed to be appointed:

[Provided that in case of a relative, who is an employee other than key managerial personnel, the restriction under this clause shall not apply for his / her employment.]
 - b. is or has been an employee or proprietor or a partner, in any of the three financial years immediately preceding the financial year in which he is proposed to be appointed, of —
 - (i) a firm of auditors or company secretaries in practice or cost auditors of the listed entity or its holding, subsidiary or associate company; or
 - (ii) any legal or a consulting firm that has or had any transaction with the listed entity, its holding, subsidiary or associate company amounting to ten per cent or more of the gross turnover of such firm;
 - c. holds together with his relatives two per cent or more of the total voting power of the listed entity; or
 - d. is a chief executive or director, by whatever name called, of any non-profit organisation that receives twenty-five per cent or more of its receipts or corpus from the listed entity, any of its promoters, directors or its holding, subsidiary or associate company or that holds two per cent or more of the total voting power of the listed entity;
 - e. is a material supplier, service provider or customer or a lessor or lessee of the listed entity;
- vii. who is not less than 21 years of age.
- viii. who is not a non-independent director of another company on the board of which any non-independent director of the listed entity is an independent director:

3.2.3 The independent Director shall abide by the "code for independent Directors "as specified in Schedule IV to the companies Act, 2013.

3.3 Other Directorships/ Committee Memberships

- 3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board's performance Accordingly, members should voluntarily limit their Directorships in other listed public limited companies in such a way that it does not interfere with their role as Director of the Company. The Nomination and Remuneration Committee shall take into account the nature of, and the time involved in a Director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.
- 3.3.2 A Director shall not serve as Director in more than 20 companies of which not more than 10 shall be public limited companies.
- 3.3.3 A Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed Company.
- 3.3.4 A Director shall not be a member in more than 10 committee or act as chairman of more than 5 committees across all companies in which he holds Directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under Section 8 of the companies Act, 2013 shall be excluded.

E. REMUNERATION POLICY FOR DIRECTORS, KEY MANAGERIAL PERSONNEL AND OTHER EMPLOYEES:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

Remuneration policy for Directors, key managerial personnel and other employees

1. Scope:

- 0.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the Directors, key managerial personnel and other employees of the Company.

2. Terms and Reference:

In this policy the following terms shall have the following meanings:

- 2.1 "Director" means a director appointed to the Board of the Company.
- 2.2 "key managerial personnel" means
- (i) The Chief Executive Officer or the managing Director or the manager;
 - (ii) The Company Secretary;
 - (iii) The Whole-time Director;
 - (iv) The Chief Financial Officer; and
 - (v) Such other office as may be prescribed under the companies Act, 2013
- 2.3 "Nomination and Remuneration committee" means the committee constituted by Board in accordance with the provisions of Section 178 of the companies Act, 2013, clause 49 of the Equity Listing Agreement and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

- 3.1 Remuneration to Executive Director and key managerial personnel
- 3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR)
- 3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the Company.
- 3.1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:
- (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Stock Options
 - (iv) Commission (Applicable in case of Executive Directors)
 - (v) Retrial benefits
 - (vi) Annual performance Bonus
- 3.1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.
- 3.2 Remuneration to Non – Executive Directors
- 3.2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders as per the provisions of the Companies Act.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

3.3. Remuneration to other employees

3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

F. OTHER DIRECTORSHIPS/ COMMITTEE MEMBERSHIPS:

- i. The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance. Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the company. The NR Committee shall take into account the nature of and the time involved in a director's service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.
- ii. Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.
- iii. Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.
- iv. Director shall not be a member in more than 10 committees or act as chairman of more than 5 committees across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded.

5. STAKEHOLDER'S RELATIONSHIP COMMITTEE:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The Committee's role includes:

- i. Resolving the grievances of the security holders of the Company including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc;
- ii. Review of measures taken for effective exercise of voting rights by shareholders;
- iii. Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;
- iv. Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company;
- v. Such other matter as may be specified by the Board from time to time.
- vi. Authority to review / investigate into any matter covered by Section 178 of the Companies Act, 2013 and matters specified in Part D of Schedule II of the Listing Regulations.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

There was one (1) Stakeholders' relationship Committee Meeting held during the year and it was held on 11.02.2026

Name	Designation	Category	No of Meetings held during the tenure	No. of meeting attended
*Mr. G. Bhanu Prakash	Chairman	ID	0	0
**Mr. Gollapinwi Mallikarjuna	Chairman	ID	1	1
Mr. K. Krishna Kishore	Member	ED	1	1
Mr. B. Suryaprakasa Rao	Member	ID	1	1
Mr. Divakar Atluri	Member	NED	1	1

*Retired w.e.f. 29.09.2025

**Appointed w.e.f. 01.10.2025

ID: Independent Director

NED: Non-Executive Director

ED: Executive Director

C. DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2025-26:

Opening balance	Received during the year	Resolved during the year	Closing balance
00	00	00	00

D. NAME AND DESIGNATION OF COMPLIANCE OFFICER:

Mr. Krishna Sainadh Kodati, Company Secretary is the Compliance Officer of the Company.

6. CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:

The Committee comprises of Directors including two Independent Directors as constituted by the Board to:

- Formulate and recommend to the Board, a Corporate Social Responsibility Policy which shall indicate the activities to be undertaken by the Company as specified in Schedule VII of the Act;
- Recommend the amount of expenditure to be incurred on the activities referred to in clause (a); and
- Monitor the Corporate Social Responsibility Policy of the Company from time to time.

The CSR Policy is uploaded on the Company's website as required under the provisions of Section 135 of the Act and Rule 9 of the Companies (Corporate Social Responsibility Policy) Rules, 2014.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

No Meetings were held during the Financial Year 2025-26.

Name	Designation	Category
Dr. G.V. Subbarao	Chairperson	Independent Director
Mr. K. Krishna Kishore	Member	Managing Director
Mr. B. Suryaprakasa Rao	Member	Independent Director
Mr. Divakar Atluri	Member	Non- Executive Director

7. RISK MANAGEMENT COMMITTEE: -

BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The Committee's role includes:

The role of the committee shall, inter alia, include the following:

- (1) To formulate a detailed risk management policy which shall include:
 - (a) A framework for identification of internal and external risks specifically faced by the listed entity, in particular including financial, operational, sectoral, sustainability, information, cyber security risks or any other risk as may be determined by the Committee.
 - (b) Measures for risk mitigation including systems and processes for internal control of identified risks.
 - (c) Business continuity plan.
- (2) To ensure that appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with the business of the Company;
- (3) To monitor and oversee implementation of the risk management policy, including evaluating the adequacy of risk management systems;
- (4) To periodically review the risk management policy, at least once in two years, including by considering the changing industry dynamics and evolving complexity;
- (5) To keep the board of directors informed about the nature and content of its discussions, recommendations and actions to be taken;
- (6) The appointment, removal and terms of remuneration of the Chief Risk Officer (if any) shall be subject to review by the Risk Management Committee.

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

No Meetings were held during the Financial Year 2025-26.

Name	Designation	Category
*Mr. T. Ravi Babu	Chairman	NED
**Mr. Divakar Atluri	Chairman	NED
Mr. K. Krishna Kishore	Member	ED
Mr. B. Suryaprakasa Rao	Member	ID
#Mr. G. Bhanu Prakash	Member	ID
**Mr. Gollapinwi Mallikarjuna	Member	ID

* Resigned w.e.f. 14.08.2025

#Retired w.e.f. 29.09.2025

**Appointed w.e.f. 15.10.2025

- Continually obtaining reasonable assurance from management that all known and emerging risks have been identified and mitigated or managed.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

8. PARTICULARS OF SENIOR MANAGEMENT INCLUDING THE CHANGES THEREIN SINCE THE CLOSE OF THE PREVIOUS FINANCIAL YEAR:

S. No	Name	Designation	Appointment Date	Resignation date
1.	Mrs. Snigdha Mothukuri	Chief Executive Officer	02-04-2018	--
2.	Mr. Srinivas Reddy Maram	Chief Executive Officer	08-11-2024	--
3.	Mr. R. Venkateswara Rao	Chief Financial Officer	02-12-2005	--
4.	Mr. Chakrapani Majumdar	Chief Operating Officer	03-08-2022	31-05-2025
5.	Mr. Y. K. Naidu	Vice President Operations	30-10-2014	--
6.	Mr. Sharad Chandra	Assistant Vice President HR	20-03-2024	--
7.	Mr. Kiran Prasad Kumar	Manager	06-10-2022	--
8.	Mr. Sunku Kashinath	General Manager	21-09-2022	--
9.	Mr. Krishna Sainadh Kodati	Company Secretary	05-04-2024	--
10.	Mr. K Someswara Rao	Vice -President	05-01-2022	30-04-2025
11.	Mr. Raju Munavath	Manager	01-07-2016	--
12.	Mrs. Swathi Marri	Manager	01-08-2017	--
13.	Mr. Suryanarayana K	Assistant General Manager	24-09-2018	--
14.	Mr. Naresh Chandra Thammareddy	Manger Vendor Management	01-10-2020	--
15.	Mr. Nagaraju Pothuraju	Manager	03-07-2023	--
16.	Mr. Gubbala Nagaprasad	Senior Manager	12-02-2024	08-08-2025
17.	Mr. B N M Guna Sundar	Manager	19-07-2021	--
18.	Mr. Sriramprasad Akkaladevi	Senior Manager	02-05-2022	--
19.	Mr. Chintaluri Vijaya Phani Kumar	Deputy General Manager	23-12-2024	--
20.	Mr. Suman Avula	Senior General Manager	02-04-2025	--
21.	Mr. Yogesh Janardhanrao Barde	Senior Manager	17-10-2022	28-02-2026
22.	Mr. Meghavaram Subhash	Manager	02-05-2025	--

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

23.	Mr. Manjunatha Gouda Lingaladinni	Senior Manager	19-07-2025	--
24.	Dr Bodduluri Anil Kumar	Assistant Vice President-QA	21-07-2025	--

9. REMUNERATION OF DIRECTORS:

d. PECUNIARY RELATIONSHIP OR TRANSACTIONS OF THE NON-EXECUTIVE DIRECTORS VIS-À-VIS THE LISTED COMPANY:

Mr. Jeevan Krishna Kuchipudi, Non-Executive Director, has a pecuniary relationship with the Company by virtue of holding 9,17,772 equity shares and 6,00,000 convertible warrants, and Mr. Diwakar Atluri has a pecuniary relationship with the Company by virtue of holding 2,00,000 equity shares.

e. CRITERIA FOR MAKING PAYMENTS TO NON-EXECUTIVE DIRECTORS:

Policy:

1. Remuneration to Executive Director and key managerial personnel
 - 1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the company within the overall limit approved by the shareholders.
 - 1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.
 - 1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:
 - (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Stock Options
 - (iv) Commission (Applicable in case of Executive Directors)
 - (v) Retirement benefits
 - 1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual Performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.
2. Remuneration to Non – Executive Directors
 - 2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders.
 - 2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.
3. Remuneration to other employees
 - 3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities should and individual performance.

f. REMUNERATION TO DIRECTORS PAID DURING THE FINANCIAL YEAR 2025-2026 AND OTHER DISCLOSURES:

Name of the Director	Salary (Rs)	Sitting Fees (Rs)	Number of Equity shares held as on 31.03.2025	Service Contracts	Stock Option Details	Fixed Component	Performance Based Incentive
Mr. K. Krishna Kishore	1,08,000	Nil	19,35,113	Nil	Nil	Nil	Nil
Mrs. Snigdha Mothukuri	48,00,000	Nil	78,500	Nil	Nil	Nil	Nil
Mr. T. Ravi Babu	Nil	Nil	3,90,700	Nil	Nil	Nil	Nil
Mr. G. Bhanu Prakash	Nil	35,000	Nil	Nil	Nil	Nil	Nil
Mr. Jeevan Krishna Kuchipudi	Nil	1,90,000	9,17,772	Nil	Nil	Nil	Nil
Mr. Nageswar Rao Yarlagadda	15,00,000	Nil	33,900	Nil	Nil	Nil	Nil
Mr. Suryaprakasa Rao Bommiseti	Nil	2,65,000	Nil	Nil	Nil	Nil	Nil
Mr. Venkata Subba Rao Guttikonda	Nil	3,25,000	Nil	Nil	Nil	Nil	Nil
Mr. Diwakar Atluri	Nil	3,25,000	2,00,00	Nil	Nil	Nil	Nil
Mr. Gollapinwi Mallikarjuna	Nil	1,90,000	Nil	Nil	Nil	Nil	Nil

INDEPENDENT DIRECTORS' MEETING:

As per clause 7 of the schedule IV of the Companies Act (Code for Independent Directors), a separate meeting of the Independent Directors of the Company (without the attendance of non-independent directors) was held on 11th February 2026, to discuss:

1. Evaluation of the performance of Non-Independent Directors and the Board of Directors as whole;
2. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

All the Independent Directors of the Company were present at the meeting.

As required under Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the company regularly familiarizes Independent Directors with the Company, their roles, rights, responsibilities in the company, nature of the industry in which the company operates, business model of the company etc. The details of the familiarization program are given at company's website (<http://www.jeevanscientific.com/>)

10. ANNUAL GENERAL MEETINGS:

A. LOCATION, DATE AND TIME OF LAST THREE AGMS AND SPECIAL/ORDINARY RESOLUTIONS THEREAT AS UNDER:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

10. ANNUAL GENERAL MEETINGS:

A. LOCATION, DATE AND TIME OF LAST THREE AGMS AND SPECIAL/ORDINARY RESOLUTIONS THEREAT AS UNDER:

Financial Year	Date	Time	Venue	Special Resolution Passed
2024-25	27.09.2025	10.00 A.M	Video Conferencing and Other Audio-Visual Means	Yes
2023-24	09.08.2024	10.00 A.M	Video Conferencing and Other Audio-Visual Means	Yes
2022-23	29.09.2023	10.30 A.M	Video Conferencing and Other Audio-Visual Means	Yes

B. PASSING OF RESOLUTIONS BY POSTAL BALLOT

There were no resolutions passed by the Company through Postal Ballot during the financial year 2025-26.

C. EXTRAORDINARY GENERAL MEETING

One (1) Extra-ordinary General Meeting was held on 12th November, 2025 during the Financial Year 2025-26.

D. SUSPENSION FROM TRADING

There was no suspension from trading in equity shares of the Company during the year 2025-26.

11. MEANS OF COMMUNICATION

The Company regularly intimates its financial results, audited/ limited reviewed, to the Stock Exchange, as soon as the same are taken on record/approved.

In terms of the requirements of SEBI (Listing Obligations & Disclosures Requirements), the un-audited financial results as well as audited financial results, shareholding pattern of the Company and Corporate Governance Report are electronically submitted, unless there are technical difficulties and are displayed through Corporate Filing and Dissemination System viz., on www.bseindia.com. The un-audited financial results as well as audited financial results, shareholding pattern of the Company and Report on Corporate Governance are displayed on www.bseindia.com.

All important information and official press releases are displayed on the website for the benefit of the public at large. Analysts' Reports/ Research Report, if any, are also uploaded on the website of the Company. The Company's website can be accessed at <http://www.jeevanscientific.com>.

12. GENERAL SHAREHOLDER INFORMATION:

A. ANNUAL GENERAL MEETING:

The 28th (Twenty Eighth) Annual General Meeting of the Company will be held as per the following schedule:

Day	Friday
Date	25th September, 2026
Time	10:00 A.M.
Venue	Through Video Conferencing / other audio video means

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

B. FINANCIAL YEAR AND FINANCIAL YEAR CALENDAR 2025-26 (TENTATIVE SCHEDULE)

The financial calendar (tentative) shall be as under:

Financial Year	2026-27
First Quarterly Results	On or before 14.08.2026
Second Quarterly Results	On or before 14.11.2026
Third Quarterly Results	On or before 14.02.2027
Fourth Quarterly Results	On or before 30.05.2027
Annual General Meeting for year ending 31st March, 2026	On or before 30.09.2027

C. Dividend Payment Date:

The Company has not paid any dividend during the year.

D. NAME AND ADDRESS OF STOCK EXCHANGE WHERE THE COMPANY'S SECURITIES ARE LISTED:

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001.

E. ANNUAL LISTING FEE TO STOCK EXCHANGES:

The equity shares of the Company are listed on BSE Ltd. The Company has paid the listing fees for the year 2026-2027 to BSE Limited.

F. REGISTRAR AND SHARE TRANSFER AGENTS:

CIL Securities Limited,

214, R.R Towers, C.A. Lane,

Abids, Hyderabad – 500001

Vide SEBI Regn. No. INR 000002276

G. SHARE TRANSFER SYSTEM:

The requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialised form with a depository and the transmission or transposition of securities held in physical or dematerialised form shall be effected only in dematerialised form.

Shares received for transfer by the Company or its Registrar and Share Transfer Agent in physical mode are processed and all valid transfers are approved. The share certificate(s) is/are duly transferred and dispatched within a period of 15 days from the date of receipt.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

H. DISTRIBUTION OF SHAREHOLDING AS ON 31ST MARCH, 2026:

Category	No. of Shareholders	%	No. of Shares	%
1 - 500	4063	78.26	516785	2.59
5001 - 1000	408	7.86	342325	1.72
10001- 2000	224	4.31	345773	1.74
20001- 3000	120	2.31	303476	1.52
30001- 4000	62	1.19	224411	1.13
40001 - 5000	61	1.17	287596	1.44
50001 - 10000	87	1.68	681345	3.42
100001 & above	167	3.22	17217254	86.44
Total:	5192	100.00	19918965	100.00

I. DEMATERIALISATION & LIQUIDITY OF SHARES:

Trading in Company's shares is permitted only in dematerialized form for all investors. Investors are therefore advised to open a demat account with a Depository participant of their choice to trade in dematerialized form. Shares held in demat and Physical mode as on March 31, 2026 is as follows:

Particulars	No. of Shares	% Share Capital
NSDL	82,28,946	41.31
CDSL	1,12,41,987	56.44
PHYSICAL	4,48,032	2.25
Total	1,99,18,965	100.00

To enable us to serve our investors better, we request shareholders whose shares are in the physical mode to dematerialize their shares and update their bank accounts with respective depository participants.

J. LOCATIONS & ADDRESS FOR CORRESPONDENCE:

Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Golconda Post, Hyderabad 500008

K. LIST OF ALL CREDIT RATINGS OBTAINED BY THE ENTITY ALONG WITH ANY REVISIONS THERETO DURING THE RELEVANT FINANCIAL YEAR, FOR ALL DEBT INSTRUMENTS OF SUCH ENTITY OR ANY FIXED DEPOSIT PROGRAMME OR ANY SCHEME OR PROPOSAL OF THE LISTED ENTITY INVOLVING MOBILIZATION OF FUNDS, WHETHER IN INDIA OR ABROAD

Since the Company has not issued any Debt Instruments or Fixed Deposit Programme, therefore company has not obtained any Credit Ratings during the Financial Year.

L. OUTSTANDING GLOBAL DEPOSITORY RECEIPTS OR AMERICAN DEPOSITORY RECEIPTS OR WARRANTS OR ANY CONVERTIBLE INSTRUMENTS, CONVERSION DATE AND LIKELY IMPACT ON EQUITY:

The Company has not issued these types of securities.

M. COMMODITY PRICE RISK OR FOREIGN EXCHANGE RISK AND HEDGING ACTIVITIES:

NIL Charges for Monitoring Foreign Investment Limit

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

N. BOOK CLOSURE DATE:

The date of Book Closure for the purpose of Annual General Meeting shall be from September 19, 2026 to September 25, 2026 (both days inclusive).

O. ELECTRONIC CONNECTIVITY: Demat ISIN Number: INE237B01018

P. NATIONAL SECURITIES DEPOSITORY LIMITED

Trade World, Kamala Mills Compound
Senapati Bapat Marg, Lower Parel
Mumbai – 400 013.

Q. CENTRAL DEPOSITORY SERVICES (INDIA) LIMITED

Phiroze Jeejeebhoy Towers, 28th Floor
Dalal Street, Mumbai – 400 023.

R. SHAREHOLDING PATTERN AS ON 31ST MARCH, 2026:

S. No.	CATEGORY OF SHAREHOLDER	No. of shares held	Percentage of shareholding
(A)	PROMOTER AND PROMOTER GROUP		
(1)	Indian:		
(a)	Individual	59,39,385	29.82
(b)	Others	85,200	0.43
	Sub-Total A(1) :	60,24,585	20.25
(2)	Foreign:	--	--
(a)	Individuals	--	--
	Sub-Total A(2) :	--	--
	Total A=A(1)+A(2)	60,24,585	30.25
(B)	PUBLIC SHAREHOLDING		
(1)	INSTITUTIONS:	--	--
(a)	Financial Institutions :Banks	--	--
(b)	Foreign Institutional Investors	--	--
	Sub-Total B(1) :	--	--
(2)	NON-INSTITUTIONS:		
(a)	Bodies Corporate	8,81,010	4.42
(b)	Individuals	1,11,82,320	53.14
(c)	Central Government ;State Government	--	--
	Sub-Total B(2) :	1,20,63,330	57.56
(C)	OTHERS:		
(1)	HUF	4,65,901	2.34
(2)	Employees	--	--
(3)	Clearing Members	--	--
(4)	Foreign Bodies	--	--
(5)	Foreign Nationals	5,00,000	2.51
(6)	Corporate Body - Others	--	--
(7)	NBFC	--	--
(8)	Non-Resident Indians	8,65,149	4.34
(9)	Trusts	--	--
	Sub-Total C:	18,31,050	9.19
	GRAND TOTAL (A+B+C):	1,99,18,965	100.00

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

13. OTHER DISCLOSURES:

A. DISCLOSURES ON MATERIALLY SIGNIFICANT RELATED PARTY TRANSACTIONS THAT MAY HAVE POTENTIAL CONFLICT WITH THE INTERESTS OF LISTED ENTITY AT LARGE:

There were no material significant related party transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the Senior Management which may have a potential conflict with the interest of the Company at large.

B. DETAILS OF NON-COMPLIANCE BY THE LISTED ENTITY, PENALTIES, STRICTURES IMPOSED ON THE LISTED ENTITY BY STOCK EXCHANGE(S) OR THE BOARD OR ANY STATUTORY AUTHORITY, ON ANY MATTER RELATED TO CAPITAL MARKETS, DURING THE LAST THREE YEARS:

During the year 2025-26, fine of Rs.2360/- was imposed by stock exchange for non-compliance with the constitution of Stakeholders Relationship Committee for the quarter ended September, 2025.

C. WHISTLE BLOWER POLICY:

The Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism as defined in Regulation 22 of SEBI (LODR) Regulations 2015 and in terms of Section 177 of the Companies Act, 2013.

With a view to adopt the highest ethical standards in the course of business, the Company has a whistle blower policy in place for reporting the instances of conduct which are not in conformity with the policy. Directors, employees, vendors or any person having dealings with the Company may report non-compliance to the Chairman of the Audit Committee, who reviews the report. Confidentiality is maintained of such reporting and it is ensured that the whistle blowers are not subjected to any discrimination. No person has been denied access to the Audit Committee.

D. COMPLIANCE WITH THE MANDATORY REQUIREMENTS AND ADOPTION OF THE NON-MANDATORY REQUIREMENTS OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

The Company has complied with the mandatory requirements of SEBI (LODR) Regulations, 2015 and is in the process of implementation of non-mandatory requirements.

E. WEB LINK WHERE POLICY FOR DETERMINING 'MATERIAL' SUBSIDIARIES IS DISCLOSED:

The Company does not have any material subsidiary as defined under Listing Regulations; however, the policy for determining its 'Material' Subsidiaries was formulated and the same is available on the website of the Company <http://www.jeevanscientific.com/>.

F. WEB LINK WHERE POLICY ON DEALING WITH RELATED PARTY TRANSACTIONS:

In line with the requirements of the Companies Act, 2013 and Listing Regulations, your Company has formulated a Policy on Related Party Transactions which is also available on Company's Website <https://www.jeevanscientific.com/>. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on a quarterly basis for transactions which are of repetitive nature and / or entered in the Ordinary Course of Business and are at Arm's Length. All Related Party Transactions are subjected to independent review by the statutory auditor to establish compliance with the requirements of Related Party Transactions under the Companies Act, 2013 and Listing Regulations.

G. DISCLOSURE OF COMMODITY PRICE RISKS AND COMMODITY HEDGING ACTIVITIES: Not Applicable

H. DETAILS OF UTILIZATION OF FUNDS RAISED THROUGH PREFERENTIAL ALLOTMENT OR QUALIFIED INSTITUTIONS PLACEMENT AS SPECIFIED UNDER REGULATION 32 (7A).

During the year under review, the Company has raised funds through Preferential Allotment and no deviation were observed.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The Company has allotted 40,85,000 equity shares to non-Promoters and 35,00,000 convertible warrants to promoters and non-promoters of the Company in the Board Meeting held on 02nd January, 2026. Details of Amount allocated and Amount utilized is provided below:

(Rs. In Lakhs)

S. No.	Objects of the Issue	Amount Allocated (in Rs.)	Amount Utilized as on 31.03.2026 (in Rs.)
1.	Capital Expenditure	500.00	365.73
2.	Working Capital Requirement	350.00	51.56
3.	Working Capital & Capital Expenditure for Subsidiary	500.00	177.67
4.	Acquisition of API/formulation unit(s)	1000.00	300.00
5.	General Corporate Purposes	724.00	189.04
	Total	3074.00	1084.00

I. CERTIFICATE FROM PRACTICING COMPANY SECRETARY

The Company has obtained certificate from Practicing Company Secretary that none of the Directors on the Board of the Company are debarred or disqualified from being appointed or continuing as Directors of Companies by the Board/Ministry of Corporate Affairs or any such authority. And the Certificate to this effect, duly signed by the Practicing Company Secretary is annexed as Annexure VIII to this Report.

J. RECOMMENDATIONS OF COMMITTEES

The Board has accepted and acted upon all the recommendations of the Committees.

K. TOTAL FEES FOR ALL SERVICES PAID BY THE LISTED ENTITY AND ITS SUBSIDIARIES, ON A CONSOLIDATED BASIS, TO THE STATUTORY AUDITOR

The Total Audit Fee for all services paid by the Company and its subsidiaries on a consolidated basis to the statutory auditor (s) is Rs. 2.10 Lakhs.

L. DISCLOSURE IN RELATION TO THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has established an appropriate mechanism for dealing with complaints in relation to Sexual Harassment of Women at Workplace, in accordance with its Policy on Prevention of Sexual Harassment at Workplace ('POSH') which is available on the website of the Company. There was no Complaints received during the financial year.

M. DISCLOSURE BY LISTED ENTITY AND ITS SUBSIDIARIES OF 'LOANS AND ADVANCES IN THE NATURE OF LOANS TO FIRMS/COMPANIES IN WHICH DIRECTORS ARE INTERESTED BY NAME AND AMOUNT

During the FY 2025-26 the Company has not advanced any loan to firms/companies in which directors are interested by name and amount.

N. DETAILS OF MATERIAL SUBSIDIARIES OF THE LISTED ENTITY; INCLUDING THE DATE AND PLACE OF INCORPORATION AND THE NAME AND DATE OF APPOINTMENT OF THE STATUTORY AUDITOR(S) OF SUCH SUBSIDIARIES: NIL

14. NON-COMPLIANCE OF ANY REQUIREMENT OF CORPORATE GOVERNANCE REPORT.

The company has complied with the requirement of Corporate Governance Report of sub-para (2) to (10) of Schedule-V of the Securities Exchange Board of India (LODR) Regulations, 2015.

15. ADOPTION OF DISCRETIONARY REQUIREMENTS AS SPECIFIED IN PART E OF SCHEDULE II of SEBI (LODR) REGULATIONS, 2015.

The company has adopted discretionary requirements to the extent of Internal Auditors reporting to the Audit Committee.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

16. DISCLOSURE OF COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS SPECIFIED IN REGULATIONS 17 TO 27 AND CLAUSES (b) TO (i) OF SUB-REGULATION (2) OF REGULATION 46 ARE AS FOLLOWS:

Regulation	Particulars	Compliance Status
17	Board of Directors	yes
18	Audit Committee	yes
19	Nomination and Remuneration Committee	yes
20	Stakeholders Relationship Committee	yes
21	Risk Management Committee	NA, Company does not fall in list of top 1000 Companies as per Marker cap in BSE
22	Vigil Mechanism	yes
23	Related Party Transactions	yes
24	Corporate Governance requirements with respect to subsidiary of Listed company	NA The Subsidiary is not a material subsidiary.
25	Obligations with respect to Independent Directors	yes
26	Obligations with respect to Directors and Senior Management	yes
27	Other Corporate Governance Requirements	yes
46 (2) (b) to (i)	Website	yes

17. CODE OF CONDUCT

The Company has formulated and implemented a Code of Conduct for Board Members and Senior Management of the Company. Requisite annual affirmations of compliance with the respective Codes have been made by the Directors and Senior Management of the Company.

18. DECLARATION ON CODE OF CONDUCT FOR THE YEAR 2025-26

This is to confirm that the Board has laid down a code of conduct for all Board members and senior management personnel of the Company. The code of Conduct has also been posted on the website of the Company. It is further confirmed that all Directors and senior management personnel of the Company have affirmed compliance with the Code of Conduct of the Company for the Financial Year ended on March 31, 2026 as envisaged in Regulation 26(3) of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015.

19. MD/ CEO & CFO Certification

The Managing Director and CFO certification of the financial statements as specified in Regulation 17(8) read with Part B of Schedule II of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the Financial Year 2025-26 is provided in this Annual Report as Annexure VII.

20. RECONCILIATION OF SHARE CAPITAL:

A qualified Practicing Company Secretary carried out audit to reconcile the total admitted capital with the National Securities Depository Limited (NSDL) and the Central Depository Services (India) Limited (CDSL) and the total issued and listed capital. Reconciliation of Share Capital Audit Report confirms that the total paid up capital was in agreement with the total number of shares in physical form and the total number of dematerialized shares held with NSDL and CDSL.

21. DISCLOSURE OF PENDING CASES / INSTANCES OF NON-COMPLIANCE:

There were no non-compliances by the Company and no instances of penalties and strictures imposed on the Company by the Stock Exchanges or SEBI or any other statutory authority on any matter related to the capital market during the financial year 2025-26.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

22. COMPLIANCE WITH THE DISCRETIONARY REQUIREMENTS UNDER LISTING REGULATIONS:

The Board of Directors periodically reviewed the compliance of all applicable laws and steps taken by the Company to rectify instances of non-compliance, if any. The Company is in compliance with all mandatory requirements of Listing Regulations. In addition, the Company has also adopted the following non-mandatory requirements to the extent mentioned below:

- Audit qualifications: Company's financial statements have no qualifications.
- Reporting of Internal Auditor: The Internal Auditor of the Company directly reports to the Audit Committee on functional matters.

The Company has submitted quarterly compliance report on Corporate Governance with the Stock Exchanges, in accordance with the requirements of Regulation 27(2) (a) of the Listing Regulations.

23. DISCLOSURE OF ACCOUNTING TREATMENT:

The Company has complied with the appropriate accounting policies and has ensured that they have been applied consistently. There have been no deviations from the treatment prescribed in the Accounting Standards notified under Section 133 of the Companies Act, 2013.

24. GREEN INITIATIVE IN THE CORPORATE GOVERNANCE

As part of the green initiative process, the Company has taken an initiative of sending documents like notice calling Annual General Meeting, Corporate Governance Report, Directors Report, audited financial Statements, Auditors Report, Dividend intimations etc., by email are sent only to those shareholders whose email addresses are not registered with the Company and for bounced mail cases. Shareholders are requested to register their email id with Registrar and Share Transfer Agent/concerned depository to enable the Company to send the documents in electronic form or inform the Company, in writing, in case they wish to receive the above documents in paper mode.

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

**Place: Hyderabad
Date: 13-08-2026**

**Sd/-
Krishna Kishore Kuchipudi
Managing Director
(DIN: 00876539)**

**Sd/-
Snigdha Mothukuri
Executive Director
(DIN: 08934860)**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure II

CERTIFICATE ON CORPORATE GOVERNANCE

**TO THE MEMBERS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

We have examined the compliance of the conditions of Corporate Governance by Jeevan Scientific Technology Limited ('the Company') for the year ended on March 31, 2026, as stipulated under Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para-C, D & E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').

The compliance of the conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations for the year ended on March 31, 2026.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For Aakanksha Dubey & Co.

Sd/-

**Aakanksha Sachin Dubey
Practicing Company Secretary
C.P. No. 20064 & M. No. 49041
Peer Review Cer. No. 3363/2023
UDIN: A049041H001092875**

**Place: Hyderabad
Date: 12.08.2026**

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

1. Industry and The Drug Development Process

The drug development process involves the systematic evaluation of drug candidates to establish their safety, efficacy and quality in accordance with applicable regulatory requirements. Development of a new medicine remains a capital-intensive, complex, high-risk and time-consuming undertaking, with development timelines and costs varying materially by therapeutic area, modality, development strategy and regulatory pathway. Industry estimates indicate that successful development of a new medicine can take more than a decade and require substantial investment.

The drug development process broadly comprises pre-clinical and clinical development. During the pre-clinical stage, a drug candidate is evaluated through in-vitro and in-vivo studies, generally over a period of one to three years, to characterize its pharmacology, toxicology and suitability for advancement into human studies. Following successful completion of pre-clinical development and receipt of the requisite regulatory authorizations, the candidate progresses to clinical development.

Clinical development represents a significant component of the overall drug development lifecycle. During this stage, the candidate is evaluated in human participants, including healthy volunteers and patients with the relevant disease or condition, to establish safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy.

These trials are generally conducted in the following sequential phases, which may overlap or be combined:

- Phase I trials generally involve a limited number of participants, typically 20 to 80, and are primarily designed to assess initial safety, tolerability, pharmacokinetics, pharmacodynamics and dose-related characteristics. These studies commonly extend over approximately six months to one year, although duration varies by molecule and development programme. In therapeutic areas such as oncology, first-in-human studies may be conducted in patients rather than healthy volunteers where the mechanism or toxicity profile warrants such an approach.
- Phase II trials generally involve approximately 100 to 200 participants with the target disease or condition and are designed to generate preliminary evidence of efficacy, explore dose-response relationships and further characterize safety. These studies commonly extend over one to two years, depending on the indication and protocol design.
- Phase III trials generally enrol several hundred to several thousand participants and are designed to confirm efficacy and safety in the intended patient population. Such studies are typically multi-centre and may involve multiple countries, with duration varying materially by therapeutic area, endpoint requirements and recruitment conditions.
- Phase IV or post-approval studies are conducted after marketing authorization to further characterize the safety, effectiveness, utilization and risk-benefit profile of an approved product and may include regulatory commitments, observational studies and other evidence-generation activities.

Real-world data (RWD) and real-world evidence (RWE), generated outside conventional randomized clinical trials, are increasingly used to evaluate treatment utilization, effectiveness, safety, health outcomes and health-economic considerations. Their role is expanding across post-approval evidence generation, regulatory decision-making, market access and lifecycle management.

Markets, Industry Structure and Developments Summary

India's pharmaceutical industry remained a strategically important global manufacturing and export sector in FY2025-26. Industry estimates indicate that the Indian pharmaceutical market was approximately USD 60 billion as of March 2026, comprising approximately USD 29 billion of domestic sales and USD 31 billion of exports. Pharmaceutical exports exceeded USD 31 billion in FY2025-26 despite global pricing pressures, regulatory requirements and geopolitical and logistics-related headwinds. Current industry commentary indicates that India's earlier aspiration of reaching approximately USD 130 billion by 2030 may be challenging under the prevailing environment, with a more measured industry outlook of approximately USD 80-90 billion by

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

2030. These developments reinforce the importance of higher-value products, complex generics, biosimilars, peptides and other differentiated offerings.

The Indian Contract Research Organization (CRO) services market continues to demonstrate attractive structural growth. A 2026 market assessment estimates the Indian CRO services market at approximately USD 2.5 billion in 2026 and projects it to reach approximately USD 4.41 billion by 2030, representing a CAGR of approximately 9.9%. The market outlook is supported by increasing pharmaceutical and biotechnology R&D expenditure, greater outsourcing of clinical and drug-development activities, India's cost competitiveness, a large and diverse patient population, and strengthening regulatory and quality infrastructure.

Key growth factors include:

- Increasing complexity of clinical development and demand for specialized research, bioanalytical and evidence-generation capabilities.
- Continued policy support for pharmaceutical manufacturing, research and development, and the broader life-sciences ecosystem.
- Increasing outsourcing of research and development activities by global pharmaceutical and biotechnology companies, supported by India's scientific talent pool, cost competitiveness and diverse patient population.
- Expanding opportunities in complex generics, biologics, biosimilars and other specialized modalities, together with increasing demand for lifecycle management and post-approval services.

Taken together, these structural trends continue to support India's emergence as an important hub for global pharmaceutical development, clinical research and outsourced life-sciences services.

The global drug discovery services market is estimated at approximately USD 20.52 billion in 2025 and is projected to reach approximately USD 39.79 billion by 2030, representing a CAGR of approximately 14.4%. Growth is being supported by increased pharmaceutical and biotechnology R&D expenditure, expanding development pipelines, the growing adoption of outsourced discovery models, demand for faster lead optimization and increasing application of artificial intelligence and machine learning in target identification and drug discovery. Asia-Pacific is expected to remain an important growth region, supported by its large patient population, expanding R&D capabilities and increasing outsourcing activity.

The drug discovery services market spans small-molecule and biologic programmes. While small molecules continue to represent a substantial share of discovery activity, growth in biologics, biosimilars, peptides and other advanced modalities is increasing demand for specialized scientific, analytical and translational capabilities across the development continuum.

Continued growth in pharmaceutical and biotechnology R&D expenditure is expected to support demand for drug discovery and development services. As development programmes become more complex, sponsors increasingly require sophisticated analytical platforms, specialized scientific expertise and flexible external capacity, creating opportunities for CROs and other outsourced service providers.

The increasing strategic use of outsourced R&D enables pharmaceutical and biotechnology companies to focus internal resources on core competencies while accessing specialized capabilities, technology and capacity. Cost efficiency, access to skilled talent, scalability and the need to accelerate development timelines are expected to remain important drivers of outsourcing. The generic medicines market is also expected to expand, with current estimates placing the global market at approximately USD 480 billion in 2026 and projecting it to approach USD 720 billion by 2033. Within this environment, complex generics, biosimilars and differentiated products provide additional opportunities for specialized CRO and development-service providers.

In addition to the factors described above, several structural developments are expected to support demand for JSTL's services:

- Increased complexity in clinical development: Clinical trials are becoming progressively more complex as a result of new therapeutic modalities, more sophisticated endpoints and biomarkers, narrower patient eligibility criteria, evolving regulatory expectations, greater use of decentralized and hybrid trial approaches, and increased evidence requirements across the product lifecycle. These factors can increase recruitment complexity, operational burden, study duration and overall development costs. Consequently, sponsors are increasingly seeking experienced partners capable of delivering high-quality studies with disciplined execution, regulatory compliance and cost-effective operating models.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- Increasing importance of demonstrating the value of new therapies: As healthcare systems and other stakeholders place greater emphasis on outcomes, affordability and evidence of value, pharmaceutical companies are increasingly using real-world data and real-world evidence to support market access, lifecycle management and post-approval decision-making. The ability to translate real-world datasets into credible evidence can strengthen understanding of treatment effectiveness, safety, utilization and health-economic outcomes, thereby supporting the broader commercial and clinical value proposition of new therapies.

Company and Our Competitive Strengths

We believe JSTL is well positioned to support pharmaceutical and biotechnology companies across the drug development lifecycle, with a focus on high-quality clinical research, bioanalytical and pharmacovigilance services. Our objective is to help customers generate reliable evidence, navigate complex regulatory requirements and advance their development programmes efficiently and responsibly.

Our purpose and mission are to support the healthcare industry by enabling our customers to develop and deliver therapies that can improve patient outcomes. We pursue this objective through a comprehensive portfolio of clinical research and related services designed to improve development efficiency, maintain rigorous quality standards and create sustainable value for customers.

Our medical, scientific and clinical research expertise, combined with technology-enabled processes and knowledge of international regulatory requirements, enables us to support customers in the development of safe, effective and compliant products while seeking to reduce avoidable development time and cost.

Our clinical development services span Phase I through Phase IV and selected pre- and post-approval activities. The portfolio includes high-value bioanalytical services covering small and large molecules, as well as programmes involving generics, biosimilars and other emerging development areas. We engage with customers through integrated and tailored service models designed to address programme-specific scientific, operational and regulatory requirements.

We have developed significant expertise in the design and execution of clinical research programmes across a broad range of therapeutic areas and dosage forms. Our experience includes approximately 900 clinical studies, more than 250 bioanalytical method developments for small molecules and 10 bioanalytical method developments for large molecules, with experience across more than 250 drugs and molecules. Our ability to assess study feasibility, support specialized participant recruitment and develop fit-for-purpose regulatory and operational strategies remains an important component of our competitive positioning.

Our understanding of the drug development lifecycle has enabled us to evolve our service portfolio in line with customer requirements and industry developments. We continue to invest in experienced scientific and operational personnel, modern infrastructure, technology and quality systems to strengthen delivery capabilities and enhance our ability to support increasingly specialized development programmes. We have also successfully conducted complex clinical studies like Glucose Clamp Studies for Insulins, Orally Inhaled Nasal Drug Products – A Metered Dose Inhaler Bioequivalence Study with adequate procedures, infrastructure and execution. With the current strength and confidence we are also entering the area of Bioequivalence studies of Transdermal Patches and Niche Complex Generics to establish and position JSTL as a specialty clinical services provider.

2. Opportunities and Threats

The normalization of business activity following the pandemic, together with continued investment by domestic and international pharmaceutical companies and evolving regulatory frameworks, has supported the recovery and expansion of outsourced research services. At the same time, the industry is experiencing heightened expectations around data integrity, inspection readiness, cybersecurity, technology adoption, patient recruitment and quality management. Sustainable growth therefore requires disciplined execution, continuous strengthening of quality systems, effective regulatory compliance and the ability to adapt rapidly to changing customer and market requirements.

3. Segment-wise Performance

The business strategy of JSTL is focused on sustainable, quality-led growth, with continued emphasis on strengthening its integrated clinical research capabilities. During the Financial Year under report, the Clinical Research Services division continued to broaden and deepen its portfolio across clinical operations, bioanalytical research, clinical trials, trial management and pharmacovigilance.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

JSTL benefits from an integrated scientific and operational team with experience across multiple areas of clinical research. The Company offers a diversified portfolio including Bioavailability/Bioequivalence (BA/BE) studies, Phase I to Phase IV clinical trials and pharmacovigilance services. The technical team has experience in executing programmes across diverse therapeutic areas and in supporting requirements of multiple regulatory authorities, with approximately 18 regulatory inspections successfully completed.

a. Clinical Operations – BA/BE

BA/BE studies continue to be a core component of JSTL's service portfolio, supported by continued investment in the capability, infrastructure and operational readiness of its clinical facility. The Company's clinical pharmacology centre is designed to support a broad range of study designs and participant requirements while maintaining applicable quality and regulatory standards. Currently the facility is in 20,000 sq. ft accommodating 156 beds across 4 clinical pharmacology units with 8 special care unit beds with an addition of 24 beds to existing 132 beds and 2 special care unit beds to the previous facility with CDSCO approval. Currently we are planning to expand new clinical and bioanalytical facility with additional 100 beds across 4 clinical pharmacology units and 4 special care unit beds, additional volunteer screening areas and facility to accommodate 8-10 LCMS/MS machines which will enhance the capacity and help provide flexibility in scheduling studies as per customer demand in the current financial year to meet the flow of bioequivalence studies demand.

The facility operates in accordance with applicable statutory and regulatory requirements, including CDSCO requirements. It has successfully undergone inspections by regulators including the USFDA, WHO, UK-MHRA and CDSCO, as well as sponsor audits, supporting JSTL's focus on quality, participant safety, data integrity and reliable study execution for customers developing products for global markets.

b. Bioanalytical Research

JSTL's bioanalytical research laboratory is equipped with advanced instrumentation, including twelve (17) LC-MS/MS systems, of which two (3) are Sciex 6500+ systems, together with an ELISA reader supporting large-molecule analytical capability. These capabilities enable the laboratory to support bioanalytical activities for small molecules, complex generics, hormones, biologics, biosimilars and monoclonal antibodies, subject to study-specific requirements. The laboratory operates in accordance with applicable statutory, GLP and regulatory requirements.

The laboratory has successfully undergone regulatory inspections including USFDA, WHO, UK-MHRA and CDSCO inspections, as well as sponsor audits. JSTL combines trained scientific personnel, established analytical platforms and a dedicated research and development environment to support diverse sponsor requirements. The Company continues to evaluate additional instrumentation, capabilities and regulatory accreditations to expand its addressable international markets and strengthen its position as an integrated clinical research service provider.

c. Pathology Laboratory

JSTL operates an in-house NABL-accredited pathology laboratory supporting diagnostic and screening activities for clinical research participants. The laboratory provides a range of routine assessments, including haematology, serology, biochemistry and urinalysis, and is equipped to support the medical screening and clinical assessment requirements of applicable research programs. JSTL is planning for the expansion of the pathology laboratory into a Central Laboratory where we can offer services to global pharmaceutical companies supporting their global clinical trial programs, and specialized diagnostic services in the upcoming niche areas.

d. Clinical Trials and Trial Management

JSTL's Clinical Trials team has experience in executing clinical research programmes across multiple therapeutic areas and geographies. The team includes clinical investigators and project management professionals experienced in pharmacokinetic, pharmacodynamic and interventional research. Project management oversees technical and administrative execution, while trained clinical research professionals monitor study conduct across participating sites to support timely delivery, protocol compliance and data quality.

JSTL is also developing capabilities in Clinical Data Management, Biostatistics and Medical Writing as integrated and stand-alone services. Capability enhancement is being pursued in interventional trials, observational studies, risk-based monitoring and other evidence-generation models to broaden customer

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

engagement, improve lifecycle coverage and strengthen opportunities for cross-selling across the service portfolio.

e. Pharmacovigilance Services

JSTL has an experienced Pharmacovigilance team supporting pharmaceutical and biotechnology customers in domestic and international markets. Using established processes, technology platforms and trained personnel, the team provides services including PSURs, signal detection and management, Risk Management Plans, PADERs, PSMFs and PBRERs. The Company intends to continue strengthening this capability in response to increasing post-marketing safety and regulatory reporting requirements.

f. Other Services

JSTL is leveraging its scientific expertise, regulatory experience and established operating infrastructure to broaden its service portfolio. The organizational structure is being aligned with evolving business requirements, including the development of decentralized service lines such as Clinical Data Management, Biostatistics and Medical Writing, with the objective of improving integrated service delivery and customer responsiveness.

4. **Outlook** The outlook for FY2026–27 remains constructive for the pharmaceutical and CRO sectors, although the operating environment is increasingly shaped by regulatory complexity, pricing pressure, geopolitical developments and evolving outsourcing models. India's pharmaceutical exports exceeded USD 31 billion in FY2025–26, while exports increased 6.8% year-on-year to USD 8.1 billion in Q1 FY2026–27. These trends indicate continued underlying international demand, while also highlighting the need for Indian service providers to maintain high standards of quality, regulatory compliance, cost efficiency and differentiated scientific capabilities.
 - Strengthening its position as a full-service CRO and selectively expanding its international reach across Latin America, the Middle East and South-East Asia.
 - Deepening customer engagement and increasing cross-selling opportunities across complementary service lines.
 - Leveraging technology, automation, data analytics and digitalization to improve operating efficiency, quality oversight and compliance.
 - Expanding through its subsidiary, Nayas Laboratories, into advanced drug-delivery technologies, formulation development and polymer-based innovation.

These initiatives are intended to strengthen JSTL's competitive positioning, broaden its addressable market and create sustainable value for customers and shareholders while maintaining disciplined attention to quality, compliance and execution.

Current industry trends indicate continued growth opportunities across CRO services, including BA/BE, clinical trials and pharmacovigilance. India's CRO services market is estimated at approximately USD 1.87 billion in 2026 and is projected to reach approximately USD 3.03 billion by 2031 at a CAGR of approximately 10.2%. India's pharmacovigilance market is estimated at approximately USD 249.6 million in 2026 and is projected to reach approximately USD 409.2 million by 2033 at a CAGR of approximately 7.3%. These market dynamics provide a favourable structural backdrop for JSTL, subject to effective execution and competitive positioning.

Service portfolio diversification and expansion of the customer base continue to be pursued with emphasis on process lifecycle management, regulatory compliance and continual audit readiness. The Company is evaluating opportunities in complex generics, large molecules, biosimilars and other specialized development areas, while continuing to strengthen a process-oriented operating model and a service-led customer culture.

The Company's full-service CRO strategy is intended to provide customers with access to a broader range of end-to-end clinical research services, supporting deeper relationships, improved customer retention and cross-selling opportunities. Consistent delivery of high-quality, reliable services within agreed timelines and at competitive commercial terms remains central to the Company's growth strategy. Clinical trials and pharmacovigilance are expected to remain important areas of focus in the coming years.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

JSTL, through its subsidiary Nayas Laboratories Private Limited, has expanded its service portfolio into advanced drug-delivery technologies and formulation research, including innovative pharmaceutical polymers and specialized development platforms.

Nayas Laboratories Private Limited

Nayas aims to operate as a quality- and technology-driven independent formulation research and development organization, with a focus on drug-delivery technologies, complex generics, 505(b)(2) and Para IV development opportunities. Its facilities and technology platforms are intended to support development of differentiated formulations and globally relevant dossiers across selected dosage forms and pharmaceutical technologies.

Nayas follows an end-to-end service model extending from conceptualization through development and commercialization support. Its activities encompass drug-delivery systems, formulation development and pharmaceutical polymers, supported by scientific expertise, research capabilities and a customer-centric approach to development.

Nayas's service offerings include:

- Novel & Patentable Biomedical Polymers
- Drug Delivery Technology Platforms
- Formulation & Analytical Development
- Quality and Regulatory Services

5. Risks and Concerns

The global clinical research industry operates within a framework of ICH principles and applicable country-specific regulatory requirements. Regulatory expectations for CROs increasingly emphasize risk-based quality management, data integrity, computerized system controls, inspection readiness, cybersecurity and documented oversight of critical activities. Accordingly, CROs must continually assess emerging risks, strengthen quality systems and maintain appropriately trained personnel. Talent retention and development remain important considerations as demand increases for specialized scientific, operational, technology and regulatory capabilities.

6. Internal Control systems and their Adequacy

We maintain internal control mechanisms across key functions including finance, supply chain, Quality, Operations, Human Resources and IT. Periodic review mechanisms are used across functions to monitor performance, identify emerging issues and facilitate timely remediation. The Quality Assurance function conducts periodic audits of relevant systems and processes and tracks corrective and preventive actions. Internal financial controls are subject to the review and certification requirements applicable to the Company's statutory and internal audit framework. Our operating philosophy continues to be anchored in Quality, Integrity and Safety, supported by strong governance and accountability.

7. Financial Performance with respect to Operational Performance

Revenues – Standalone

During the year under review, the Company on a standalone basis has recorded an income of Rs.5511.90 Lakhs and profit of Rs. 182.83 Lakhs as against the income of Rs. 4423.90 and profit of Rs. 72.20 Lakhs respectively in the previous financial year ending 31.03.2025.

Revenues – Consolidated

During the year under review, the Company on a consolidated basis has recorded an income of Rs. 6250.98 Lakhs and profit of Rs. 121.15 Lakhs as against the income of Rs. 4749.62 Lakhs and profit of Rs. 4.53 Lakhs respectively in the previous financial year ending 31.03.2025.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

8. Material developments in Human Resources / Industrial Relations from, including number of people employed.

There are no material developments in Human Resources / Industrial Relations from FY 24 to FY 25.

Particulars	31 March FY 26	31 March FY 25
Staff	285	263
Workmen	--	--
Third Party	14	16
Total	299	279

9. Details of any change in Return or Net Worth as compared to the immediately previous financial year.

RATIOS:			
Particulars	2025-26	2024-25	Remarks
Current Ratio	3.10	3.07	Current assets and current liabilities grew at broadly the same rate, leaving the ratio unchanged.
Debt Equity Ratio	0.20	0.25	Equity grew faster than borrowings following the preferential allotment during the year.
Debt Service Coverage Ratio	0.35	0.22	Improvement is driven by higher earnings before interest, tax, depreciation and amortisation in the current year.
Return on Equity	2.66%	1.45%	Profit after tax more than doubled from Rs. 73.57 lakhs to 165.01 lakhs.
Inventory Turnover Ratio	42.34	44.93	Inventory grew marginally faster than revenue, a higher stock of consumables being held at the year end.
Trade Receivables Turnover Ratio	3.28	3.31	Receivables grew in line with revenue and the collection period is unchanged at about 110 days.
Trade Payable Turnover Ratio	1.28	1.56	Trade payables grew faster than credit purchases, longer credit having been availed from vendors.
Net Capital Turnover Ratio	1.57	2.16	Working capital increased following the equity issue during the year, at a faster rate than the growth in revenue.
Net Profit Ratio	3.06%	1.69%	Revenue grew by 23.7% while total expenses grew by 20.7%, improving the margin.
Return on Capital Employed	4.55%	2.79%	Increase in profit before interest and tax from Rs.180.61 lakhs to 401.71 lakhs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

10. Any other Sector Specific ratios, as applicable: Not Applicable

11. Cautionary Statement

Although we believe we have been prudent in our projections, estimates, assumptions, expectations or predictions while making certain statements, realization is dependent on various factors. Should any known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure- IV

COMPLIANCE CERTIFICATE

[Pursuant to Regulation 13 of the Securities Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021]

To,
The Members,
Jeevan Scientific Technology Limited
Hyderabad, Telangana, India

We, Aakanksha Sachin Dubey, Practicing Company Secretary, have been appointed as the Secretarial Auditor by the Board of Directors of Jeevan Scientific Technology Limited (hereinafter referred to as 'the Company'), having CIN: L72200TG1999PLC031016 and having its registered office at Plot No.1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda (Post), Hyderabad- 500008, Telangana. This certificate is issued under Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (hereinafter referred to as "the Regulations"), for the year ended 31st March, 2026.

Management Responsibility:

It is the responsibility of the Management of the Company to implement the Scheme(s) including designing, maintaining records and devising proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Verification:

The Company has implemented JSTL- ESOP Scheme 2016" viz Employee Stock Option Scheme in accordance with the Regulations and the Special Resolution(s) passed by the members at the General Meeting of the Company held on 30th September, 2016.

For the purpose of verifying the compliance of the Regulations, We have examined the following:

1. Scheme(s) received from/furnished by the Company;
2. Articles of Association of the Company;
3. Resolutions passed at the meeting of the Board of Directors;
4. Shareholders resolutions passed at the General Meeting(s)
5. Minutes of the meetings of the Nomination and Remuneration Committee;
6. Relevant Accounting Standards;
7. Detailed terms and conditions of the scheme as approved by Nomination and Remuneration Committee;
8. Exercise Price / Pricing formula;
9. Disclosure by the Board of Directors;
10. Relevant provisions of the Regulations, Companies Act, 2013 and Rules made thereunder;

As sought and made available to us and the explanations provided by the Company. Certification:

In our opinion and to the best of my knowledge and according to the verifications as considered necessary and explanations furnished to me by the Company and its Officers, We certify that the Company has implemented the "JSTL- ESOP Scheme 2016" in accordance with the applicable provisions of the Regulations and Resolution(s) of the Company in the General Meeting(s).

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Assumption & Limitation of Scope and Review:

1. Ensuring the authenticity of documents and information furnished is the responsibility of the Board of Directors of the Company.
2. Our responsibility is to give certificate based upon our examination of relevant documents and information. It is neither an audit nor an investigation.
3. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.
4. This certificate is solely for your information and it is not to be used, circulated, quoted, or otherwise referred to for any purpose other than for the Regulations.

For Aakanksha Dubey & Co.

Sd/-

**Aakanksha Sachin Dubey
Practicing Company Secretary
C.P. No. 20064 & M. No. 49041
Peer Review Cer. No. 3363/2023
UDIN: A049041H001093183**

**Place: Hyderabad
Date: 12.08.2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure- V

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis: **Not Applicable as all the Related Party Transactions have been entered into at an arm's length basis.**
2. Details of material contracts or arrangement or transactions at arm's length basis:

Sl. No.	Name(s) of the related party and nature of relationship	Nature of contracts/arrangements/transactions:	Duration of the contracts / arrangements/ transactions	Salient terms of the contracts or arrangements if any:	Value of Transaction	Date(s) of approval by the Board, if any: Approved by Audit Committee and Board Meeting in last FY:
1.	Mr. K. Krishna Kishore (Managing Director)	Remuneration	Not Applicable	As approved by the Board of Directors	1,08,00,000	06-02-2025
2.	Mrs. Snigdha (Executive Director)	Remuneration	Not Applicable	As approved by the Board of Directors	48,00,000	06-02-2025
3.	Mr. Nageswar Rao Yarlagadda (Executive Director)	Remuneration	Not Applicable	As approved by the Board of Directors	15,00,000	06-02-2025
4.	Mr. Diwakar Atluri (Non-Executive Director)	Sitting Fee	Not Applicable	As approved by the Board of Directors	1,75,000	06-02-2025
5.	Mr. Suryaprakasa Rao Bommiseti (Non-Executive Director)	Sitting Fee	Not Applicable	As approved by the Board of Directors	1,75,000	06-02-2025
6.	Mr. Venkata Subba Rao Guttikonda (Non-Executive Director)	Sitting Fee	Not Applicable	As approved by the Board of Directors	1,75,000	06-02-2025
7.	Mr. K. Jeevan Krishna Non-Executive Director)	Sitting Fee	Not Applicable	As approved by the Board of Directors	1,00,000	06-02-2025
8.	Mr. T. Ravi Babu	Sitting Fee	Not Applicable	As approved by the Board of Directors	1,00,000	06-02-2025
9.	Mr. G. Bharu Prakash	Sitting Fee	Not Applicable	As approved by the Board of Directors	1,75,000	06-02-2025

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

**Sd/-
Krishna Kishore Kuchipudi
Managing Director
(DIN: 00876539)**

**Sd/-
Snigdha Mothukuri
Executive Director
(DIN: 08934860)**

**Place: Hyderabad
Date: 13-08-2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure – VI (a)

STATEMENT SHOWING THE NAMES OF TOP TEN EMPLOYEES PURSUANT TO SEC. 197 READ WITH RULE 5 (1) (2) and (3) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

- The ratio of remuneration to each director to the median remuneration of the employees of the company for the financial year.

(Amount in INR)

Director	Total Remuneration (in Rs.)	Ratio to median remuneration
Mr. K Krishna Kishore	1,08,00,000	1:0.033
Mrs. M Snigdha	48,00,000	1:0.075
Mr. Y. Nageswara Rao	15,00,000	1:0.24

- The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.

(Amount in INR)

Name	Designation	Remuneration (in Rs.)		Increase/ (Decrease) %
		FY 2025-26	FY 2024-25	
K. Krishna Kishore	Managing Director	1,08,00,000	1,08,00,000	-
M Snigdha	Whole-time Director	48,00,000	48,00,000	-
Y. Nageswara Rao	Whole-time Director	15,00,000	15,00,000	-
K. Jeevan Krishna	Non- Executive Director	Nil	32,55,000	(100%)
Dr. Maram Srinivas Reddy,	CEO	83,75,625	31,69,200	164.28%
Mr. Venkateswara Rao Ravipati	CFO	20,48,338	2,91,667	602.28%
Krishna Sainadh Kodati	Company Secretary	12,74,381	11,05,665	11.53%

- The percentage increase in the median remuneration of employees in the financial year

(Amount in INR)

Particulars	Remuneration		Increase/ (Decrease) %
	FY 2025-26	FY 2024-25	
Median Remuneration of all the employees per annum*	3,60,000	3,03,702	18.53%

*Employees who have served for whole of the respective financial years have been considered.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

4.

Particulars	Number
The number of employees on the rolls of the company as on March 31, 2026	285

5. **Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration**

Particulars	Increase/ (Decrease) %
Average percentage increase in the remuneration of all Employees* (Other than Key Managerial Personnel)	16
Average Percentage increase in the Remuneration of Key Managerial Personnel	--

*Employees who have served for whole of the respective financial years have been considered.

6. **Affirmation that the remuneration is as per the remuneration policy of the company.**

The Company is in compliance with its remuneration policy.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure – VI (b)

Statement showing the names of the Top ten Employees in terms of Remuneration drawn (As per Rule 5 (3) Of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

Top 10 employees of the Company based on Remuneration drawn for FY 2025-26:

S. No	Name of the employees	Designation of the Employee	Remuneration per Annum (Rs.)	Nature Employment whether Contractual or otherwise	Qualification and Experience of the employee	Date of Commencement of Employment	Age	Last Employment held by such employee before joining the company	% Of Shares held	Relative of any Director
1	Dr. Maram Srinivas Reddy	CEO	9,000,000	Permanent	MSc & PhD & 26.8 Y	08.11.2024	50.11	Acclimus Biosciences	-	No
2	Kondapa Naidu Yedhupati	Senior Vice President - Operations	5,400,000	Permanent	M.Pharm & 26.3 Years	30.10.2014	54.05	Azidus Laboratories	0.30	No
3	Rapaka Daniel Vijayakar	General Manager	3,200,000	Permanent	MBA & 21.7 Years	19.12.2024	46.05	Akshar Global	-	No
4	Chintaluri Vijaya Phani Kumar	Deputy General Manager	2,950,000	Permanent	M.Pharm & 18.6 Years	23.12.2024	43.1	Lotus Labs	-	No
5	Sunku Kashinath	General Manager	2,650,000	Permanent	M.Pharm & 21s.9 Years	21.09.2022	46.02	Axis Clinicals	0.06	No
6	Sharad Chandra	AVP HR	2,877,600	Permanent	MBA & 28.4 Years	20.03.2024	54	Vimta Labs	-	No
7	Dr. Suman Avula	Sr General Manager	4,000,000	Permanent	M.Pharm, Phd & 26.3 Years	02 Apr 2025	50.1	ClinSync	-	No
8	Venkateswara Rao Ravipati	CFO	2,200,000	Permanent	MBA & 23.6 Years	02.12.2005	40.1	-	-	No
9	Shivendranath R Jha	Senior Manager	2,000,000	Permanent	B Pharm * 9.1 Years	18 Jun 2025	31.09	Veeda Clinical	0.12	No
10	Dr Anil Kumar Bodduluri	AVP	4,000,000	Permanent	M.Pharm,Phd & 23 Years	21 Jul 2025	51	Cohance Lifesciences	-	No
11	Dr Kiran Kumar VS	GM	35,00,000	Permanent	Phd & 24 Years	06 July 2026	49	VerGO	-	No

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure- VII

CEO and CFO Certification in respect of Financial Statements and Cash Flow Statement

(Pursuant to regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015
For the Financial Year ended March 31, 2026

We have reviewed the Financial Statements and the Cash Flow Statement for the year ended 31st March 2026 and we hereby certify and confirm to the best of our knowledge and belief the following:

- a. The Financial Statements and Cash Flow statement do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
- b. The Financial Statements and the Cash Flow Statement together present a true and fair view of the affairs of the Company and are in compliance with existing accounting standards, applicable laws and regulations.
- c. There are no transactions entered in to by the Company during the year ended 31st March 2026 which are fraudulent, illegal or violative of Company's Code of Conduct.
- d. We accept responsibility for establishing and maintaining internal controls for Financial Reporting and we have evaluated the effectiveness of these internal control systems of the Company pertaining to financial reporting. Deficiencies noted, if any, are discussed with the Auditors and Audit Committee, as appropriate, and suitable actions are taken to rectify the same.
- e. There have been no significant changes in the above-mentioned internal controls over financial reporting during the relevant period.
- f. That there have been no significant changes in the accounting policies during the relevant period.
- g. We have not noticed any significant fraud particularly those involving the, management or an employee having a significant role in the Company's internal control system over Financial Reporting.

Place: Hyderabad
Date: 13.08.2026

Sd/-
K. Krishna Kishore
Managing Director

Sd/-
Venkateswara Rao Ravipati
Chief Financial Officer (CFO)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure- VIII

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
Jeevan Scientific Technology Limited
Hyderabad

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Jeevan Scientific Technology Limited having CIN: L72200TG1999PLC031016 and having registered office at plot no. 1 & 2, Sai Krupa enclave Manikonda jagir, near Lanco hills, Hyderabad, Telangana - 500008 India (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2026 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of Appointment in Company
1.	Mr. Krishna Kishore Kuchipudi	00876539	02/02/1999
2.	Mr. Nageswar Rao Yarlagadda	00293474	23/06/2021
3.	Mr. Venkata Subba Rao Guttikonda	01900749	25/03/2022
4.	Mr. Suryaprakasa Rao Bommiseti	08089189	25/03/2022
5.	Mr. Jeevan Krishna Kuchipudi	08207809	02/11/2020
6.	Mrs. Snigdha Mothukuri	08934860	02/11/2020
7.	Mr. Divakar Atluri	00033386	14/08/2023
8.	Mr. Gollapinwi Mallikarjuna	11189083	14/08/2025

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Aakanksha Dubey & Co.

Sd/-
Aakanksha Sachin Dubey
Practicing Company Secretary
C.P. No. 20064 & M. No. 49041
Peer Review Cer. No. 3363/2023
UDIN: A049041H001092776

Place: Hyderabad
Date: 12.08.2026

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure- IX

Form AOC - 1

Statement containing salient features of the financial statements of Subsidiaries and Associates

(Pursuant to proviso to sub-section (3) of section 129 read with Rule 5 of the Companies (Accounts) Rules, 2014)

1. Name of the Subsidiary: Nayas Laboratories Private Limited
2. The date since when subsidiary was acquired: 30.01.2023
3. Reporting Period: 01.04.2025 to 31.03.2026
4. Reporting Currency: Indian Rupee

Amount In Rupees

Sl. No.	Particulars	Nayas Laboratories Private Limited
1.	Share Capital	3,37,50,000
2.	Reserves and surplus	1,70,76,080
3.	Total Assets	15,89,70,278
4.	Total Liabilities	15,89,70,278
5.	Investments	Nil
6.	Turnover	7,67,52,484
7.	Profit / loss before Taxation	(53,21,198)
8.	Provision for Taxation	Nil
9.	Profit / loss after Taxation	(60,14,893)
10.	Proposed Dividend	Nil
11.	% of Shareholding	59.26

The following information shall be furnished at the end of the statement:

1. Names of Subsidiaries which are yet to commence operation: None
2. Names of subsidiaries which have been liquidated or sold during the year: None

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1. Name of the Associate: **NAYA PHARMA PRIVATE LIMITED**
2. The date since when subsidiary was acquired: 07.01.2026
3. Reporting Period: 01.04.2025 to 31.03.2026
4. Reporting Currency: Indian Rupee

Amount In Rupees

Sl. No.	Particulars	NAYA PHARMA PRIVATE LIMITED
1.	Share Capital	5,31,71,980
2.	Reserves and surplus	1,19,58,544
3.	Total Assets	7,67,38,327
4.	Total Liabilities	7,67,38,327
5.	Investments	Nil
6.	Turnover	Nil
7.	Profit / loss before Taxation	(4,92,523)
8.	Provision for Taxation	Nil
9.	Profit / loss after Taxation	(4,92,523)
10.	Proposed Dividend	Nil
11.	% of Shareholding	31.03

The following information shall be furnished at the end of the statement:

1. Names of Subsidiaries which are yet to commence operation: None
2. Names of subsidiaries which have been liquidated or sold during the year: None

Declaration on Code of Conduct as required by Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, Krishna Kishore Kuchipudi, Managing Director of the Company hereby declare that all the members of Board of Directors and Senior Management Personnel have affirmed compliance with Code of Conduct, as applicable to them, in respect of the financial year 2025-26.

For Jeevan Scientific Technology Limited

Sd/-
Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

Place: Hyderabad
Date: 13.08.2026

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

INDEPENDENT AUDITORS REPORT

To the members of,

M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED ("the Company"), which comprise the Balance Sheet as at March 31, 2026, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of material accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026 and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing ("SA's") specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below as key audit matters to be communicated in our report.

Key Audit Matter	Auditor's Response
Revenue Recognition Revenue is recognized to the extent that economic benefit will flow to the Company and the revenue can be reliably measured. It is measured at fair value consideration received or receivable, net of returns and allowances, discounts and rebates. The Company recognizes revenue when it satisfies its performance obligation by transferring the services to the customers. Revenue is key driver of the business and judgment is involved in determining when contractual obligations have been performed and to the extent that the right to consideration has been earned.	Principal audit procedures performed included the following: • We understood business revenue recognition policy and how they are applied, including the relevant controls, and tested controls over revenue recognition; • Analytical review of the revenue recognized over the year • Agreeing on a sample basis amounts of revenue to customer contracts and verifying the extent, timing and customer acceptance of services, where relevant. • We performed cut-off testing for a sample of

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The management of the Company focuses on revenue as a key performance measure which could create an incentive for revenue to be recognized before the risks and rewards have been transferred. We therefore identified Revenue Recognition as a significant risk and key audit matter.	revenue transactions around the period end date, to check that they were recognized in the appropriate period; • We discussed key contractual arrangements with management and obtained relevant documentation, including in respect of rebate and returns arrangements. • The Company's accounting policy on Revenue recognition is shown in note 2.16 to the financial statements and related disclosures are included in notes. • Based on our audit procedures we did not identify any evidence of material misstatement in the revenue recognized for the year ended 31st March 2026 in the standalone financial statements.
--	--

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon. The Management Discussion and Analysis, Board's report including annexures to Board's report, Report on Corporate Governance is expected to be made available to us after the date of this auditor's report.

- Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- When we read the Management Discussion and Analysis, Board's report including annexures to Board's report, Report on Corporate Governance if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance as required under SA 720 'The Auditor's responsibilities Relating to Other Information'.

Management's and Board of Directors Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, including other comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken based on these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c. The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
 - d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.
 - e. On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to standalone financial statements.
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
 - h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us :
 - i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there are for material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the to the Investor Education and Protection Fund by the Company.
 - iv.
 - (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- v. The company has not declared or paid any dividend during the year.
- vi. Based on our examination, which included test checks, the Company has used an accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.
- 2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

**For PAVULURI & Co.
Chartered Accountants
Firm Reg. No: 012194S**

**Sd/-
(CA N RAJESH)
PARTNER
M.No: F-223169
UDIN # 26223169ERAPOJ4197**

**Place : Hyderabad
Date: 29.05.2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure "A" to the Independent Auditor's Report

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Company") as of March 31, 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's and Board of Directors Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Inherent Limitations of Internal Financial Controls with reference to standalone financial statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For PAVULURI & Co.
Chartered Accountants
Firm Reg. No: 012194S**

**Sd/-
(CA N RAJESH)
PARTNER
M.No: F-223169
UDIN # 26223169ERAPOJ4197**

**Place : Hyderabad
Date: 29.05.2026**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

ANNEXURE 'B' TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of the company of even date)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:
 - (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment, Capital Work In Progress and relevant details of Right of use Assets.
 - (B) The Company has maintained proper records showing full particulars of intangible assets.
 - (b) The Company has a program of physical verification of Property, Plant and Equipment and Capital Work In Progress so as to cover all the assets once every three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were due for verification during the year and were physically verified by the Management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
 - (c) Based on our examination of the property tax receipts, registered sale deed / transfer deed / conveyance deed provided to us, we report that, the title in respect of all immovable properties disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.
 - (d) The Company has not revalued any of its Property, Plant and Equipment (including right-of-use assets) and intangible assets during the year.
 - (e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2026 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. (a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventory.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the company with such banks are in agreement with the books of account of the Company.
- iii. (a) The Company has made investments in, and granted loans and advances in the nature of loans to, its subsidiary and its associate during the year. It has also given a guarantee to a bank on behalf of its subsidiary. The aggregate amounts are as follows.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Particulars	Guarantees	Security	Loans	Advances in the nature of loans
Aggregate amount granted or provided during the year – subsidiary	Nil	Nil	481.54	Nil
Aggregate amount granted or provided during the year – associate	Nil	Nil	57.02	Nil
Balance outstanding at the balance sheet date – subsidiary	740.00	Nil	599.26	Nil
Balance outstanding at the balance sheet date – associate	Nil	Nil	57.02	Nil

- (b) In our opinion, the investments made and the guarantee provided during the year, and the terms and conditions of the grant of loans, are not prejudicial to the Company's interest.
- (c) In respect of the loans granted, no schedule of repayment has been stipulated
- (d) There is no amount overdue for more than ninety days in respect of the loans granted.
- (e) No loan granted has fallen due during the year and been renewed or extended, or settled by fresh loans granted to the same parties.
- (f) The Company has granted loan which is repayable on demand or without specifying any terms or period of repayment in the following cases.

Name of the related party	Nature of relationship	Aggregate amount given during the year Rs in Lakhs	Percentage to total loans
Nayas Laboratories Pvt Ltd	Subsidiary	481.54	89.41%
Naya Pharma Pvt Ltd	Associate	57.02	10.59%

- iv. According to the information and explanations given to us and on the basis of our examination of the records of the company, The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made, guarantees, and securities provided, as applicable.
- v. The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.
- vi. The maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 for the business activities carried out by the Company. Hence, reporting under clause (vi) of the Order is not applicable to the Company.
- vii. In respect of statutory dues:
- (a) In our opinion, the Company has generally been regular in depositing undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues applicable to it with the appropriate authorities.

There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2026 for a period of more than six months from the date they became payable.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (b) According to the information and explanations given to us, the following are the disputed amounts payable relating to GST.

Name of the Statute	Nature of Dispute	Amount (lakhs)	Period to which the amount relates (Lakhs)	Forum where the dispute is pending
Goods & Services Tax Act	Interest on GST	53.21	FY 2018-19: 27.23, FY 2019-20: 19.00, FY 2020-21: 6.98	Additional Commissioner GST- Ranga Reddy

- viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- ix. (a) In our opinion, the company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.
- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.
- x. (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.
- (b) During the year the Company has made a preferential allotment of equity shares and of share warrants convertible into equity shares. In our opinion, the requirements of section 42 and section 62 of the Companies Act, 2013 have been complied with and the funds raised have been applied for the purposes for which they were raised.
- xi. (a) To the best of our knowledge, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
- (b) To the best of our knowledge, no report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
- (c) As per the information provided to us the company has not received any whistle blower complaints during the year (and up to the date of this report).
- xii. The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.
- xiii. In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.
- xiv. (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
- (b) We have considered, the internal audit reports for the year under audit, issued to the Company during the year and covering the period up to March, 2026.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- xv. In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors, and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi. (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable.
- (b) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.
- xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors of the Company during the year.
- xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx. (a) The provisions of section 135 of the Companies Act, 2013 were not applicable to the Company for the year ended 31 March 2026 and accordingly there was no amount required to be spent towards Corporate Social Responsibility. Reporting under clause 3(xx)(a) of the Order is therefore not applicable.
- (b) There is no amount remaining unspent in respect of any ongoing project as at the end of the previous financial year or as at the end of the current financial year. Accordingly, reporting under clause 3(xx)(b) of the Order is not applicable.

Place : Hyderabad
Date: 29.05.2026

For PAVULURI & Co.
Chartered Accountants
Firm Reg. No: 012194S

Sd/-
(CA N RAJESH)
PARTNER
M.No: F-223169
UDIN # 26223169ERAPOJ4197

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Statement of Standalone Audited Assets and Liabilities As at 31 March 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

	Note no.	As at 31 March 2026 Audited	As at 31 March 2025 Audited
Assets			
(1)Non-current Assets			
a) Property, plant and equipment	3	2,092.93	1,757.43
b) Other intangible assets	3	705.94	686.57
c) Right of use assets	3	292.79	427.72
d) Financial Assets			
i)Investments	4	500.00	200.00
ii)Other financial assets	10	68.94	63.17
e) Other non current assets	5	1,207.54	857.54
f) Deferred tax asset (net)	6	-	77.63
		4,868.13	4,070.06
(2)Current Assets			
a) Inventories	7	161.41	93.35
b) Financial Assets			
i) Trade receivables	8	1,853.38	1,439.09
ii) Cash and cash equivalents	9	946.79	20.59
iii)Other financial assets	10	860.05	661.80
c) Current tax assets (net)	11	609.95	338.61
d) Other current assets	12	625.56	438.01
		5,057.13	2,991.45
TOTAL ASSETS		9,925.27	7,061.51
Equity and Liabilities			
Equity			
a) Equity Share Capital	13	1,991.90	1,583.40
b) Other Equity	14	5,337.88	3,508.41
		7,329.77	5,091.81
Liabilities			
(1)Non-current Liabilities			
a) Financial liabilities			
(i) Borrowings	15	635.10	602.21
(ii) Lease liabilities	16	244.44	335.76
b) Provisions	17	73.88	55.84
c) Deferred tax Liability (net)	6	10.65	-
		964.07	993.81
(2)Current Liabilities			
a)Financial liabilities			
i) Borrowings	18	522.93	222.48
ii) Lease liabilities	16	91.32	126.86
iii) Trade payables	19		
(a) Total outstanding dues of micro and small enterprises		193.30	99.39
(b) Total Outstanding dues of creditors other than micro and small enterprises		330.83	174.08
iv) Other financial liabilities	20	126.27	106.74
b) Other current liabilities	21	319.78	232.67
c) Provisions	22	47.01	13.68
		1,631.44	975.89
TOTAL EQUITY AND LIABILITIES		9,925.28	7,061.50

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223169
UDIN: 26223169ERAPOJ4197

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00676539

Sd/-
M. Snigdha
Executive Director
DIN: 08934860

Sd/-
R. Venkateswara Rao
Chief Financial Officer

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Stand Alone Statement of Profit and Loss for the for the Year Ended 31st March, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Note No.	For Year Ended 2025-26	For Year Ended 2024-25
Income			
I. Revenue from operations	23	5,393.13	4,360.99
II. Other Income	24	118.78	62.92
III. Total revenue(I+II)		5,511.91	4,423.90
IV. Expenses			
Cost of Material consumed	25	443.27	365.10
Employee benefit expenses	26	1,799.40	1,565.30
Finance costs	27	137.77	103.56
Depreciation on Property, Plant & Equipment	3	288.73	261.79
Depreciation on Right-of-use Assets	3	128.21	119.73
Amortisation on Process Knowhow	3	148.52	147.39
Other expenses	28	2,302.09	1,783.97
Total expenses		5,247.97	4,346.86
V. Profit/ (Loss) before tax (III)-(IV)		263.94	77.05
Tax expenses			
Current Tax		44.56	12.02
Less: Mat Credit (Entitlement) / utilization		(33.91)	(12.02)
Deferred Tax		88.28	3.48
Total tax expenses		98.93	3.48
Profit / (Loss) for the period		165.01	73.57
Other Comprehensive Income			
A (i) Items that will not be reclassified to profit and loss Re-measurements of post-employment		17.82	(1.37)
(ii) Income tax relating to items that will not be reclassified to profit and loss			
B (i) Items that will be reclassified to profit and loss			
(ii) Income tax relating to items that will be reclassified to profit and loss			
Total Comprehensive Income		182.83	72.20
Earning per equity share (Face value of Rs.10/- each)			
Basic		0.98	0.47
Diluted		0.98	0.46

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223189
UDIN: 26223169ERAPQJ4197

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00876539

Sd/-
M Snigdha
Executive Director
DIN: 08934860

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Standalone Statement of changes in equity for the year ended 31 March 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

A Equity share capital

Particulars	No of Shares	Amount
Balance as at 01 April 2024	1,54,80,215	1548.02
Shares during the Year	3,53,750	35.38
Balance as at 31 March 2025	1,58,33,965	1,583.40
Shares during the Year	40,85,000	408.50
Balance as at 31 March 2026	1,99,18,965	1,991.90

B Other equity

Particulars	Reserves and Surplus					Other comprehensive income	Total other equity
	Retained earnings	Securities premium	Share-based payment reserve	Money received against share warrants	Shares forfeited reserves	Re-measurement gains/ (losses) on defined benefit plans	
Balance as at 1 April 2025	833.91	2,358.46	282.72	0.01	28.17	13.15	3,508.42
Profit for the year	165.01	-	-	-	-	-	165.01
Issue of equity shares on exercise of options	-	1,225.50	-	-	-	-	1,225.50
Money Received against Share Warrants	-	-	-	350.00	-	-	350.00
Share-based payment expenses	-	-	71.14	-	-	-	71.14
Re-measurement gains/ (losses) on defined benefit plans net of tax	-	-	-	-	-	17.82	17.82
Balance as at 31 March 2026	998.92	3,583.96	353.86	350.01	28.17	30.97	5,337.88
Balance as at 1 April 2024	760.34	2,037.71	499.38	0.01	28.17	14.52	3,332.13
Profit for the year	73.57	-	-	-	-	-	73.57
Share-based payment expenses	-	-	104.09	-	-	-	104.09
Transfer on Exercise of Employee Stock Options	-	320.75	(320.75)	-	-	-	-
Re-measurement gains/ (losses) on defined benefit plans net of tax	-	-	-	-	-	(1.37)	(1.37)
Balance as at 31 March 2025	833.91	2,358.46	282.72	0.01	28.17	13.15	3,508.41

Nature and purpose of reserves

Retained earnings

The balance in the Retained Earnings primarily represents the surplus after payment of dividend and transfer to reserves.

Securities premium

Securities premium is used to record the premium on issue of shares. The reserve can be utilised only for limited purposes such as issuance of bonus shares in accordance with the provisions of the Companies Act, 2013.

Re-measurement gains/ (losses) on defined benefit plans

Remeasurements of the net defined benefits plan reserve comprises the cumulative net gains/ losses on actuarial valuation of post-employment obligations.

Share-based payment reserve

Share-based payment reserve is used to recognise the value of equity-settled share-based payments provided to employees as part of their remuneration. The amounts recorded in share-based payment reserve are transferred to securities premium upon exercise of stock options and transferred to general reserve on account of stock options not exercised by employees.

Money Received against Share Warrants

The reserve represents subscription money received on share warrants which are convertible into equity shares, pending conversion.

Shares forfeited reserve

The reserve represents amounts received on shares that were subsequently forfeited. The accompanying notes are integral part of the financial statements.

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223189
UDIN: 26223169ERAPOJ4197

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00876539

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
M Snigdha
Executive Director
DIN: 08934860

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Statement of Standalone Audited Cash Flows for the Year Ended 31st March, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash flow from operating activities		
Net Profit/(loss) before tax	263.94	77.05
Adjustments for:		
Depreciation and amortisation expenses	565.45	528.91
Dividend received	(11.56)	(5.03)
Interest received	(32.14)	(41.17)
Fair value (gain)/loss on financial assets measured at amortized cost, net	(3.61)	(3.60)
Share based payments to employees	71.14	104.09
Net foreign exchange loss/(gain)	(45.38)	2.36
Finance cost	128.09	84.24
Operating profit before working capital changes	935.92	746.85
Changes in Working Capital		
Inventories	(68.07)	7.45
Trade receivables	(368.90)	(248.43)
Other Financial assets	(200.40)	(264.52)
Other assets	(435.63)	(96.03)
Trade payables	250.65	87.11
Other financial liabilities	19.54	2.64
Other liabilities	87.11	34.65
Provisions	24.63	14.11
Cash generated from operations before Tax	244.86	283.83
Taxes Paid	10.65	12.02
Net cash from operating activity	255.50	295.85
Cash flow from investing activities		
Purchase of property, plant and equipment including capital advances	(1,135.39)	(1,030.32)
Investment in Associates	(300.00)	-
Dividend Received	11.56	5.03
Interest Received	32.14	41.17
Net cash used in investing activity	(1,391.68)	(984.11)
Cash flow from financing activity		
Repayment of non current borrowings	74.85	424.17
Repayment of current borrowings	258.51	(23.41)
Interest paid	(128.09)	(84.24)
Proceeds from issuance of Equity Shares (Including Securities Premium)	1,634.00	-
Money Received against Share Warrants	350.00	-
Proceeds from issuance of Equity Shares (ESOPS Exercise)	-	35.38
Repayment of principle portion of lease liability	(126.86)	305.94
Net cash generated in financing activity	2,062.41	657.84
Net increase in cash and cash equivalents (A+B+C)	926.23	(30.43)
Cash and cash equivalents at the beginning of the year/period	20.58	51.01
Cash and cash equivalents at the end of the year/period	946.80	20.58

The above Cash Flow Statement has been prepared using indirect method.

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223169
UDIN: 26223169ERAPQJ4197

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00676539

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
M Snigdha
Executive Director
DIN: 08934860

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1. NOTES TO STANDALONE FINANCIAL STATEMENTS

DESCRIPTION OF THE COMPANY AND MATERIAL ACCOUNTING POLICIES

1.1 Company Information

The Company is a public limited company incorporated and domiciled in India, with its registered office at Plot No. 1 and 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad 500008, Telangana, India. Its equity shares are listed on the BSE Limited. The Company was incorporated on 2 February 1999 to carry on the business of clinical research and data management services, and operates as an independent clinical contract research organization offering clinical research solutions to clients across the globe.

These financial statements are authorised by the Board of Directors for issue in accordance with their resolution on 29 May 2026.

1.2 Basis of Preparation of financial Statements

a) Statement of Compliance

These Standalone financial statements of Jeevan Scientific Technology Limited have been prepared and presented in accordance with and in compliance in all material aspects, with the Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 (the "Act") read along with the Companies (Indian Accounting Standards) Rules 2015, and presentation requirements of Division II of Schedule III to the Companies Act, 2013, and as amended from time to time together with the comparative period data as at and for the year ended 31 March 2026.

These financial statements have been prepared by the Company as a going concern on the basis of relevant Ind AS that are effective at the Company's annual reporting date, 31 March 2026. These financial statements for the year ended 31 March 2026 were approved by the Company's Board of Directors on 29 May 2026.

b) Basis of measurement

The standalone financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- a) Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- b) Employee defined benefit assets/(liability) are recognized as the net total of the fair value of plan assets, plus actuarial losses, less actuarial gains and the present value of the defined benefit obligation, and
- c) Long-term borrowings are measured at amortized cost using the effective interest rate method and
- d) Right-of-use the assets are recognised at the present value of lease payments that are not paid at that date. This amount is adjusted for any lease payments made at or before the commencement date, lease incentives received and initial direct costs, incurred, if any.

2. Summary of material accounting policies

2.1 Current and noncurrent classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

All the assets and liabilities have been classified as current or noncurrent as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013 and Ind AS 1, presentation of financial statements.

An asset is classified as current when it satisfies any of the following criteria:

- a) It is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- b) It is held primarily for the purpose of being traded;
- c) It is expected to be realized within twelve months after the reporting date; or
- d) It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

All other assets are classified as non-current.

A liability is classified as current when it satisfies any of the following criteria:

- a) It is expected to be settled in the Company's normal operating cycle;
- b) It is held primarily for the purpose of being traded;
- c) It is due to be settled within twelve months after the reporting date; or
- d) The Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification

The Company classifies all other liabilities as noncurrent.

Current assets/ liabilities include the current portion of noncurrent assets/ liabilities respectively. Deferred tax assets and liabilities are always disclosed as non-current.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

2.2 Functional and presentation currency

These financial statements are presented in Indian rupees, which is also the functional currency of the Company. All the financial information presented in Indian rupees has been rounded to the nearest lakhs.

2.3 Basis of preparation – addition on rounding and comparatives

These financial statements are presented in Indian rupees, which is the Company's functional currency. All amounts have been rounded to the nearest lakh with two decimal places, except where otherwise indicated. Amounts of less than ₹500 that would otherwise round to nil are presented as "0.00". Comparative figures have been regrouped and reclassified wherever necessary to conform to the current year's presentation.

2.4 Fair value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- in the principal market for the asset or liability, or
- in the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimising the use of unobservable inputs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

All assets and liabilities for which fair value is measured or disclosed in the Ind AS financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the Ind AS financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Company's management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for sale in discontinued operations.

External valuers are involved, wherever considered necessary. For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.

This note summarizes accounting policy for fair value. Other fair value related disclosures are given in the relevant notes.

2.5 Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded by the Company at their respective functional currency spot rates at the date, the transaction first qualifies for recognition.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date. Exchange differences arising on settlement or translation of monetary items are recognised in the statement of profit and loss.

Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the initial transaction.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.

The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in other comprehensive income ("OCI") or profit or loss are also recognised in OCI or profit or loss, respectively).

2.6 Property plant and equipment:

The cost of an item of property, plant and equipment are recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Freehold land is carried at historical cost less any accumulated impairment losses.

Items of property, plant and equipment (including capital-work-in progress) are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any.

Cost includes expenditures that are directly attributable to the acquisition of the asset i.e., freight, non-refundable duties and taxes applicable, and other expenses related to acquisition and installation.

The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

Depreciation

Depreciation on items of PPE is provided on straight line basis, computed on the basis of useful lives as mentioned in Schedule II to the Companies Act, 2013. Depreciation on additions / disposals is provided on a pro-rata basis i.e. from / up to the date on which asset is ready for use / disposed-off.

The estimated useful lives are as follows:

Plant and machinery	10 years
Electrical Installations	10 years
Computers	3 years
Servers & Networks	6 years
Vehicles- Motor car	8 years
Furniture and Fixtures	10 years
Office Equipment	5 years
Building_ Commercial	30 Years
Laboratory Equipment	10 Years

The residual values, useful lives and method of depreciation are reviewed at each financial year end and adjusted prospectively, if appropriate.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part will be derecognized. The costs of repairs and maintenance are recognized in the statement of profit and loss as incurred.

Items of stores and spares that meet the definition of Property, plant and equipment are capitalized at cost, otherwise, such items are classified as inventories.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date is disclosed as capital advances under other assets. The cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress.

2.7 Intangible assets

Research and development expenses:

Expenditure on research activities is recognised in profit or loss as incurred.

Development expenditure is capitalised as part of the cost of the resulting intangible asset only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to and has sufficient resources to complete development and to use or sell the asset.

Otherwise, it is recognised in profit or loss as incurred.

Subsequent to initial recognition, development expenditure, capitalized if any, is measured at cost less accumulated amortisation and any accumulated impairment losses.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Process Knowhow:

The company continually invests in methods development in the bioanalytical laboratory, essential for supporting the business and enhancing capabilities. These proprietary methods, expected to be utilized over 7 years, are fundamental for bioanalysis in various global clinical studies. Accordingly, the company recognizes these expenses as intangible assets and amortises them over a period of 7 years.

2.8 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a. Financial assets

Initial recognition and measurement

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL);
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost, if both of the following conditions are met: (i) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and (ii) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the statement of profit and loss. The losses arising from impairment are recognised in the statement of profit and loss. This category generally applies to trade and other receivables.

Debt instrument at FVTOCI

A 'debt instrument' is classified as FVTOCI, if both of the following criteria are met: (i) The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and (ii) The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in OCI. However, the Company recognizes interest income, impairment losses and foreign exchange gain or loss in the statement of profit and loss. On de-recognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to statement of profit and loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Equity Instruments

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as FVTPL. If the Company decides to classify an equity instrument as FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to statement of profit and loss. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's balance sheet) when:

- a) The rights to receive cash flows from the asset have expired, or
- b) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Impairment of Financial Assets

The company assesses at each balance sheet date whether a financial asset or a group of financial assets is impaired.

In accordance with Ind AS 109, the company uses "Expected Credit Loss" (ECL) model, for evaluating impairment of Financial Assets other than those measured at Fair Value Through Profit and Loss (FVTPL).

Expected credit losses are measured through a loss allowance at an amount equal to:

- The 12 months expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date);
- Full lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument)

The company follows simplified approach for recognition of impairment loss allowance on trade receivables and under the simplified approach, the company does not track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECL at each reporting date right from its initial recognition. The company uses a provision matrix to determine impairment loss allowance on trade receivables. The provision matrix is based on its historically observed default rates over the expected life of trade receivable and is adjusted for forward looking estimates. At every reporting date, the historical observed default rates are updated.

For other assets, the company uses 12-month ECL to provide for impairment loss where there is no significant increase in credit risk. If there is significant increase in credit risk full lifetime ECL is used.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value i.e., loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts.

Subsequent measurement

The measurement of financial liabilities depends on their classification.

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading, unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognised in the statement of profit and loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/losses attributable to changes in own credit risk are recognized in OCI. These gains/losses are not subsequently transferred to the statement of profit and loss.

However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the statement of profit and loss.

Loans and borrowings

Borrowings is the category most relevant to the Company. After initial recognition, interest-bearing borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in the statement of profit and loss when the liabilities are derecognised as well as through the EIR amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

De-recognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Financial guarantee contracts

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issue of the guarantee. Where the guarantee is given on behalf of a subsidiary or an associate without charging a commission, the fair value at inception is treated as a capital contribution and added to the carrying amount of the investment. Subsequently, the liability is measured at the higher of the amount of the loss allowance determined in accordance with Ind AS 109 and the amount initially recognised less the cumulative amount of income recognised.

Reclassification of financial assets and liabilities

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no re-classification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a re-classification is made only if there is a change in the business model for managing those assets. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the re-classification prospectively from the re-classification date, which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

previously recognised gains, losses (including impairment gains or losses) or interest.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet, if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

2.9 Investment in Subsidiaries, Associates and Joint Ventures

Investments in subsidiaries and associates are carried at cost less any accumulated impairment losses, in accordance with the option available under Ind AS 27, Separate Financial Statements. Cost comprises the purchase price and any directly attributable costs of acquisition. Where an indication of impairment exists, the carrying amount of the investment is compared with its recoverable amount, being the higher of value in use and fair value less costs of disposal, and any impairment loss is recognised in the Statement of Profit and Loss. On disposal, the difference between the net disposal proceeds and the carrying amount is recognised in the Statement of Profit and Loss.

2.10 Derivative financial instruments and hedge accounting

The Company currently does not use derivative financial instruments, such as forward currency contracts, currency and interest rate swaps, to hedge its foreign currency risks and interest rate risks. If and when the company uses such derivative financial instruments, they will be initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Any gains or losses arising from changes in the fair value of derivatives are taken directly to the statement of profit and loss.

2.11 Cash & Cash Equivalents

Cash and bank balances comprise of cash balance in hand, in current accounts with banks, and other short-term deposits. For this purpose, "short-term" means investments having maturity of three months or less from the date of investment, and which are subject to an insignificant risk of change in value. Bank overdrafts that are repayable on demand and form an integral part of our cash management are included as a component of cash and cash equivalents for the purpose of the statement of cash flows.

2.12 Inventory

Inventories are valued at the lower of cost and net realizable value.

Inventories consisting of materials, stores and spares and loose tools are valued at cost or net realizable value by using weighted average method.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

2.13 Impairment of non-financial assets

The carrying amounts of the Company's non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment.

If any such indication exists, then the asset's recoverable amount is estimated.

For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March 31.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflow of other assets or groups of assets (the "cash-generating unit").

The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to project future cash flows after the fifth year. To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, the Company extrapolates cash flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth rate does not exceed the long-term average growth rate for the products, industries, or country in which the entity operates, or for the market in which the asset is used.

An impairment loss is recognized in the statement of profit and loss if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.

Reversal of Impairment of Assets

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

2.14 Employee benefits

Short term employee benefits

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

The Company's contributions to defined contribution plans are charged to the statement of profit and loss as and when the services are received from the employees.

Defined benefit plans

The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the advice of qualified actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market interest rates on government bonds are used. The current service cost of the defined benefit plan, recognized in the statement of profit and loss in employee benefit expense, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognized immediately in the statement of profit and loss.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions for defined benefit obligation and plan assets are recognized in OCI in the period in which they arise. When the benefits under a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in the statement of profit and loss. The Company recognizes gains or losses on the settlement of a defined benefit plan obligation when the settlement occurs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Termination benefits

Termination benefits are recognized as an expense in the statement of profit and loss when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense in the statement of profit and loss if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

Other long-term employee benefits

The Company's net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognised in the statement of profit and loss in the period in which they arise.

Compensated absences

The Company's current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilised compensated absences and utilise them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary.

Share based payments

Employees of the Company receive remuneration in the form of Share-based payments, whereby employees render services as consideration for equity instruments.

Equity-Settled Transactions The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using Black Scholes valuation model.

Options granted under the Company's scheme vest in graded tranches. Each tranche is treated as a separate grant with its own vesting period and its own fair value, and the resulting expense is recognised over the vesting period of that tranche.

That cost is recognized, together with a corresponding increase in share-based payment (SBP) reserves in equity, over the period in which the performance and/or service conditions are fulfilled in employee benefits expense. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of equity instruments that will ultimately vest. The Statement of profit and loss expense or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period and is recognized in employee benefits expense.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Company's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

2.15 Provisions, contingent liabilities and contingent assets

Provisions

A provision is recognized in the statement of profit and loss if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Contingent liabilities and contingent assets

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are not recognized in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

Onerous contracts

A provision for onerous contracts is recognised in the statement of profit and loss when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognises any impairment loss on the assets associated with that contract.

Reimbursement rights

Expected reimbursements for expenditures required to settle a provision are recognised in the statement of profit and loss only when receipt of such reimbursements is virtually certain. Such reimbursements are recognised as a separate asset in the balance sheet, with a corresponding credit to the specific expense for which the provision has been made.

2.16 Revenue recognition:

Ind AS 115 recognizes revenue on transfer of the control of goods or services, either over a period of time or at a point in time, at an amount that the entity expects to be entitled in exchange for those goods or services. In order to align with Ind AS 115, the Accounting policy on revenue recognition was reviewed and revised.

The Company primarily earns revenue from Contract research and testing services.

Revenue is recognised upon transfer of control of promised services to customers in an amount that reflects the consideration the Company expect to receive in exchange for those services.

Revenue from providing services is recognised in the accounting period in which such services are rendered. At contract inception, the Company assesses its promise to transfer services to a customer to identify separate performance obligations. The Company applies judgment to determine whether each service promised to a customer is capable of being distinct, and are distinct in the context of the contract, if not, the promised services are combined and accounted as a single performance obligation. The company allocates the arrangement consideration to separately identifiable performance obligation based on their relative stand-alone selling price or residual method.

In case of fixed-price contracts, the customer pays the fixed amount based on a payment schedule. If the services rendered by the company exceed the payment, a contract asset is recognised. If the payments exceed the services rendered, a contract liability is recognised.

Revenues in excess/short of invoicing are classified as assets/liabilities, as the case may be.

Contract balances

Contract assets. A contract asset is recognised for revenue earned from the rendering of services where the Company's right to consideration is conditional on something other than the passage of time, typically the certification of work by the customer. Contract assets are subject to impairment assessment under the expected credit loss model. Upon the right to consideration becoming unconditional, the amount is reclassified to trade receivables.

Trade receivables. A receivable is recognised when the Company's right to consideration is unconditional, that is, when only the passage of time is required before payment falls due.

Contract liabilities. A contract liability is recognised when consideration is received, or is unconditionally receivable, from a customer before the Company transfers the related services. Contract liabilities are

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

recognised as revenue when the Company performs under the contract.

2.17 Dividend and Interest Income

Dividend income is recognised in profit or loss on the date on which the company's right to receive payment is established.

Interest Income mainly comprises of interest on Margin money deposit with banks relating to bank guarantee and term deposits.

Interest income or expense is recognised using the effective interest method (EIR).

Interest is recognized using the time-proportion method, based on rates implicit in the transactions.

2.18 Borrowing Costs

Borrowing costs are interest and other costs incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset. Other borrowing costs are recognised as an expense in the period in which they are incurred.

2.19 Tax Expenses

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in Other comprehensive income.

The Company has determined that interest and penalties related to income taxes, including uncertain tax treatments, do not meet the definition of income taxes, and therefore accounted for them under Ind AS 37 Provisions, Contingent Liabilities and Contingent Assets.

Current tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity in correlation to the underlying transaction). Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions, where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities and assets are recognized for all taxable temporary differences and deductible temporary differences.

Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Deferred tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity in correlation to the underlying transaction).

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Minimum alternate tax (MAT) paid in a year is charged to the statement of profit and loss as current tax for the year. The deferred tax asset is recognised for MAT credit available only to the extent that it is probable that the Company will pay normal income tax during the specified year, i.e., the year for which MAT credit is allowed to be carried forward. In the year in which the Company recognizes MAT credit as an asset, it is created by way of credit to the statement of profit and loss and shown as part of deferred tax asset. The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent that it is no longer probable that it will pay normal tax during the specified period.

Goods and Service Tax (GST) paid on acquisition of assets or on incurring expenses

When the tax incurred on purchase of assets or services is not recoverable from the taxation authority, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable. Otherwise, expenses and assets are recognized net of the amount of taxes paid. The net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet.

2.20 Leases

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company as a lessee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities.

The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received.

Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets. If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

The right-of-use assets are also subject to impairment. Refer to the accounting policies in section of Impairment of non-financial assets.

Lease liabilities

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Variable lease payments that do not depend on an index or a rate are recognized as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is re-measured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. The Company's lease liabilities are included in Borrowings.

Short-term leases and leases of low-value assets

The Company applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered to be of low value. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.

2.21 Earnings Per Share

Basic earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the year.

The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

Diluted earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect of interest and other financing costs or income (net of attributable taxes) associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

2.22 Segment reporting

The Company is engaged in the in "Clinical "Research Services and the same constitutes a single reportable business segment as per Ind AS 108.

2.23 Share capital

Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

2.24 Cash flow statement

Cash flows are reported using the indirect method prescribed in Ind AS 7, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments, and items of income or expense associated with investing or financing cash flows. Cash flows from operating, investing and financing activities are segregated. Cash and cash equivalents for the purpose of the Statement of Cash Flows comprise cash on hand, balances in current accounts with banks and short-term deposits with an original maturity of three months or less that are readily convertible into known amounts of cash and subject to an insignificant risk of change in value.

2.25 Dividend distribution to equity holders

The Company recognises a liability to make cash distributions to its equity holders when the distribution is authorised and is no longer at the discretion of the Company. A distribution is authorised when it is approved by the shareholders in general meeting; in the case of an interim dividend, when it is approved by the Board of Directors. A corresponding amount is recognised directly in equity.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

2.26 Significant accounting judgements, estimates, and assumption

The preparation of the financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. These estimates and associated assumptions are based on historical experiences and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, the areas involving critical estimates or Judgment are:

Determining the lease term of contracts with renewal and termination options

The Company determines the lease term as the noncancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Company has several lease contracts that include extension and termination options. The Company applies judgement in evaluating whether it is reasonably certain to exercise the option to renew or terminate the lease. That is, it considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate. Furthermore, the periods covered by termination options are included as part of the lease term only when they are reasonably certain not to be exercised.

Property, plant and equipment

The depreciation of property, plant and equipment is derived on determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The useful lives and residual values of Company's assets are determined by management at the time of acquisition of asset and is reviewed periodically, including at each financial year end. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life.

Impairment of financial and non-financial assets

Significant management judgement is required to determine the amounts of impairment loss on the financial and nonfinancial assets. The calculations of impairment loss are sensitive to underlying assumptions.

Tax provisions and contingencies

Significant management judgement is required to determine the amounts of tax provisions and contingencies. Deferred tax assets are recognised for unused tax losses and MAT credit entitlements to the extent it is probable that taxable profit will be available against which these losses and credit entitlements can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Defined benefit plans

The cost of the defined benefit plan and the present value of the obligation are determined using actuarial valuation. An actuarial valuation involves various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds where remaining maturity of such bond correspond to expected term of defined benefit obligation.

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using internal valuation techniques. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments.

2.27 Standards issued but not yet effective

The Ministry of Corporate Affairs notifies new standards and amendments to existing standards under the Companies (Indian Accounting Standards) Rules from time to time. For the year ended 31 March 2026 there is no such standard or amendment which has been notified and is not yet effective that the Company expects to have a material effect on its financial statements.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note No. 3:

Property, plant and equipment

Particulars

Gross carrying value

Balance as at 01 April 2024

Additions for the year

Disposals for the year

Balance as at 31 March 2025

Gross carrying value

Balance as at 31 March 2025

Additions for the year

Disposals for the year

Balance as at 31 March 2026

Accumulated depreciation

Balance as at 01 April 2024

Depreciation charge for the year

On Disposals

Balance as at 31 March 2025

Accumulated depreciation

Balance as at 31 March 2025

Depreciation charge for the year

On Disposals

Balance as at 31 March 2026

Net carrying value

As on 31 March 2025

As on 31 March 2026

	Building	Plant & Machinery	Furniture & Fixtures	Motor Vehicles	Office & Laboratory Equipment	Computers	Books	Total
Balance as at 01 April 2024	450.03	228.42	345.28	202.00	1,996.98	249.87	0.90	3,473.48
Additions for the year	-	6.05	6.09	222.04	467.86	6.22	-	728.26
Disposals for the year	-	-	-	6.15	-	-	-	6.15
Balance as at 31 March 2025	450.03	234.47	351.37	417.89	2,464.84	256.09	0.90	4,195.99
Balance as at 31 March 2025	450.03	234.47	351.37	417.89	2,464.84	256.09	0.90	4,195.99
Additions for the year	-	4.39	9.69	0.81	627.00	7.51	-	649.40
Disposals for the year	-	-	-	0.72	-	-	-	0.72
Balance as at 31 March 2026	450.03	238.86	361.06	417.98	3,111.84	263.60	0.90	4,844.27
Accumulated depreciation								
Balance as at 01 April 2024	102.85	169.85	253.88	103.33	1,281.26	229.57	0.90	2,141.64
Depreciation charge for the year	11.67	18.00	25.86	33.86	203.94	9.32	-	302.65
On Disposals	-	-	-	6.15	-	-	-	6.15
Balance as at 31 March 2025	114.52	187.85	279.74	131.04	1,485.20	238.89	0.90	2,438.14
Accumulated depreciation								
Balance as at 31 March 2025	114.52	187.85	279.74	131.04	1,485.20	238.89	0.90	2,438.14
Depreciation charge for the year	11.67	14.32	21.52	48.10	214.42	5.79	-	313.82
On Disposals	-	-	-	0.63	-	-	-	0.63
Balance as at 31 March 2026	126.19	202.17	301.26	176.51	1,699.62	244.68	0.90	2,751.33
Net carrying value								
As on 31 March 2025	335.51	46.62	71.63	286.85	999.64	17.20	-	1,757.43
As on 31 March 2026	323.84	36.69	59.80	241.47	1,412.22	18.92	-	2,082.93

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note No. 3:
Intangible Assets

Particulars	Software	Copyrights	Process Know how	Total
Gross carrying value				
Balance as at 01 April 2024	172.50	12.04	1,292.00	1,476.54
Additions for the year	-	-	286.05	286.05
Disposals for the year	-	-	-	-
Balance as at 31 March 2025	172.50	12.04	1,578.05	1,762.59
Gross carrying value				
Balance as at 31 March 2025	172.50	12.04	1,578.05	1,762.59
Additions for the year	-	-	170.41	170.41
Disposals for the year	-	-	-	-
Balance as at 31 March 2026	172.50	12.04	1,748.46	1,933.00
Accumulated depreciation				
Balance as at 01 April 2024	161.70	12.04	749.39	923.13
Amortization charge for the year	5.50	-	147.39	152.89
On Disposals	-	-	-	-
Balance as at 31 March 2025	167.20	12.04	896.78	1,076.02
Accumulated depreciation				
Balance as at 31 March 2025	167.20	12.04	896.78	1,076.02
Amortization charge for the year	2.53	-	148.52	151.05
On Disposals	-	-	-	-
Balance as at 31 March 2026	169.73	12.04	1,045.30	1,227.07
Net carrying value				
As on 31 March 2025	5.30	-	681.27	686.57
As on 31 March 2026	2.77	-	703.16	705.94

Note No. 3:
Right-of-use assets

Particulars	Lease hold Building	Total
Gross carrying value		
Balance as at 01 April 2024	381.26	381.26
Additions for the year	423.65	423.65
Disposals for the year	11.30	11.30
Balance as at 31 March 2025	793.61	793.61
Gross carrying value		
Balance as at 31 March 2025	793.61	793.61
Additions for the year	-	-
Disposals for the year	6.72	6.72
Balance as at 31 March 2026	786.89	786.89
Accumulated Depreciation		
Amortisation for the year	246.17	246.17
Balance as at 01 April 2024	-	-
Depreciation for the year	119.73	119.73
Balance as at 31 March 2025	365.90	365.90
Accumulated Depreciation		
Amortisation for the year	365.90	365.90
Balance as at 31 March 2025	-	-
Depreciation for the year	128.21	128.21
Balance as at 31 March 2026	494.11	494.11
Net carrying value		
As on 31 March 2025	427.72	427.72
As on 31 March 2026	292.79	292.79

Notes:

Notes:

- I The title deeds of all immovable properties are held in the name of the company. The company has not revalued its property plant and equipment.
- ii. **Pledge on Property, Plant and Equipment**
Property, Plant and Equipment (Other than Vehicles) with a net carrying amount aggregating Rs.850 lakhs (March 31, 2025-Rs. 1381.77 Lakhs) are subject to aPari Passu first charge on the company's Term loans. Further, the Property, Plant and Equipment (Other than Vehicles) are subject to Pari Passu second chargeon the company's current borrowings. Also, refer notes. 15 & 18
- iii. **Hypothecation on Vehicles**
Vehicles with Net Carrying amount aggregating Rs. 206.21 Lakhs (March 31, 2025- Rs. 204.73 Lakhs) are subject to hypothecation.
- IV. During the year Depreciaion on Property, Plant & Equipment Rs.27.61 Lakhs transfer to Process Knowhow.
- V. There is no capital work in progress as at 31 March 2026 or 31 March 2025, and accordingly no ageing schedule of capital work in progress is presented.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Notes to financial statements for the Year Ended 31st Mar, 2026

(Rupees in Lakhs)

4. Non current investments

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Naya Pharma Pvt Ltd (Associate Company with 31.03% of Share Holding)	300.00	-
Nayas Laboratories Pvt Ltd (Subsidiary Company with 59.26% of Share Holding)	200.00	200.00
Total	500.00	200.00

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Investments measured at cost		
In Equity shares of subsidiary companies(20,00,000 equity shares of Rs.10/- each in of Nayas Laboratories Private Limited) fully paid-up	500.00	200.00
In Equity shares of Associated companies(16,50,165 equity shares of Rs.18.18/- each in of Naya Pharma Private Limited) fully paid-up		
	500.00	200.00
Total of investments measured at Cost		
Foot notes:		
Aggreagate value of quoted investments and market value thereof	-	-
Aggreagate value of unquoted investments	500.00	200.00

Notes:

The Company has complied with number of layers prescribed under clause 87 of Section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of layers) Rules, 2017.

The Company has invested in Naya Pharma Private Limited on 07th January, 2026

5. Other non current Assets

PARTICULARS	As on 31.03.2026	As on 31.03.2025
i) Capital Advances to related Parties	630.54	630.54
ii) Capital Advances to Others	577.00	227.00
Total	1,207.54	857.54

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

6. Deferred Tax Asset (Net)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Deferred Tax Assets	78.90	195.49
Add/Less: Deferred Tax Liabilities	(89.55)	(117.86)
Total	(10.65)	77.63

7. Inventories

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Consumables, at the lower of cost and net relisable value	161.41	93.35
Total	161.41	93.35

8. Trade receivables (Unsecured)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Considered good	1,875.08	1,439.09
Trade receivables which have significant increase in credit risk	-	-
Credit impaired	-	-
	1,875.08	1,439.09
Less: Allowances for expected credit losses	21.70	-
Total	1,853.38	1,439.09

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Ageing schedules

Trade receivables ageing schedule for the year ended 31 March 2026

PARTICULARS	Outstanding for following periods from due date of payment						Total
	Not due	Less than 6 months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	
(i) Undisputed trade receivables- considered good	-	1,518.86	42.84	7.07	36.98	269.33	1,875.08
(ii) Undisputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
(iii) Disputed trade receivables- considered good	-	-	-	-	-	-	-
(iv) Disputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
Less: Allowances for expected credit losses	-	-	-	-	-	(21.70)	(21.70)
Total trade receivables Current	-	1,518.86	42.84	7.07	36.98	247.63	1,853.38

Ageing schedules

Trade receivables ageing schedule for the year ended 31 March 2025

PARTICULARS	Outstanding for following periods from due date of payment						Total
	Not due	Less than 6 months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	
(i) Undisputed trade receivables- considered good	-	1,004.70	134.73	60.58	230.62	8.46	1,439.09
(ii) Undisputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
(iii) Disputed trade receivables- considered good	-	-	-	-	-	-	-
(iv) Disputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
Less: Allowances for expected credit losses	-	-	-	-	-	-	-
Total trade receivables Current	-	1,004.70	134.73	60.58	230.62	8.46	1,439.09

9. Cash and Cash Equivalents

PARTICULARS	As on 31.03.2025	As on 31.03.2024
Balances with Banks in current accounts	6.20	2.61
Cash on hand	40.60	17.98
In term deposits with maturity less than 3 months	900.00	-
Total	946.79	20.59

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

10. Other Financial Assets

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Interest Receivable	48.77	22.55
Loans to Subsidiaries & Associates	656.27	484.26
Other Receivables	155.00	155.00
Total	860.05	661.80
Non Current Financial Assets		
Security Deposit	68.54	62.77
Bank fixed deposits with maturity of more than 12 months	0.39	0.39
Total	68.94	63.17

11. Current Tax Assets (Net)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Tax deducted at source	564.02	326.59
MAT Credit Entitlement	45.93	12.02
Total	609.95	338.61

12. Other Current Assets

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Prepaid Expenses	63.64	50.93
Balances with Government authorities- GST	0.55	3.35
Advances to vendors	347.17	191.18
Advances to employees	34.10	39.15
Other Receivables	56.25	8.25
Unbilled Revenue (Contract Asset-Note 30)	123.84	145.15
Total	625.56	438.01

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

13. Share capital

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Authorised 2,50,00,000 equity shares of Rs.10/- each (31 March 2026: 2,50,00,000 equity Shares of Rs.10/- each)	2,500.00	2,100.00
Issued, subscribed and paid- up 1,99,18,965 (31 March, 2026) equity Shares of Rs. 10/- each fully paid-up	1,991.90	1,583.40

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

PARTICULARS	As on 31.03.2026		As on 31.03.2025	
	Number	Amount	Number	Amount
At the beginning of the period	1,58,33,965	1,583.40	1,54,80,215	1,548.02
Issued during the period	40,85,000	408.50	3,53,750.00	35.38
Outstanding at the end of the period	1,99,18,965	1,991.90	1,58,33,965	1,583.40

- b. Rights, preferences and restrictions attaching to equity shares The Company has a single class of equity shares having a par value of ₹10 per share. Each holder of equity shares is entitled to one vote per share. Any dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in the case of an interim dividend. In the event of liquidation, the equity shareholders are entitled to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to the number of equity shares held.

c. Details of shareholders holding more than 5% share in the company

PARTICULARS	As on 31.03.2026		As on 31.03.2025	
	Number of Shares	% of Share Holding	Number of Shares	% of Share Holding
Sri K. Krishna Kishore	21,35,113	10.71%	21,35,113	13.48%
Smt. K. Vanaja	15,73,800	7.90%	15,73,800	9.94%
M/s. Padmaja Private Trust	15,00,000	7.53%	-	0

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

d. Details of shares held by promoters

PARTICULARS	As on 31.03.2026		As on 31.03.2026		% Change during the year
	Number of Shares	% of Share Holding	Number of Shares	% of Share Holding	
Sri K. Krishna Kishore	21,35,113	10.71%	21,35,113	13.48%	-2.77%
Smt. K. Vanaja	15,73,800	7.90%	15,73,800	9.94%	-2.04%
K. Gopi Krishna	7,20,000	3.61%	7,20,000	4.55%	-0.94%
K. Jeevan Krishna	9,17,772	4.61%	9,17,772	5.80%	-1.19%
T. Sri Devi	1,21,000	0.61%	1,21,000	0.76%	-0.15%
Jeevan Mitra Chitfund Private Limited	85,200	0.43%	85,200	0.54%	-0.11%
T. Ravi Babu	3,93,200	1.97%	3,93,200	2.48%	-0.51%
Snigdha Mothukuri	78,500	0.39%	78,500	0.50%	-0.11%

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

14. Other equity

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Securities premium reserve		
Opening Balance	2,358.46	2,037.71
Options Exercised	1,225.50	320.75
Closing Balance	3,583.96	2,358.46
Share-based payment reserve		
Opening Balance	282.70	499.36
Addition	71.14	104.09
Options Exercised	-	(320.75)
Closing Balance	353.84	282.70
Shares forfeited reserves		
Opening Balance	20.17	20.17
Closing Balance	20.17	20.17
Retained Earnings		
Opening Balance	833.91	760.34
Options granted during the year	-	-
Profit/Loss adjusted during the year	165.01	73.57
Dividends	-	-
Closing Balance	998.92	833.91
Money received against share warrants		
Opening Balance	0.01	0.01
Current year transfer	350.00	-
Closing Balance	350.01	0.01
Other Comprehensive Income		
Opening Balance	13.15	14.52
Re-measurement gains/ (losses) on defined benefit plans	17.82	(1.37)
Closing Balance	30.97	13.15
Total	5,337.88	3,508.41

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

15. Non Current borrowings

PARTICULARS	Non Current portion		Current Portion	
	As on 31.03.2026	As on 31.03.2025	As on 31.03.2026	As on 31.03.2025
Term Loan- secured				
A) From Banks				
i) Vehicle Loans	106.24	147.57	41.30	37.82
ii) Machinery loans	498.12	364.63	106.88	73.67
iii) Covid Loan	15.75	75.00	59.16	53.92
B) Intercompany Loans	15.00	15.00	-	-
Total	635.10	602.21	207.34	165.41

Loan	Sanctioned amount	Rate of interest	Repayment	Commencing
Machinery loan – Karur Vysya Bank	420	10.25%	60 monthly instalments	28-Jun-25
Machinery loan – Karur Vysya Bank	255	9.25%	85 monthly instalments	30-Jan-26
Covid loan – Karur Vysya Bank	175	8.15%	38 monthly instalments	5-Apr-24
Car loan – HDFC Bank	30.06	8.80%	48 monthly instalments	7-Sep-23
Car loan – Mercedes-Benz Financial Services	95.15	8.78%	60 monthly instalments	5-Sep-24
Car loan – Mercedes-Benz Financial Services	81.00	8.62%	60 monthly instalments	5-Mar-25
Machinery loans and the Covid loan from Karur Vysya Bank are secured by hypothecation of the machinery and assets acquired out of the bank finance, and by a pari passu first charge on property, plant and equipment other than vehicles. Vehicle loans are secured by hypothecation of the vehicles financed. Refer note 3. There has been no default in the repayment of principal or interest on any borrowing during either year, and no borrowing has been guaranteed by a director except as disclosed in note 18.				

16. Lease liabilities

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Non-current lease liabilities	244.44	335.76
Total	244.44	335.76
Current lease liabilities	91.32	126.86
Total	91.32	126.86

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

17. Non Current Provisions

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Provision for Employee benefit- Gratuity	73.88	55.84
Total	73.88	55.84

18. Current Borrowings

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Loan repayable on Demand		
i) From Banks	315.59	57.09
ii) Current Maturity of Longterm Borrowings	207.34	165.40
Total	522.93	222.49

Notes:

The cash credit facility from Karur Vysya Bank is primarily secured by hypothecation of the entire current assets of the Company, present and future, and by a pari passu second charge on property, plant and equipment other than vehicles. It is additionally guaranteed by a director. Working capital limits in excess of Rs. 5 crores have been sanctioned on the security of current assets, and the quarterly returns filed with the bank agree with the books of account.

19. Trade Payables

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Total outstanding dues of micro and small enterprises	193.30	99.39
Total Outstanding dues of creditors other than micro and small enterprises	330.82	174.08
Total	524.12	273.47

Trade payables ageing

Trade payables ageing for the year ended 31 March 2026

PARTICULARS	Outstanding for following periods from due date of payment					Total
	Not due	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	193.30	-	-	-	193.30
(ii) Others	-	318.05	2.25	7.57	2.94	330.81
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
	-	511.35	2.25	7.57	2.94	524.11

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Trade payables ageing

Trade payables ageing for the year ended 31 March 2025

PARTICULARS	Outstanding for following periods from due date of payment					Total
	Not due	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	99.39	-	-	-	99.39
(ii) Others	-	156.39	2.25	13.28	2.16	174.08
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
	-	255.78	2.25	13.28	2.16	273.47

Dues to Micro and Small Enterprises

The information as required to be disclosed Micro and Small Enterprises under the Micro, Small and Medium Enterprises Development Act, 2006 (Act) is as given below and the information mentioned in Balance Sheet. Trade Payables dues to Micro and Small Enterprises, has been determined on the basis of information available with the Company and relied on by the auditors:

	As on 31.03.2026	As on 31.03.2025
i) Principal amount remaining unpaid as on 31st March (overdue amounts)	193.30	99.39
ii) Interest due thereon as on 31st March	Nil	Nil
iii) Interest paid by the Company in terms of Section 16 of Micro, Small and Medium Enterprises Development Act, 2006 along with the amount of payment made to the suppliers beyond the appointed day during the year.	Nil	Nil
iv) Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Act.	Nil	Nil
v) Interest accrued and remaining unpaid as at 31st March	Nil	Nil
vi) Further, interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises for the purpose of disallowance as a deductible expenditure under Section 23 of the Act.	Nil	Nil

Amount shown against dues to Micro & Small Enterprises under the head trade payables represents amount outstanding as on 31st March but not due for payment.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

20. Other Financial liabilities (Current)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Interest Payable on GST	53.21	53.21
Rent Payable	1.32	1.32
Other Payables	71.74	52.21
Total	126.27	106.74

21. Other Current Liabilities

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Statutory Dues- TDS	18.47	63.22
Statutory Dues-Professional tax	0.53	0.49
Statutory Dues-GST	16.16	0.23
Statutory Dues- Provident Fund	9.03	7.26
Statutory Dues- ESI	0.65	0.67
Salaries payable	148.30	109.88
Directors Remuneration Payable	8.50	6.98
Provision for expenses	5.54	2.19
Advance received from Customers (Contract Liability- Note 30)	11.14	3.97
Prepaid Revenue (Contract Liability- Note 30)	101.46	37.77
Total	319.78	232.67

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

22. Current Provisions

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Provision for Income Tax	44.56	12.02
Provision for Employee benefit- Gratuity	2.45	1.66
Total	47.01	13.68

23. Revenue from operations

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Clinical Research Services- Domestic	2,806.74	3,304.26
Clinical Research Services- Export	2,586.39	1,056.73
Total	5,393.13	4,360.99

Note: Disaggregation of revenue, contract balances and information about major customers are in note 30.

24. Other income

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Interest on Income Tax Refund	-	15.97
Interest from Fixed Deposits	0.41	2.81
Interest From Unsecured Loans	31.74	22.39
Interest on Lease Deposits measured at amortised cost	3.61	3.60
Miscellaneous Income	22.35	0.79
Dividend Income from Chit Fund	11.56	5.03
Profit on sale of Property, Plant & Equipment	0.14	0.75
Insurance Claims	-	10.33
Net Gain/ (Loss) on Foreign Currency Transactions and Transalation.	45.38	(2.36)
Rent Received	3.60	3.60
Total	118.78	62.92

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

25. Cost of Material Consumed

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Opening Stock	93.35	100.79
Purchases	511.33	357.66
	604.68	458.45
Less: Closing Stock	161.41	93.35
Total	443.27	365.10

26. Employees benefit expenses

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Salaries & Allowances	1,466.06	1,201.98
Staff Welfare Expenses	41.32	33.01
Gratuity	41.12	17.78
Leave encashment	8.76	4.90
Director's Remuneration	171.00	203.55
Share Based payments to employees	71.14	104.09
Total	1,799.40	1,565.30

27. Finance Cost

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Interest expense	-	-
on Lease Liabilities	36.59	34.45
on Vehicle Loans	14.67	7.30
on Cash Credit and Bill Discounting Facilities	34.72	25.52
Other borrowing cost	9.67	19.32
on Term loan from Bank	42.11	16.96
Total	137.77	103.56

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

28. Other expenses

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Rent - Short Term Leases	2.88	2.53
Electricity	121.89	98.73
Licenses & Renewals	167.52	95.15
Repairs & Maintenance	134.02	62.90
Insurance	37.18	40.96
Communication Charges	14.66	14.17
Travelling, Conveyance	75.67	73.16
Printing & Stationery	13.31	11.01
Advertisement, Publicity & Business Promotion	44.32	21.85
Sales Commission	263.48	219.16
Professional Charges	420.05	428.70
Auditors Remuneration		
: For Statutory Audit	1.50	1.50
: For Tax Audit	0.25	0.25
: For Certification	0.25	0.25
General Expenses	51.55	34.52
Office Maintenance	61.40	59.41
Director's Sitting fees	12.05	7.35
Registrar's fee	1.88	0.96
Garden Maintenance	3.96	3.40
CSR Expenses	-	5.50
BSE Listing Fee	3.25	3.25
ROC Filing Fee	3.84	0.25
Volunteer Expenses	794.62	581.85
Water Charges	0.56	0.69
Property Tax Paid	2.05	2.05
Bank charges	7.91	5.68
Loan Processing Charges	9.38	8.24
Loss on Chit	29.00	-
Allowances for expected credit losses	21.70	-
Statutory Fee	1.71	-
Interest on Income Tax	0.23	0.50
Total	2,302.09	1,783.97

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2026 | (All amounts in ₹ lakhs, unless otherwise stated)

29. Changes in liabilities arising from financing activities

For the year ended 31 March 2026

PARTICULARS	Current Borrowings	Non-current Borrowings	Lease liabilities	Total
As at 1 April 2025	222.49	602.20	462.62	1,287.31
Proceeds from borrowings during the year	558.94	107.74	-	666.68
Repayment of borrowings during the year	(258.51)	(74.84)	-	(333.35)
Interest accretion on lease liabilities	-	-	36.59	36.59
Recognition of right-of-use liability during the year	-	-	-	-
Payment of lease liability (principal and interest)	-	-	(163.45)	(163.45)
Effect of changes in foreign exchange rates	-	-	-	-
As at 31 March 2026	522.92	635.10	335.76	1,493.78

For the year ended 31 March 2025

PARTICULARS	Current Borrowings	Non-current Borrowings	Lease liabilities	Total
As at 1 April 2024	246.71	177.20	156.68	580.59
Proceeds from borrowings during the year	10.16	585.99	-	596.15
Repayment of borrowings during the year	(34.38)	(160.99)	-	(195.37)
Interest accretion on lease liabilities	-	-	34.45	34.45
Recognition of right-of-use liability during the year	-	-	423.65	423.65
Payment of lease liability (principal and interest)	-	-	(152.16)	(152.16)
As at 31 March 2025	222.49	602.20	462.62	1,287.31

30. Revenue from contracts with customers

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue from contracts with customers	-	-
Sale of services	5,393.13	4,360.99
Other operating revenue (refer note below)	-	-
Total revenue from operations	5,393.13	4,360.99

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(a) Disaggregation of revenue

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
By geography (based on location of the customer)		
Domestic (within India)	2,806.74	3,304.26
Exports (outside India)	2,586.39	1,056.73
Total	5,393.13	4,360.99
By type of service		
Clinical research and bio-analytical services	5,393.13	4,360.99
By timing of revenue recognition		
Services transferred over time	5,393.13	4,360.99
Services transferred at a point in time	–	–
Total	5,393.13	4,360.99

(b) Reconciliation of revenue recognised with contract price

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue as per contracted price	,269.29	4,223.04
Add: Unbilled revenue on account of work performed but not certified	123.84	137.95
Less: Billing in excess of contract revenue	–	–
Revenue from contracts with customers	393.13	4,360.99

(c) Contract balances

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Trade receivables (gross)	1,875.08	1,439.09
Less: allowance for expected credit losses	(21.70)	–
Trade receivables (net) – refer note 8	1,853.38	1,439.09
Contract assets – unbilled revenue (included in other current assets, note 12)	123.84	145.15
Contract liabilities – advance from customers (note 21)	11.14	3.97
Contract liabilities – revenue billed in advance (note 21)	101.46	37.77

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Contract assets represent the Company's right to consideration for work performed but not billed at the reporting date. Contract assets are transferred to trade receivables when the right becomes unconditional, which is generally on certification of work by the customer. Contract liabilities represent consideration received from customers in advance of the related performance obligation being satisfied. Revenue recognised during the year that was included in the contract liability balance at the beginning of the year: Rs. 37.77 lakhs (previous year Rs. 49.81 lakhs)

(e) Information about major customers

Ind AS 108 requires disclosure of reliance on major customers. During the year ended 31 March 2026, revenue from 2 no of customer(s) individually exceeded 10% of total revenue from operations, aggregating Rs.1,505.36 lakhs (previous year: 2 no of customer(s), Rs.1,481.26 lakhs).

31. Auditor's remuneration (excluding taxes)

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
(a) As auditor – statutory audit fees	1.50	1.50
(b) For Tax Audit	0.25	0.25
(c) For Certification	0.25	0.25
Total	2.00	2.00

32.Earning per Share

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit attributable to equity holders of the Company (₹ lakhs)	165.01	73.57
Number of equity shares at the beginning of the year	1,58,33,965	1,54,80,215
Add: equity shares issued during the year	40,85,000	3,53,750
Less: buy-back of equity shares	—	—
Number of equity shares outstanding at the end of the year	1,99,18,965	1,58,33,965
Weighted average number of equity shares – basic	1,68,30,033	1,58,33,965
Add: dilutive effect of employee stock options outstanding	-	-
Weighted average number of equity shares – diluted	1,68,30,033	1,58,33,965
Basic earnings per share (face value ₹10 each) (₹)	0.98	0.47
Diluted earnings per share (face value ₹10 each) (₹)	0.98	0.46

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

33. Income Taxes

(a) Income tax expense recognised in the Statement of Profit and Loss

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Current tax		
Current income tax charge	44.56	12.02
MAT credit (entitlement) / utilisation	(33.91)	(12.02)
Adjustment of tax relating to earlier periods	—	—
Total current tax	10.65	—
Deferred tax		
Relating to origination and reversal of temporary differences	88.28	3.48
Income tax expense reported in the Statement of Profit and Loss	98.93	3.48

(b) Income tax recognised in Other Comprehensive Income

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Re-measurement gains / (losses) on defined benefit plans	17.82	(1.37)

(c) Reconciliation of tax expense and accounting profit

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Accounting profit before income tax	263.94	77.05
Tax at India's statutory income tax rate of 26%	68.62	20.03
Effect of adjustments in respect of current income tax of previous years	—	—
Effect of items taxable separately	—	—
Effect of expenses not deductible for tax purposes		
Others	30.31	(16.55)
Total tax expense reported in the Statement of Profit and Loss	98.93	3.48
Effective income tax rate	37.48%	4.52%

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(d) Deferred tax balances

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Deferred tax liabilities		
Difference between written down value of assets as per books and as per tax laws	13.43	6.65
Right-of-use assets	76.12	111.21
Gross deferred tax liabilities	89.55	117.86
Deferred tax assets		
Post-employment benefits – gratuity	19.85	14.95
Lease liabilities	87.29	120.28
Carry forward business loss and unabsorbed depreciation	(28.24)	60.26
Allowance for expected credit losses	–	–
Gross deferred tax assets	78.90	195.49
Net deferred tax liabilities / (assets)	10.65	(77.63)

(e) MAT credit

MAT credit entitlement of Rs. 45.93 lakhs (previous year Rs.12.02 lakhs) recognised within current tax assets. The details of MAT credit is provided below.

Amount in Rs in Lakhs	Asst Year to which it relates	Last year of MAT credit Availment
33.91	2026-27	2041-42
12.02	2025-26	2040-41

34. Segment information

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, whose operating results are regularly reviewed by the Company's chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and for which discrete financial information is available. Operating segments of the Company are reported in a manner consistent with the internal reporting provided to the chief operating decision maker.

The Company has only one operating segment, namely clinical research services, which is therefore also the only reportable segment. Accordingly, no separate segment disclosures are presented.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Entity-wide disclosures

Revenue from external customers, by geography	For the year ended 31 March 2026	For the year ended 31 March 2025
India (country of domicile)	2,806.74	3,304.26
Outside India	2,586.39	1,056.73
Total	5,393.13	4,360.99

Non-current assets, by location	For the year ended 31 March 2026	For the year ended 31 March 2025
India	4,299.20	3,729.26
Outside India	—	—

Non-current assets above comprise property, plant and equipment, right-of-use assets, other intangible assets and other non-current assets, and exclude financial instruments and deferred tax assets, as permitted by Ind AS 108.33(b). All of the Company's operating facilities are located in India.

35. Employee benefits

(a) Employee benefits expense

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Salaries, wages and bonus	1,466.06	1,201.98
Gratuity	41.12	17.78
Leave encashment	8.76	4.90
Share-based payments to employees	71.14	104.09
Directors' remuneration	171.00	203.55
Staff welfare expenses	41.32	33.01
Total	1,799.40	1,565.31

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(b) Defined contribution plans

The Company makes contributions to the Employees' Provident Fund and the Employees' State Insurance Scheme, which are defined contribution plans, for qualifying employees. The Company's obligation is limited to the amount contributed and it has no further contractual or constructive obligation. The following amounts have been recognised as an expense in the Statement of Profit and Loss.

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Employer's contribution to provident fund	46.32	37.51
Employer's contribution to employees' state insurance	5.78	6.85
Total	52.10	44.36

(c) Defined benefit plan – gratuity

The Company operates a defined benefit gratuity plan for its employees. Under the plan, every employee who has completed at least five years of service is entitled to gratuity on departure at fifteen days of last drawn salary for each completed year of service.

The plan is unfunded. The Company has not established a trust and no plan assets are held; benefits are paid by the Company as and when they fall due. The plan is administered in accordance with the Payment of Gratuity Act, 1972 and the liability is determined by an independent actuary using the projected unit credit method.

Amounts recognised in the Statement of Profit and Loss and in Other Comprehensive Income

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Current service cost	20.73	14.89
Interest on net defined benefit liability	3.84	2.89
Past service cost (vested / non-vested benefits)	16.55	—
(A) Amount charged to the Statement of Profit and Loss	41.12	17.78
Actuarial (gain) / loss on the defined benefit obligation	(17.82)	1.37
(B) Amount recognised in Other Comprehensive Income	(17.82)	1.37
Total (A + B)	23.30	19.15

Net defined benefit liability recognised in the Balance Sheet

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Present value of the defined benefit obligation	76.33	57.51
Less: fair value of plan assets	—	—
Net liability recognised in the Balance Sheet	76.33	57.51
Current portion (note 22)	2.45	1.66
Non-current portion (note 17)	73.88	55.85

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Movement in the present value of the defined benefit obligation

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Defined benefit obligation at the beginning of the year	57.51	42.03
Current service cost	20.73	14.89
Interest cost	3.84	2.89
Past service cost	16.55	—
Actuarial (gain) / loss arising from changes in financial assumptions	(17.82)	1.30
Actuarial (gain) / loss arising from experience adjustments	—	0.07
Benefits paid	(4.47)	(3.67)
Defined benefit obligation at the end of the year	76.34	57.51

Principal actuarial assumptions

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Discount rate	7.62%	6.77%
Rate of increase in compensation levels	4.00%	4.00%
Employee attrition rate	3.00%	3.00%
Expected average remaining working life (years)	17.10	17.19

Sensitivity analysis

	DR- Discount Rate		ER: Salary Escalation Rate	
	PVO DR+1%	PVO DR-1%	PVO ER+1%	PVO ER-1%
PVO	68.80	85.19	85.23	68.66

Expected Payout

Year	Expected Outgo First	Expected Outgo Second	Expected Outgo Third	Expected Outgo Fourth	Expected Outgo Fifth	Expected Outgo Six to Ten Years
Payouts	2.45	2.96	3.33	3.72	4.51	37.75

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Asset Liability comparisons

Year	31-03-2022	31-03-2023	31-03-2024	31-03-2025	31-03-2026
PVO at end of period	28.47	31.96	42.03	57.51	76.33
Plan Assets	-	-	-	-	-
Surplus/ (Deficit)	(28.47)	(31.96)	(42.03)	(57.51)	(76.33)
Experience adjustments on plan assets	-	-	-	-	-

36. Related Party Transactions

(a) Names of related parties and nature of the relationship

Nature of relationship	Name of the related party
Subsidiary	Nayas Laboratories Private Limited (incorporated in India; 59.26% held by the Company)
Associate	Naya Pharma Private Limited (incorporated in India; 31.03% held by the Company; became an associate during the year ended 31 March 2026)
Key management personnel	Mr. K Krishna Kishore, Managing Director Ms. M Snigdha, Executive Director Mr. Y Nageswara Rao, Whole-time Director Mr. Maram Srinivas Reddy, Chief Executive Officer Mr. Venkateswara Rao Ravipati, Chief Financial Officer Mr. Krishna Sainadh Kodati, Company Secretary
Non-executive and independent directors	Mr. Jeevan Krishna Kuchipudi, Non-Executive Director Mr. G Mallikarjuna, Independent Director Mr. G V Subba Rao, Independent Director Mr. B Suryaprakasa Rao, Independent Director Mr. Divakar Atluri, Non-Executive Non-Independent Director Mr. G Bhanu Prakash, Independent Director (Retired on 29/09/2025)
Enterprises owned or significantly influenced by key management personnel or their relatives	Jeevana Mitra Finance Corporation Jeevan Mitra Constructions LLP (formerly Jeevana Mitra Chitfund Private Limited)
Promoters and promoter group	Mr. K Krishna Kishore, Mrs. K Vanaja, Mr. K Jeevan Krishna, Mr. K Gopi Krishna, Mr. T Ravi Babu, Mrs. T Sridevi, Ms. Snigdha Mothukuri, Jeevana Mitra Finance Corporation, Jeevan Mitra Constructions LLP

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(b) Transactions with related parties during the year

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Compensation of key management personnel		
Short-term employee benefits	287.97	216.61
Post-employment benefits	10.10	6.94
Share-based payments	-	84.82
Total compensation of key management personnel	298.07	308.37
Remuneration – individual break-up		
Mr. K Krishna Kishore	108.00	108.00
Ms. M Snigdha	48.00	48.00
Mr. Y Nageswara Rao	15.00	15.00
Mr. Maram Srinivas Reddy	83.75	31.69
Mr. Venkateswara Rao Ravipati	20.48	4.55
Mr. Krishna Sainadh Kodati	12.74	9.37
Sitting fees paid to directors		
Mr. G Bhanu Prakash	0.35	1.05
Mr. B Suryaprakasa Rao	2.65	1.95
Mr. G V Venkata Subba Rao	3.25	1.15
Mr. Divakar Atluri	3.25	1.95
Mr. K Jeevan Krishna	1.90	0.50
Mr. G Mallikarjuna	1.90	-
Transactions with the subsidiary – Nayas Laboratories Private Limited		
Investment in equity shares	-	-
Loans given during the year	481.54	349.37
Loans repaid during the year	(366.54)	-
Interest income on loans (at 7% per annum)	28.47	22.39
Corporate guarantee given / outstanding	740.00	740.00
Transactions with the associate – Naya Pharma Private Limited		
Investment in equity shares	300.00	-
Loans given during the year	57.02	-
Interest income on loans (at 11% per annum)	0.68	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(c) Outstanding balances as at the reporting date

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Rent payable		
Jeevana Mitra Finance Corporation	0.36	0.36
Mr. K Krishna Kishore	0.48	0.48
Mrs. K Vanaja	0.48	0.48
Remuneration payable		
Mr. K Krishna Kishore	3.30	3.30
Ms. M Snigdha	3.98	2.57
Mr. K Jeevan Krishna	—	—
Mr. Y Nageswara Rao	1.22	1.10
Loans receivable		
Nayas Laboratories Private Limited (subsidiary)	599.26	484.26
Naya Pharma Private Limited (associate)	57.02	—
Interest accrued on the above loans	48.77	22.55
Investments		
Nayas Laboratories Private Limited (subsidiary)	200.00	200.00
Naya Pharma Private Limited (associate)	300.00	—
Commitments and guarantees		
Corporate guarantee given to Karur Vysya Bank for facilities availed by Nayas Laboratories Private Limited	740.00	740.00

(d) Terms and conditions

Transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates. Outstanding balances at the year end are unsecured and settlement occurs in cash.

Loans given to Nayas Laboratories Private Limited of ₹599.26 lakhs (previous year ₹484.26 lakhs) and to Naya Pharma Private Limited of ₹57.02 lakhs (previous year: nil) are for business purposes and carry interest at 7% and 11% per annum respectively. The Company has given a corporate guarantee of ₹740.00 lakhs to Karur Vysya Bank in respect of loans obtained by Nayas Laboratories Private Limited. The corporate guarantee is disclosed as a contingent liability in note 45. The loans are repayable on demand.

No amounts due from related parties have been written off or provided for during the year (previous year: nil).

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

37. Transactions and balances in foreign currency

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Earnings in foreign exchange		
Export of services (FOB value)	2,586.39	1,056.73
Expenditure in foreign currency	-	-
Travel	28.26	12.27
Capital goods	604.05	477.51

38. Financial instruments – categories, fair values and fair value hierarchy

(a) Categories of financial instruments

Particulars	31 Mar 2026 Amortised cost	31 Mar 2026 FVTPL / FVTOCI	31 Mar 2025 Amortised cost	31 Mar 2025 FVTPL / FVTOCI
Financial assets				
Cash and cash equivalents	946.79	-	20.59	-
Trade receivables	1,853.38	-	1,439.09	-
Other financial assets (current and non-current)	928.99	-	724.97	-
Investments in subsidiary and associate (at cost – Ind AS 27)	500.00	-	200.00	-
Financial liabilities				
Borrowings (current and non-current)	1,158.03	-	824.70	-
Lease liabilities	335.76	-	462.62	-
Trade payables	524.12	-	273.47	-
Other financial liabilities	126.27	-	106.74	-

(b) Fair values of financial assets and liabilities

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 – valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable;
- Level 3 – valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Particulars	31 Mar 2026 Carrying value	31 Mar 2026 Fair value	31 Mar 2025 Carrying value	31 Mar 2025 Fair value	Level
Financial assets					
Cash and cash equivalents and other bank balances	946.79	946.79	20.59	20.59	3
Trade and other receivables	1,853.38	1,853.38	1,439.09	1,439.09	3
Other financial assets	928.99	928.99	724.97	724.97	3
Total	3,729.16	3,729.16	2,184.65	2,184.65	
Financial liabilities					
Trade payables	524.12	524.12	273.47	273.47	3
Non-current borrowings	635.10	635.10	602.21	602.21	3
Current borrowings	522.93	522.93	222.49	222.49	3
Lease liabilities	335.76	335.76	462.62	462.62	3
Other financial liabilities	126.27	126.27	106.74	106.74	3
Total	2,144.18	2,144.18	1,667.53	1,667.53	

There have been no transfers between levels during the year. Management has assessed that the carrying values of the financial assets and financial liabilities for which fair values are disclosed reasonably approximate their fair values, because these instruments have short-term maturities or carry interest at rates that approximate market rates.

39. Financial risk management objectives and policies

The Company's principal financial liabilities comprise borrowings, lease liabilities, trade payables and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include investments, trade and other receivables, cash and cash equivalents, bank balances and security deposits that arise directly from its operations.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's senior management oversees the management of these risks under policies approved by the Board of Directors. The Board provides written principles for overall risk management, as well as policies covering specific areas such as foreign exchange risk, interest rate risk, credit risk and the investment of excess liquidity.

(a) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises interest rate risk, currency risk and other price risk. Financial instruments affected by market risk include borrowings and trade payables.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the Company's financial instruments will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to its borrowings carrying floating rates of interest. The following table demonstrates the sensitivity to a reasonably possible change in interest rates on the floating rate borrowings, with all other variables held constant.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Particulars	Increase / (decrease) in basis points	Effect on profit before tax
Floating rate borrowings outstanding – 31 March 2026		9.00%
31 March 2026 – INR	+50	(1.93)
31 March 2026 – INR	(50)	1.93
Floating rate borrowings outstanding – 31 March 2025		9.00%
31 March 2025 – INR	+50	(1.41)
31 March 2025 – INR	(50)	1.42

The Company has cash credit facility from Karur Vysya Bank as floating rate borrowings; The vehicle, machinery and COVID term loans are at fixed rates and have been excluded since the fixed rate borrowings are not exposed to cash flow interest rate risk.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to its export receivables. The Company does not use derivative financial instruments to hedge its foreign currency exposures; accordingly the entire exposure set out below is unhedged.

Unhedged foreign currency exposure	31 Mar 2026 USD lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 USD lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	7.17	679.24	4.08	348.90
Trade payables	-	-	-	-

Unhedged foreign currency exposure	31 Mar 2026 EURO lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 EURO lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	1.27	138.35	0.47	43.39
Trade payables	-	-	-	-

Unhedged foreign currency exposure	31 Mar 2026 GBP lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 GBT lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	0.14	17.30	0.06	6.64
Trade payables	-	-	-	-

Unhedged foreign currency exposure	31 Mar 2026 CAD lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 CAD lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	1.02	68.65	0.75	44.53
Trade payables	-	-	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The following table demonstrates the sensitivity to a reasonably possible change in the USD / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per USD) [was described as "present average rate"]	92.91	92.91	86.23	86.23
Effect on profit before tax	33.31	(33.31)	17.59	(17.59)

The following table demonstrates the sensitivity to a reasonably possible change in the EURO / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per EURO) [was described as "present average rate"]	107.50	107.50	93.45	93.45
Effect on profit before tax	6.83	(6.83)	2.20	(2.20)

The following table demonstrates the sensitivity to a reasonably possible change in the GBP / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per GBP) [was described as "present average rate"]	123.94	123.94	114.95	114.95
Effect on profit before tax	0.87	(0.87)	0.34	(0.34)

The following table demonstrates the sensitivity to a reasonably possible change in the CAD / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per CAD) [was described as "present average rate"]	67.66	67.66	62.38	62.38
Effect on profit before tax	3.45	(3.45)	2.34	(2.34)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

b) Credit risk

Credit risk is the risk of loss that may arise on outstanding financial instruments if a counterparty defaults on its obligations. The Company's exposure to credit risk arises principally from trade receivables. Other financial assets such as security deposits and bank deposits are held with government authorities and scheduled banks and the Company does not expect any credit risk in respect of these.

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer, including the default risk of the industry and the country in which the customer operates. Credit risk is managed through credit approvals, the establishment of credit limits and continuous monitoring of the creditworthiness of customers to whom the Company grants credit in the normal course of business. The Company's credit period for trade receivables generally ranges from 30 to 90 days.

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Neither past due nor impaired	—	—
Past due but not impaired		
Less than 365 days	1,561.70	1,139.43
More than 365 days	313.38	299.66
Less: allowance for expected credit losses	(21.70)	—
Total	1,853.38	1,439.09

Movement in the allowance for expected credit losses

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Balance at the beginning of the year	—	—
Allowance created during the year	21.70	—
Amounts written off / written back during the year	—	—
Balance at the end of the year	21.70	—

An allowance for expected credit losses of ₹21.70 lakhs has been created for the first time during the year and relates to receivables outstanding for more than three years. The Company applies the simplified approach permitted by Ind AS 109 and recognises lifetime expected credit losses on trade receivables using a provision matrix based on historical default experience adjusted for forward-looking information.

(c) Liquidity risk

The Company's objective is to maintain optimum levels of liquidity to meet its cash and collateral requirements at all times. The Company relies on a mix of borrowings and operating cash flows to meet its funding needs. The Company monitors rolling forecasts of its liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Company does not breach borrowing limits or covenants on any of its facilities.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The table below summarises the maturity profile of the Company's financial liabilities based on carrying amounts by contractual maturity.

Maturities	Upto 1 year	1-3 Years	3-5 Years	Above 5 Years	Total
As at 31 March 2026					
Non-current borrowings	165.41	348.27	121.42	-	635.10
Lease liabilities	91.32	244.44	-	-	335.76
Current borrowings	522.93	-	-	-	522.93
Trade payables	511.35	9.82	2.94	-	524.11
Other financial liabilities	126.27	-	-	-	126.27
Total	1,417.28	602.53	124.36	-	2,144.17
As at 31 March 2025					
Non-current borrowings	165.41	339.57	97.23	-	602.21
Lease liabilities	126.86	335.76	-	-	462.62
Current borrowings	222.49	-	-	-	222.49
Trade payables	255.78	15.53	2.16	-	273.47
Other financial liabilities	106.74	-	-	-	106.74
Total	877.28	690.86	99.39	-	1,667.53

The Company had undrawn committed borrowing facilities of ₹334.41 lakhs as at 31 March 2026 (previous year Rs. 592.91 lakhs).

40. Corporate social responsibility expenditure

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
(i) Amount required to be spent by the Company during the year	-	5.50
(ii) Amount required to be set off for the financial year, if any	-	-
(iii) Total CSR obligation for the financial year	-	5.50
(iv) Amount of expenditure incurred – (a) construction / acquisition of any asset	-	-
(b) on purposes other than (a) above	-	5.50
(v) Shortfall / (excess spent) at the end of the year	-	-
(vi) Total of previous years' shortfall	-	-
(vii) Reason for shortfall	Not applicable	Not applicable
(viii) Nature of CSR activities	Not applicable	Contribution to Madhavi Konda and Diabetes and You (DAY) Society
(ix) Details of related party transactions in relation to CSR expenditure	Nil	Nil
(x) Movement in any provision made on account of a contractual obligation	Nil	Nil

Section 135 of the Companies Act, 2013 did not apply to the Company for the year ended 31 March 2026.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

41. Analytical ratios

Ratio	Numerator	Denominator	31 Mar 2026	31 Mar 2025	Variance %	Reason for variance in excess of 25%
Current ratio (times)	Current assets	Current liabilities	3.10	3.07	1.13	Not applicable
Debt-equity ratio (times)	Total debt	Shareholders' equity	0.20	0.25	(19.39)	Not applicable
Debt service coverage ratio (times)	Earnings available for debt service	Debt service	0.35	0.22	58.40	Improvement is driven by higher earnings before interest, tax, depreciation and amortisation in the current year.
Return on equity (%)	Profit after tax	Average shareholders' equity	2.66%	1.45%	172.00	Profit after tax more than doubled from ₹73.57 lakhs to ₹165.01 lakhs.
Inventory turnover (times)	Revenue from operations	Average inventory	42.34	44.93	(5.76)	Not applicable
Trade receivables turnover (times)	Revenue from operations	Average trade receivables	3.28	3.31	(1.14)	Not applicable
Trade payables turnover (times)	Net credit purchases	Average trade payables	1.28	1.56	(17.58)	Not applicable
Net capital turnover (times)	Revenue from operations	Working capital	1.57	2.16	(27.24)	Working capital increased following the equity issue during the year, at a faster rate than the growth in revenue.
Net profit ratio (%)	Profit after tax	Revenue from operations	3.06%	1.69%	104.77	Revenue grew by 23.7% while total expenses grew by 20.7%, improving the margin.
Return on capital employed (%)	Earnings before interest and tax	Capital employed	4.55%	2.79%	63.21	Increase in profit before interest and tax from ₹180.61 lakhs to ₹401.71 lakhs.

Return on investment has not been presented as it is not applicable because the Company holds no investments other than in its subsidiary and associate.

42. Other statutory information

- (i) The Company does not hold any benami property and no proceeding has been initiated or is pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and the rules made thereunder.
- (ii) The Company has not entered into any transaction with a company struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.
- (iii) There are no charges or satisfaction of charges which are yet to be registered with the Registrar of Companies beyond the statutory period.
- (iv) The Company has not traded or invested in crypto currency or virtual currency during the financial year.
- (v) The Company has not advanced or loaned or invested funds to any other person or entity, including a foreign entity, with the understanding that the intermediary shall directly or indirectly lend to or invest in other persons or entities identified by or on behalf of the Company, or provide any guarantee, security or the

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

like to or on behalf of such persons or entities.

- (vi) The Company has not received any funds from any person or entity, including a foreign entity, with the understanding that the Company shall directly or indirectly lend to or invest in other persons or entities identified by or on behalf of the funding party, or provide any guarantee, security or the like on behalf of such persons or entities.
- (vii) The Company has not entered into any transaction which is not recorded in the books of account and which has been surrendered or disclosed as income during the year in any tax assessment under the Income Tax Act, 1961.
- (viii) The Company has not been declared a wilful defaulter by any bank, financial institution or other lender.
- (ix) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with the Companies (Restriction on Number of Layers) Rules, 2017.
- (x) No scheme of arrangement has been approved by the competent authority in terms of sections 230 to 237 of the Companies Act, 2013 during the year.
- (xi) The Company has been sanctioned working capital limits in excess of ₹5 crores in aggregate from banks on the basis of security of current assets. The quarterly returns and statements of current assets filed by the Company with such banks are in agreement with the books of account of the Company.
- (xii) The Company has not revalued any of its property, plant and equipment (including right-of-use assets) or intangible assets during the year.
- (xiii) The title deeds of all immovable properties disclosed in the financial statements as property, plant and equipment are held in the name of the Company.
- (xiv) For details of loans and advances granted to promoters, directors, key managerial personnel and related parties, refer note 49.

43. Capital management

For the purpose of the Company's capital management, capital includes issued equity capital, securities premium and all other equity reserves attributable to the equity holders of the Company. The primary objective of the Company's capital management is to maximise shareholder value.

The Company manages its capital structure and makes adjustments in the light of changes in economic conditions and the requirements of its financial covenants. To maintain or adjust the capital structure the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, being net debt divided by total capital plus net debt. Net debt comprises interest-bearing loans and borrowings and lease liabilities, less cash and cash equivalents.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Non-current borrowings	635.10	602.21
Current borrowings	522.93	222.49
Lease liabilities	335.76	462.62
Less: cash and cash equivalents	(946.79)	(20.59)
Net debt	547.00	1,266.73
Equity share capital	1,991.90	1,583.40
Other equity	5,337.88	3,508.41
Total capital	7,329.78	5,091.81
Total capital and net debt	7,876.78	6,358.54
Gearing ratio	0.07	0.20

44. Leases

The Company has lease contracts for buildings. The leases generally have lease terms of between two and four years. The Company's obligations under its leases are secured by the lessor's title to the leased assets. The Company is generally restricted from assigning and sub-leasing the leased assets. Certain lease contracts include extension and termination options, which are discussed below.

The Company also has certain leases with lease terms of twelve months or less and leases of low-value assets. The Company applies the short-term lease and low-value asset recognition exemptions to these leases.

Refer to note 3 for the carrying amounts of right-of-use assets recognised and the movements during the year. Set out below are the carrying amounts of lease liabilities and the movements during the year:

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
At the beginning of the year	462.62	156.68
Additions	—	423.65
Leases terminated	—	—
Accretion of interest	36.59	34.45
Payments	(163.45)	(152.16)
At the end of the year	335.76	462.62
Current	91.32	126.86
Non-current	244.44	335.76

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The following amounts have been recognised in the Statement of Profit and Loss:

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation expense on right-of-use assets	128.21	119.73
Interest expense on lease liabilities	36.59	34.45
Expense relating to short-term leases	2.88	2.53
Expense relating to leases of low-value assets	—	—
Variable lease payments	—	—
Total amount recognised in the Statement of Profit and Loss	167.68	156.71

The Company had total cash outflows for leases of ₹166.33 lakhs (previous year ₹154.69 lakhs), comprising lease payments of ₹163.45 lakhs (previous year ₹152.16 lakhs) and short-term lease payments of ₹2.88 lakhs (previous year ₹2.53 lakhs).

The Company has several lease contracts that include extension and termination options. These options are negotiated by management to provide flexibility in managing the leased asset portfolio and to align with the Company's business needs. Management exercises significant judgement in determining whether these extension and termination options are reasonably certain to be exercised. The weighted average incremental borrowing rate applied to lease liabilities is 10% per annum, with maturities falling due up to the financial year 2028-29.

The maturity profile of lease liabilities is set out in note 39(c), which presents financial liabilities at their carrying amounts by contractual maturity.

45. Contingent liabilities and commitments

(a) Contingent liabilities not provided for

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Corporate guarantee given to Karur Vysya Bank in respect of credit facilities availed by Nayas Laboratories Private Limited, the Company's subsidiary	740.00	740.00
Claims against the Company not acknowledged as debts – goods and services tax	-	-
Claims against the Company not acknowledged as debts – income tax	-	-
Other claims not acknowledged as debts	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The disputed liability of ₹53.21 lakhs towards interest on goods and services tax, which is pending before the Additional Commissioner of GST, Ranga Reddy and is reported under paragraph 3(vii)(b) of the auditor's report, has been provided in full and is carried within other financial liabilities in note 20. It is therefore not disclosed as a contingent liability above.

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)	-	-
Other commitments	-	-

46. Share-based payments

(a) Description of the scheme

The Company has implemented the JSTL Employee Stock Option Scheme 2016, adopted in accordance with the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 (now the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021) and the special resolution passed by the members at the general meeting held on 30 September 2016. The Nomination and Remuneration Committee administers the scheme. All options are equity-settled and are exercisable into one equity share of ₹10 each.

Particulars	JSTL Employee Stock Option Scheme 2016
Date of shareholders' approval	30 September 2016
Total number of options approved	25,00,000
Vesting requirement	Not less than one year and not more than five years from the date of grant. Options granted under the outstanding tranches vest 10%, 20%, 30% and 40% on completion of one, two, three and four years respectively from the date of grant.
Exercise price	₹10 per option, being the face value of the equity share, as determined by the Nomination and Remuneration Committee
Exercise period	Five years from the respective date of vesting, failing which the options lapse
Exercise period on cessation of employment	Resignation – 30 days from the date of tendering resignation; retirement – six months; death or permanent incapacitation – one year, in each case in respect of vested options only
Maximum term of options granted	Five years from vesting
Source of shares	Primary – fresh allotment
Variation in terms of options during the year	None
Method of settlement	Equity-settled
Treatment of lapsed and forfeited options	Available for further grant under the scheme
Transferability	Options are not transferable and may be exercised only by the optionee, or on death by the legal heirs
Method used to account for the scheme	Fair value method; options valued using the Black-Scholes model

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(b) Grants outstanding at the reporting date and their vesting profile

Grant	Date of grant	Options granted and outstanding	Vested up to 31 March 2026	Unvested at 31 March 2026
Fourth grant	30 May 2024	1,50,000	15,000	1,35,000
Fifth grant	14 August 2025	2,80,000	–	2,80,000
Total		4,30,000	15,000	4,15,000

The unvested options above become exercisable as follows:

Financial year of vesting	Fourth grant	Fifth grant	Total
2026-27	30,000	28,000	58,000
2027-28	45,000	56,000	1,01,000
2028-29	60,000	84,000	1,44,000
2029-30	–	1,12,000	1,12,000
Total	1,35,000	2,80,000	4,15,000

(c) Expense recognised

Particulars	FY 2025-26	FY 2024-25
Expense arising from equity-settled share-based payment transactions	71.14	104.09
Total expense recognised in employee benefits expense (note 26)	71.14	104.09

47. Disclosure under section 186(4) of the Companies Act, 2013

Name of the party	Relationship	Nature	Amount (Rs. lakhs)	Rate of interest	Terms of repayment	Purpose
Nayas Laboratories Private Limited	Subsidiary	Loan outstanding	599.26	7% p.a	On Demand	Business purposes
Nayas Laboratories Private Limited	Subsidiary	Corporate guarantee	740.00			Credit facilities from Karur Vysya Bank
Nayas Laboratories Private Limited	Subsidiary	Investment in equity shares	200.00			Strategic investment
Naya Pharma Private Limited	Associate	Loan outstanding	57.02	11% p.a	On Demand	Business purposes
Naya Pharma Private Limited	Associate	Investment in equity shares	300.00			Strategic investment
Total			1,896.28			

The loans, investments and guarantee above were approved in accordance with sections 185 and 186.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

48. Utilisation of funds raised during the year

Particulars	Date of allotment	Amount raised (₹ lakhs)	Amount utilised (₹ lakhs)	Unutilised balance and where held
Equity shares – 40,85,000 shares at ₹40 per share	02-01-2026	1,634.00	1,084.00	550.00
Money received against share warrants	02-01-2026	350.00	-	350.00
Total		1,984.00	1,084.00	900.00

Warrants Details & Terms & Conditions of Warrants:

Number of Warrants: 35,00,000

Date of Allotment: 02-01-2026

Price: 40 (Face Value Rs. 10/- each at a premium of Rs.30/- each)

Last Date of Conversion: 02-07-2027

Terms & Conditions of Warrants:

- a) An amount equivalent to 25% of the Warrant Price shall be payable at the time of subscription and allotment of each Warrant. The remaining 75% shall be payable at the time of exercise of the Warrant and allotment of Equity Shares. The amount paid shall be adjusted against the issue price of the resultant Equity Shares.
- b) Each Warrant shall entitle the holder to apply for and be allotted 1 (One) Equity Share of face value Rs. 10/- (Rupees Ten only) at any time within 18 (Eighteen) months from the date of allotment (the "Warrant Exercise Period").
- c) The Warrants and the Equity Shares allotted upon their conversion shall be subject to lock-in, as specified under the SEBI ICDR Regulations.
- d) The Warrants shall be allotted in dematerialized form within 15 (Fifteen) days from the date of passing this resolution, provided that if any required regulatory approvals are pending, such allotment shall be made within 15 days from receipt of the last such approval.
- e) The number of Equity Shares and issue price shall be subject to adjustments, as may be permitted under applicable regulations, in the event of corporate actions like bonus issue, stock split, rights issue, etc.
- f) The Warrants and the Equity Shares arising on conversion shall not be transferred, hypothecated or encumbered during the lock-in period except as permitted under applicable laws.
- g) The right to exercise Warrants may be exercised by the holder in one or more tranches within the Warrant Exercise Period by submitting a written notice along with payment of the balance amount. The Company shall allot the corresponding Equity Shares in dematerialized form, without further approval of the Members.
- h) The Equity Shares issued upon conversion shall rank pari passu in all respects with existing Equity Shares, including dividend and voting rights, and shall be subject to applicable laws and the Articles of Association of the Company.
- i) In the event the holder fails to exercise the Warrants within the Warrant Exercise Period, the Warrants shall lapse and the 25% upfront amount paid shall stand forfeited by the Company.
- j) Until conversion, Warrants shall not carry any rights of shareholders of the Company.
- k) The Warrants shall be subject to adjustment in case of any corporate action during the interim period as per SEBI ICDR Regulations or other applicable laws.
- l) The Equity Shares arising on conversion shall be listed on the Stock Exchange where the Company's equity shares are listed, subject to necessary regulatory approvals.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- m) The Proposed Warrant Allottees shall be required to bring in 100% of the consideration into the designated bank account of the Company, for the Equity Shares to be allotted, on or prior to the date of allotment thereof, from their respective bank account.
- n) The Warrants by itself, until exercised and converted into equity shares, shall not give to the Proposed Warrant Allottees thereof any rights with respect to that of an equity shareholder of the Company.
- o) The Warrants and the equity shares allotted pursuant to exercise of such Warrants shall be governed by the regulations and guidelines issued by SEBI or any other statutory authority as the case may be or any modifications thereof.

49. Loans and advances granted to promoters, directors, key managerial personnel and related parties

Type of borrower	Amount outstanding 31 Mar 2026	% of total loans and advances 31 Mar 2026	Amount outstanding 31 Mar 2025	% of total loans and advances 31 Mar 2025
Promoters	Nil	—	Nil	—
Directors	Nil	—	Nil	—
Key managerial personnel	Nil	—	Nil	—
Related parties – subsidiary (Nayas Laboratories Private Limited)	599.26 *	91.31%	484.26 *	100.00%
Related parties – associate (Naya Pharma Private Limited)	57.02 *	8.69%	Nil	—

* These loans are repayable on demand and carry no stipulated repayment schedule. Percentages are computed on the total loans and advances in the nature of loans outstanding at each reporting date.

50. Events after the reporting period

These standalone financial statements were authorised for issue by the Board of Directors of the Company on 29 May 2026. There were no material events after the reporting period requiring adjustment of, or disclosure in, these financial statements.

51. Previous year figures

Previous period and previous year figures have been regrouped and reclassified wherever necessary to conform to the current period's classification, in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013.

The accompanying notes 1 to 51 form an integral part of these standalone financial statements.

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223159
UDIN: 26223169ERAPOJ4197

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00876539

Sd/-
R. Venkateswara Rao
Chief Financial Officer

Sd/-
M. Snigdha
Executive Director
DIN: 08934860

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CONSOLIDATED INDEPENDENT AUDITOR'S REPORT

To the Members of

M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of M/s. Jeevan Scientific Technology Limited ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), and its associate, which comprise the Consolidated Balance Sheet as at 31 March 2026, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year then ended, and a summary of material accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the report of the other auditor on the separate financial statements of the associate referred to in the Other Matters section below, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India, of the state of affairs of the Group and its associate as at 31 March 2026, and their consolidated profit, consolidated total comprehensive income, consolidated changes in equity and consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group and its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditor in terms of their report referred to in the Other Matters section below is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matter described below to be the key audit matter to be communicated in our report.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Key Audit Matter	Auditor's Response
Revenue Recognition Revenue is recognised to the extent that economic benefit will flow to the Company and the revenue can be reliably measured. It is measured at the fair value of consideration received or receivable, net of returns and allowances, discounts and rebates. The Company recognises revenue when it satisfies its performance obligation by transferring the services to the customer. Revenue is a key driver of the business and judgment is involved in determining when contractual obligations have been performed and the extent to which the right to consideration has been earned. The management of the Company focuses on revenue as a key performance measure, which could create an incentive for revenue to be recognised before the risks and rewards have been transferred. We therefore identified revenue recognition as a significant risk and a key audit matter.	Principal audit procedures performed included the following: We understood the business revenue recognition policy and how it is applied, including the relevant controls, and tested controls over revenue recognition; Analytical review of the revenue recognised over the year; Agreeing, on a sample basis, amounts of revenue to customer contracts and verifying the extent, timing and customer acceptance of services, where relevant; We performed cut-off testing for a sample of revenue transactions around the period end date, to check that they were recognised in the appropriate period; We discussed key contractual arrangements with management and obtained relevant documentation, including in respect of rebate and returns arrangements. The Group's accounting policy on revenue recognition is shown in note 2.15 to the consolidated financial statements and the related disclosures are included in the notes. Based on our audit procedures we did not identify any evidence of material misstatement in the revenue recognised for the year ended 31 March 2026 in the consolidated financial statements.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, the Board's Report including annexures to the Board's Report, and the Report on Corporate Governance and Shareholders' Information, but does not include the consolidated financial statements, the standalone financial statements and our auditor's report thereon. The Management Discussion and Analysis, the Board's Report including annexures to the Board's Report and the Report on Corporate Governance are expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, compare it with the financial statements of the subsidiary and the associate to the extent it relates to those entities, and consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. Other information so far as it relates to the subsidiary is traced from its financial statements audited by us; and so far as it relates to the associate, from its financial statements audited by the other auditor.

When we read the Management Discussion and Analysis, the Board's Report including annexures to the Board's Report and the Report on Corporate Governance, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance as required under SA 720, 'The Auditor's Responsibilities Relating to Other Information'.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Responsibilities of Management and the Board of Directors for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated cash flows and consolidated changes in equity of the Group and its associate in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. The respective Boards of Directors of the companies included in the Group and of its associate are responsible for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Boards of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Boards of Directors either intend to liquidate their respective entities or to cease operations, or have no realistic alternative but to do so.

The respective Boards of Directors of the companies included in the Group and of its associate are also responsible for overseeing the financial reporting process of the Group and of its associate.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group and its associate to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities or business activities included in the consolidated financial statements of which we are the independent auditors. For the associate included in the consolidated financial statements, which has been audited by another auditor, such other auditor remains responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) evaluating the effect of any identified misstatements in the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

We have audited the financial statements of the Holding Company's subsidiary, M/s Nayas Laboratories Private Limited, whose financial statements reflect total assets of ₹1,589.70 lakhs as at 31 March 2026, total revenues of ₹767.52 lakhs, total loss after tax of ₹60.15 lakhs, total comprehensive loss of ₹60.15 lakhs and net cash inflows of ₹0.92 lakhs for the year ended on that date, as considered in the consolidated financial statements.

The consolidated financial statements also include the Group's share of loss of ₹1.53 lakhs for the year ended 31 March 2026 in respect of its associate, M/s Naya Pharma Private Limited, whose financial statements reflect total assets of ₹767.38 lakhs as at 31 March 2026 and no revenue from operations for the year ended on that date. These financial statements have been audited by another auditor whose report has been furnished to us by the Management, and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of the associate, is based solely on the report of that other auditor.

Our opinion on the consolidated financial statements is not modified in respect of the above matter with regard to our reliance on the work done and the report of the other auditor.

Our opinion on the consolidated financial statements above, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters.

Report on Other Legal and Regulatory Requirements

As required by section 143(3) of the Act, based on our audit of the Holding Company and its subsidiary and on the consideration of the report of the other auditor on the separate financial statements of the associate referred to in the Other Matters section above, we report, to the extent applicable, that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (b) In our opinion, proper books of account as required by law relating to the preparation of the aforesaid consolidated financial statements have been kept by the Group and its associate, including relevant records, so far as it appears from our examination of those books and the report of the other auditor.
- (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, the Consolidated Statement of Cash Flows and the Consolidated Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
- (d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under section 133 of the Act.
- (e) On the basis of the written representations received from the directors of the Holding Company as on 31 March 2026 taken on record by the Board of Directors of the Holding Company, and the report of the statutory auditor of its subsidiary and its associate, none of the directors of the Group companies and of its associate is disqualified as on 31 March 2026 from being appointed as a director in terms of section 164(2) of the Act.
- (f) With respect to the adequacy of the internal financial controls with reference to consolidated financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure A", which is based on our audit of the Holding Company and its subsidiary and on the report of the other auditor of its associate. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the internal financial controls with reference to consolidated financial statements of those companies.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding Company to its directors during the year is in accordance with the provisions of section 197 of the Act. The provisions of section 197 of the Act are not applicable to the subsidiary and the associate, being private limited companies, and accordingly reporting under section 197(16) in respect of whether the remuneration paid by them to their directors is in accordance with section 197 of the Act is not applicable.
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
- (i) There are no pending litigations therefore there is no impact on the consolidated financial position of the Group and its associate.
- (ii) The Group and its associate did not have any material foreseeable losses on long-term contracts including derivative contracts.
- (iii) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company and its subsidiary and associate incorporated in India.
- (iv) (a) The respective Managements of the Holding Company and its subsidiary and associate, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or its subsidiary or associate to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company or its subsidiary or associate ("Ultimate Beneficiaries"), or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (b) The respective Managements of the Holding Company and its subsidiary and associate, whose financial statements have been audited under the Act, have represented to us that, to the best of their knowledge and belief, no funds have been received by the Holding Company or its subsidiary or associate from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company or its subsidiary or associate shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries"), or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances performed by us and those performed by the other auditor of the associate, whose financial statements have been audited under the Act, nothing has come to our or the other auditor's notice that has caused us or the other auditor to believe that the representations under sub-clauses (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- (v) The Holding Company and its subsidiary and associate have neither declared nor paid any dividend during the year.
- (vi) Based on our examination, which included test checks performed by us on the Holding Company and its subsidiary, and that performed by the other auditor of the associate, whose financial statements have been audited under the Act, the Holding Company, its subsidiary and its associate have used accounting software systems for maintaining their respective books of account for the financial year ended 31 March 2026 which have the feature of recording an audit trail (edit log) facility, and the same has operated throughout the year for all relevant transactions recorded in the software systems. Further, during the course of audit, we and the other auditor have not come across any instance of the audit trail feature being tampered with. Additionally, the audit trail has been preserved by the Holding Company and the above-referred companies as per the statutory requirements for record retention.
- (i) With respect to the matters specified in clause (xxi) of paragraph 3 and paragraph 4 of the Companies (Auditor's Report) Order, 2020 ("CARO" / "the Order") issued by the Central Government in terms of section 143(11) of the Act, we report that the consolidated financial statements include the Holding Company and Nayas Laboratories Private Limited, its subsidiary, both of which are companies incorporated in India to which reporting under the Order applies, and Naya Pharma Private Limited, its associate. There are no qualifications or adverse remarks by the respective auditors in the Companies (Auditor's Report) Order reports of these companies.

for PAVULURI & Co.
Chartered Accountants
Firm Registration No. 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No. F-223169
UDIN: 26223169KNYU117099

Date: 29 May 2026
Place: Hyderabad

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure "A" to the Independent Auditor's Report

(Referred to in paragraph (f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on the Internal Financial Controls with reference to consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (the "Act")

In conjunction with our audit of the consolidated financial statements of the Company as at and for the year ended 31 March 2026, we have audited the internal financial controls with reference to consolidated financial statements of Jeevan Scientific Technology Limited (hereinafter referred to as "the Holding Company") and its subsidiary and its associate, which are companies incorporated in India, as of that date.

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The respective Company's management and Board of Directors of the Holding Company and of its subsidiary and associate are responsible for establishing and maintaining internal financial controls with reference to consolidated financial statements based on the internal control with reference to consolidated financial statements criteria established by the respective Companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements of the Holding Company and of its subsidiary and associate, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls with reference to consolidated financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditor of the associate company in terms of their report referred to in the Other Matters paragraph below is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements of the Holding Company and of its subsidiary and associate, which are companies incorporated in India.

Meaning of Internal Financial Controls with reference to consolidated financial statements

A company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to consolidated financial statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditor referred to in the Other Matters paragraph below, the Holding Company and its subsidiary and associate have, in all material respects, adequate internal financial controls with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at 31 March 2026, based on the criteria for internal financial control with reference to consolidated financial statements established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Other Matters

Our aforesaid report under section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to consolidated financial statements, in so far as it relates to an associate company which is a company incorporated in India, is based solely on the corresponding report of the auditor of such company.

Our opinion is not modified in respect of the above matter.

for PAVULURI & Co.
Chartered Accountants
Firm Registration No. 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No. F-223169
UDIN: 26223169KNYU17099

Date: 29 May 2026
Place: Hyderabad

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Statement of Consolidated Audited Assets and Liabilities As at 31st March, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Notes	As at 31 March 2026	As at 31 March 2025
		Audited	Audited
Assets			
(1) Non-current Assets			
a) Property, plant and equipment	3	2,543.63	2,270.50
b) Other intangible assets	3	705.94	686.57
c) Capital work in progress	3	471.05	471.05
d) Right of use assets	3	358.82	497.50
e) Financial Assets			
i) Investments	4	298.47	
ii) Other financial assets	10	86.26	78.24
f) Other non current assets	5	1,207.54	857.54
g) Deferred tax asset (net)	6	-	91.89
		5,671.71	4,953.30
(2) Current Assets			
a) Inventories	7	302.74	161.82
b) Financial Assets			
i) Trade receivables	8	2,069.31	1,594.22
ii) Cash and cash equivalents	9	950.55	24.23
iii) Other financial assets	10	213.64	155.00
c) Current tax assets (Net)	11	624.30	343.11
d) Other current assets	12	826.47	597.37
		4,987.00	2,875.75
TOTAL ASSETS		10,658.72	7,829.05
Equity and Liabilities			
Equity			
a) Equity share capital	13	1,991.90	1,583.40
b) Other equity	14	5,180.43	3,401.81
Total equity		7,172.32	4,985.20
Non controlling interest		122.66	21.91
		7,294.98	5,007.12
Liabilities			
(1) Non-current Liabilities			
a) Financial liabilities			
(i) Borrowings	15	1,009.92	1,173.03
(ii) Lease liabilities	16	287.21	386.01
b) Provisions	17	73.88	55.84
c) Deferred tax Liability (net)	6	3.33	
		1,374.34	1,614.88
(2) Current Liabilities			
a) Financial Liabilities			
i) Borrowings	18	705.98	341.30
ii) Lease liabilities	16	125.31	157.64
iii) Trade payables	19		
(a) Total outstanding dues of micro and small enterprises		222.12	114.88
(b) Total outstanding dues of Creditors other than micro and small enterprises		390.64	202.82
iv) Other financial liabilities	20	133.02	113.17
v) Other Financial Creditors			
b) Other current liabilities	21	365.31	263.56
c) Provisions	22	47.01	13.68
		1,989.39	1,207.05
TOTAL EQUITY AND LIABILITIES		10,658.72	7,829.05

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223169
UDIN: 26223169KNYU117099

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00876539

Sd/-
M. Snigdha
Executive Director
DIN: 08934860

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consolidated Statement of Profit and Loss for the Year Ended 31st March, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Note No.	For Year Ended 2025-26	For Year Ended 2024-25
Income			
I. Revenue from operations	23	6,153.71	4,684.36
II. Other Income	24	97.27	65.28
III. Total revenue(III)		6,250.98	4,749.62
IV. Expenses			
Cost of Material consumed	25	487.70	380.25
Employee benefit expenses	26	2,164.38	1,705.71
Finance costs	27	203.94	176.09
Depreciation on Property, Plant & Equipment	3	357.63	328.59
Depreciation on Right-of-use Assets	3	158.10	149.18
Amortisation on Process Knowhow	3	148.52	147.39
Other expenses	28	2,519.96	1,657.34
Total expenses		6,040.25	4,744.55
V. Profit/ (Loss) before Share of Profit/(Loss) from Associate (III)-(IV)		210.73	5.07
Share of Profit/ (Loss) from Associate accounted using Equity Method		(1.53)	-
Profit/ (Loss) before Tax		209.20	5.07
Tax expenses			
Current Tax		44.56	12.02
Lees: Mat Credit (Entitlement) / utilization		(33.91)	(12.02)
Deferred Tax		95.22	(0.84)
Total tax expenses		105.87	(0.84)
Profit / (Loss) for the period		103.33	5.90
Other Comprehensive Income			
A (i) Items that will not be reclassified to profit and loss Re-measurements of post-employment		17.82	(1.37)
(ii) Income tax relating to items that will not be reclassified to profit and loss			
B (i) Items that will be reclassified to profit and loss			
(ii) Income tax relating to items that will be reclassified to profit and loss			
Total Comprehensive Income		121.15	4.53
Net profit attributable to			
Owners of the company		115.08	13.43
Non controlling interest		(11.75)	(7.53)
Other comprehensive income attributable to:			
Owners of the company		17.82	(1.37)
Non-Controlling interest			
Earning per equity share (Face value of Rs.10/- each)			
Basic		0.68	0.086
Diluted		0.68	0.086

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223169
UDIN: 26223169KNYUI17099

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00876539

Sd/-
M Snigdha
Executive Director
DIN: 08934860

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consolidated Statement of changes in equity for the year ended 31 March 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

A Equity share capital

Particulars	No of Shares	Amount
Balance as at 1 April 2024	1,54,80,215	1,548.02
Shares during the year	3,53,750	35.38
Balance as at 31 March 2025	1,58,33,965	1,583.40
Shares during the year	40,85,000	408.50
Balance as at 31 March 2026	1,99,18,965	1,991.90

B Other equity

Particulars	Reserves and Surplus					Other comprehensive income		Total other equity
	Retained earnings	Securities premium	Share-based payment reserve	Money received against share warrants	Share forfeited reserves	Non controlling interest	Re-measurement gains/(losses) on defined benefit plans	
Balance as at 1 April 2025	727.55	2,358.46	282.72	0.01	20.17	21.91	12.90	3,423.72
Profit for the year	115.08	-	-	-	-	-	-	115.08
Fair Value loss on Financial Instruments at fair value through Profit & Loss	(0.92)	-	-	-	-	-	-	(0.92)
Issue of equity shares on exercise of options	-	1,225.50	-	-	-	-	-	1,225.50
Money Received against Share warrants	-	-	-	350.00	-	-	-	350.00
Share-based payment expenses	-	-	71.13	-	-	-	-	71.13
Noncontrolling Interest	-	-	-	-	-	100.75	-	100.75
Re-measurement gains/(losses) on defined benefit plans net of tax	-	-	-	-	-	-	17.82	17.82
Balance as at 31 March 2026	941.71	3,583.96	353.85	350.01	20.17	122.66	30.72	5,303.06
Balance as at 1 April 2024	723.02	2,037.71	499.38	0.01	20.17	19.59	14.52	3,314.40
Profit for the year	4.50	-	-	-	-	(10.43)	-	(5.90)
Share-based payment expenses	-	-	104.09	-	-	-	-	104.09
Transfer on Exercise of Employee Stock Options	-	320.75	(320.75)	-	-	-	-	-
Noncontrolling Interest	-	-	-	-	-	12.75	-	12.75
Re-measurement gains/(losses) on defined benefit plans net of tax	-	-	-	-	-	-	(1.62)	(1.62)
Balance as at 31 March 2025	727.55	2,358.46	282.72	0.01	20.17	21.91	12.90	3,423.72

Nature and purpose of reserves

Retained earnings

The balance in the Retained Earnings primarily represents the surplus after payment of dividend and transfer to reserves.

Securities premium

Securities premium is used to record the premium on issue of shares. The reserve can be utilised only for limited purposes such as issuance of bonus shares in accordance with the provisions of the Companies Act, 2013.

Re-measurement gains/(losses) on defined benefit plans

Remeasurements of the net defined benefits plan reserve comprises the cumulative net gains/ losses on actuarial valuation of post-employment obligations.

Share-based payment reserve

Share-based payment reserve is used to recognise the value of equity-settled share-based payments provided to employees as part of their remuneration. The amounts recorded in share-based payment reserve are transferred to securities premium upon exercise of stock options and transferred to general reserve on account of stock options not exercised by employees.

Money Received against Share Warrants

The reserve represents subscription money received on share warrants which are convertible into equity shares, pending conversion.

Shares forfeited reserve

The reserve represents amounts received on shares that were subsequently forfeited.

The accompanying notes are integral part of the financial statements.

As per our report of even date for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223169
UDIN: 26223169KNYU17099

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00876539

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
M Snigdha
Executive Director
DIN: 08934860

Sd/-
Kodali Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Statement of Consolidated Audited Cash flow for the year ended 31st March, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S.No	Particulars	As at 31 March 2026	As at 31 March 2025
A.	Cash flow from operating activities		
	Net Profit before tax and extraordinary items	209.20	5.07
	Add: Share of Loss of Associate	1.53	-
	Adjustments for:		
	Depreciation	664.24	625.16
	Adjustments on account of fairvalue measurement of lease deposits	(0.91)	-
	Dividend Received	(11.56)	(5.03)
	Remeasurement Gain/Loss on Defined Benefit plans	17.82	(1.37)
	Interest Received	(3.86)	(41.38)
	Foreign exchange loss/(gain)	-	2.36
	Share based payments to employees	71.13	104.09
	Interest paid	203.94	176.09
	Operating profit before working capital changes	1,151.53	864.98
	Changes in Working Capital		
	Inventories	(140.92)	(52.83)
	Trade receivables	(475.08)	(367.46)
	Other financial assets	(58.64)	143.35
	Other assets	(860.29)	185.95
	Trade payables	295.05	102.99
	Other financial liabilities	(12.48)	56.55
	Other liabilities	101.75	46.25
	Provisions	51.37	27.50
	Cash generated from operations before Tax	52.29	1,007.29
	Tax Paid	10.65	-
	Net cash from operating activity	41.64	1,007.29
B.	Cash flow from investing activities		
	Purchase of Property, Plant & Equipment including Capital Advances	(818.06)	(1,603.14)
	investments in fixed deposits and margin money deposits with banks	(8.02)	(5.25)
	Change in Non controlling interest	112.50	-
	Dividend Received	11.56	5.03
	Investment in Associates	(300.00)	-
	Interest Received	3.86	41.38
	Net cash used in investing activity	(998.16)	(1,561.99)
C.	Cash flow from financing activity		
	Proceeds from non current borrowings	(163.11)	368.08
	Repayment of current borrowings	364.68	68.00
	Interest paid	(203.94)	(176.09)
	Proceeds from issuance of Equity Shares	1,984.00	35.38
	Repayment of Principal portion of Lease Liability	(98.80)	229.11
	Net cash generated in financing activity	1,882.84	524.48
	Net increase in cash and cash equivalents (A+B+C)	926.32	(30.22)
	Cash and cash equivalents at the beginning of the year/period	24.23	54.45
	Cash and cash equivalents at the end of the year/period	950.55	24.23

The above cashflow statement has been prepared using indirect method

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223169
UDIN: 26223169KNYU117099

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00676539

Sd/-
M Snigdha
Executive Director
DIN: 08934860

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

NOTES 1 AND 2 – GROUP INFORMATION AND MATERIAL ACCOUNTING POLICIES

forming part of the consolidated financial statements for the year ended 31 March 2026

1. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DESCRIPTION OF THE COMPANY AND MATERIAL ACCOUNTING POLICIES

1.1 Corporate Information

Jeevan Scientific Technology Limited is a public limited company incorporated and domiciled in India, with its registered office at Plot No. 1 and 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad 500008, Telangana, India. Its equity shares are listed on the BSE Limited. The Group is engaged in the business of clinical research and data management services and operates as an independent clinical contract research organisation offering clinical research solutions to clients across the globe.

These financial statements are authorised by the Board of Directors for issue in accordance with their resolution on 29th May 2026.

1.2 Basis of Preparation of financial Statements

a) Statement of Compliance

The consolidated financial statements comprise financial statements of Jeevan Scientific Technology Limited (the Company) and its Subsidiary Nayas Laboratories Private Limited (collectively, the Group) for the year ended 31 March 2026. The consolidated financial statements of Jeevan Scientific Technology Limited have been prepared and presented in accordance with and in compliance in all material aspects, with the Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 (the "Act") read along with the Companies (Indian Accounting Standards) Rules 2015, and presentation requirements of Division II of Schedule III to the Companies Act, 2013, and as amended from time to time together with the comparative period data as at and for the year ended 31 March 2026.

These consolidated financial statements have been prepared by the company as a going concern on the basis of relevant Ind AS that are effective or elected for early adoption at the company's annual reporting date 31 March 2026. These consolidated financial statements were authorised for issuance by the company's Board of Directors on 29th May 2026.

b) Basis of measurement

The consolidated financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- a) Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- b) Employee defined benefit assets/(liability) are recognized as the net total of the fair value of plan assets, plus actuarial losses, less actuarial gains and the present value of the defined benefit obligation, and
- c) Long-term borrowings are measured at amortized cost using the effective interest rate method and
- d) Right-of-use the assets are recognized at the present value of lease payments that are not paid at that date. This amount is adjusted for any lease payments made at or before the commencement date, lease incentives received and initial direct costs, incurred, if any.

1.3 Basis of Consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiary as at 31 March, 2026.

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if the Group has:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee)
- Exposure, or rights, to variable returns from its involvement with the investee, and
- The ability to use its power over the investee to affect its returns.

Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Group's voting rights and potential voting rights.
- The size of the group's holding of voting rights relative to the size and dispersion of the holdings of the other voting rights holders.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit and loss from the date the Group gains control until the date when the Group ceases to control the subsidiary.

Consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the group uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that group member's financial statements in preparing the consolidated financial statements to ensure conformity with the group's accounting policies.

The financial statements of all entities used for the purpose of consolidation are drawn up to same reporting date as that of the Company, i.e., year ended on 31 March. When the end of the reporting period of the parent is different from that of a subsidiary, the subsidiary prepares, for consolidation purposes, additional financial information as of the same date as the financial statements of the parent to enable the parent to consolidate the financial information of the subsidiary, unless it is impracticable to do so.

Consolidation procedure:

- a) Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognised in the consolidated financial statements at the acquisition date.
- b) Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary.
- c) Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group (profits or losses resulting from intragroup transactions that are recognised in assets, such as inventory and fixed assets, are eliminated in full). Intragroup losses may indicate an impairment that requires recognition in the consolidated financial statements. Ind AS 12 Income Taxes applies to temporary differences that arise from the elimination of profits and losses resulting from intragroup transactions.

Profit or loss and each component of other comprehensive income are attributed to the equity holder of the parent of the Group and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognises the assets (including goodwill) and liabilities of the subsidiary at their carrying amounts at the date when control is lost
- Derecognises the carrying amount of any non-controlling interests
- Derecognises the cumulative translation differences recorded in equity
- Recognises the fair value of the consideration received
- Recognises the fair value of any investment retained
- Recognises any surplus or deficit in profit or loss
- Recognise that distribution of shares of subsidiary to Group in Group's capacity as owners
- Reclassifies the parent's share of components previously recognised in OCI to profit or loss or transferred directly to retained earnings, if required by other Ind ASs as would be required if the Group had directly disposed of the related assets or liabilities

Details of entities controlled by the company are as under:

Name of the enterprises	Country of Incorporation	Nature of business	Shareholding/Controlling interest
Nayas laboratories private limited	India	Clinical research	59.26%
Naya Pharma Private Limited	India	API	31.03%

1.4 Investments in associates and the equity method

Investments in associates. An associate is an entity over which the Group has significant influence, being the power to participate in the financial and operating policy decisions of the investee but not control or joint control over those policies. Significant influence is presumed to exist where the Group holds between 20% and 50% of the voting rights of the investee.

The Group's investment in its associate is accounted for using the equity method. Under the equity method the investment is initially recognised at cost and the carrying amount is adjusted thereafter to recognise the Group's share of the post-acquisition profits or losses of the associate and its share of movements in other comprehensive income. Distributions received from the associate reduce the carrying amount of the investment. Goodwill relating to the associate is included in the carrying amount of the investment and is not tested for impairment separately.

The Consolidated Statement of Profit and Loss reflects the Group's share of the results of operations of the associate, presented outside operating profit and before tax. Any change in other comprehensive income of the associate is presented as part of the Group's other comprehensive income. Where there has been a change recognised directly in the equity of the associate, the Group recognises its share of that change in the Consolidated Statement of Changes in Equity. Unrealised gains and losses on transactions between the Group and the associate are eliminated to the extent of the Group's interest.

The financial statements of the associate are prepared for the same reporting period as the Group. Where necessary, adjustments are made to bring the accounting policies of the associate into line with those of the Group. After application of the equity method, the Group determines at each reporting date whether there is objective evidence that the investment in the associate is impaired. If there is, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying amount, and recognises the loss in the Consolidated Statement of Profit and Loss.

The consolidated financial statements comprise the financial statements of Jeevan Scientific Technology Limited (the Company), its subsidiary Nayas Laboratories Private Limited (collectively, the Group) and its associate Naya Pharma Private Limited for the year ended 31 March 2026.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1.5 Non-controlling interests and changes in ownership interest

Non-controlling interests represent the equity in a subsidiary not attributable, directly or indirectly, to the Group. Non-controlling interests are measured at the proportionate share of the acquiree's identifiable net assets at the acquisition date, and are presented separately within equity in the Consolidated Balance Sheet, separately from the equity attributable to the owners of the parent. Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance.

Changes in the Group's ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. The carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiary, and any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognised directly in equity and attributed to the owners of the parent.

2. Summary of material accounting policies

2.1 Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any non-controlling interests in the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are expensed as incurred.

The Group determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs. The acquired process is considered substantive if it is critical to the ability to continue producing outputs, and the inputs acquired include an organised workforce with the necessary skills, knowledge, or experience to perform that process or it significantly contributes to the ability to continue producing outputs and is considered unique or scarce or cannot be replaced without significant cost, effort, or delay in the ability to continue producing outputs.

At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognised at their acquisition date fair values. For this purpose, the liabilities assumed include contingent liabilities representing present obligation and they are measured at their acquisition fair values irrespective of the fact that outflow of resources embodying economic benefits is not probable. However, the following assets and liabilities acquired in a business combination are measured at the basis indicated below:

- Deferred tax assets or liabilities, and the liabilities or assets related to employee benefit arrangements are recognised and measured in accordance with Ind AS 12 Income Tax and Ind AS 19 Employee Benefits respectively.
- Potential tax effects of temporary differences and carry forwards of an acquiree that exist at the acquisition date or arise as a result of the acquisition are accounted in accordance with Ind AS 12.
- Liabilities or equity instruments related to share based payment arrangements of the acquiree or share – based payments arrangements of the Group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with Ind AS 102 Share-based Payments at the acquisition date.
- Assets (or disposal groups) that are classified as held for sale in accordance with Ind AS 105 Non-current Assets Held for Sale and Discontinued Operations are measured in accordance with that Standard.
- Reacquired rights are measured at a value determined on the basis of the remaining contractual term of the related contract. Such valuation does not consider potential renewal of the reacquired right.

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts by the acquiree.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

If the business combination is achieved in stages, any previously held equity interest is re-measured at its acquisition date fair value and any resulting gain or loss is recognised in profit or loss or OCI, as appropriate.

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of Ind AS 109 Financial Instruments, is measured at fair value with changes in fair value recognised in profit or loss in accordance with Ind AS 109. If the contingent consideration is not within the scope of Ind AS 109, it is measured in accordance with the appropriate Ind AS and shall be recognised in profit or loss. Contingent consideration that is classified as equity is not re-measured at subsequent reporting dates and subsequent its settlement is accounted for within equity.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognised for non-controlling interests, and any previous interest held, over the net identifiable assets acquired and liabilities assumed. If the fair value of the net assets acquired is in excess of the aggregate consideration transferred, the Group re-assesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed and reviews the procedures used to measure the amounts to be recognised at the acquisition date. If the reassessment still results in an excess of the fair value of net assets acquired over the aggregate consideration transferred, then the gain is recognised in OCI and accumulated in equity as capital reserve. However, if there is no clear evidence of bargain purchase, the entity recognises the gain directly in equity as capital reserve, without routing the same through OCI.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

A cash generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

Where goodwill has been allocated to a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted through goodwill during the measurement period, or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date. These adjustments are called as measurement period adjustments. The measurement period does not exceed one year from the acquisition date.

2.2 Current and noncurrent classification

The Group presents assets and liabilities in the balance sheet based on current/ non-current classification.

All the assets and liabilities have been classified as current or noncurrent as per the Group's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013 and Ind AS 1, presentation of financial statements.

An asset is classified as current when it satisfies any of the following criteria:

- a) It is expected to be realized in, or is intended for sale or consumption in, the Group's normal operating cycle;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- b) It is held primarily for the purpose of being traded;
- c) It is expected to be realized within twelve months after the reporting date; or
- d) It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

All other assets are classified as non-current.

A liability is classified as current when it satisfies any of the following criteria:

- a) It is expected to be settled in the Group's normal operating cycle;
- b) It is held primarily for the purpose of being traded;
- c) It is due to be settled within twelve months after the reporting date; or
- d) The Group does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification

The Group classifies all other liabilities as noncurrent.

Current assets/ liabilities include the current portion of noncurrent assets/ liabilities respectively. Deferred tax assets and liabilities are always disclosed as non-current.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Group has identified twelve months as its operating cycle.

2.3 Functional and presentation currency

These consolidated financial statements are presented in Indian rupees, which is also the functional currency of the Company. All the financial information presented in Indian rupees has presented in lakhs.

2.4 Fair value measurement

The Group measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- in the principal market for the asset or liability, or
- in the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Group.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the Ind AS financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the Ind AS financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Group's management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for sale in discontinued operations.

External valuers are involved, wherever considered necessary. For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.

This note summarizes accounting policy for fair value. Other fair value related disclosures are given in the relevant notes.

2.5 Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded by the Group at their respective functional currency spot rates at the date, the transaction first qualifies for recognition.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date. Exchange differences arising on settlement or translation of monetary items are recognised in the statement of profit and loss.

Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the initial transaction.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.

The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in other comprehensive income ("OCI") or profit or loss are also recognised in OCI or profit or loss, respectively).

2.6 Property plant and equipment:

Recognition and Measurement

The cost of an item of property, plant and equipment are recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably.

Freehold land is carried at historical cost less any accumulated impairment losses.

Items of property, plant and equipment (including capital-work-in progress) are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any.

Cost includes expenditures that are directly attributable to the acquisition of the asset i.e., freight, non-refundable duties and taxes applicable, and other expenses related to acquisition and installation.

The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use.

When significant parts of plant and equipment are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably.

Depreciation

Depreciation on items of PPE is provided on straight line basis, computed on the basis of useful lives as mentioned in Schedule II to the Companies Act, 2013. Depreciation on additions / disposals is provided on a pro-rata basis i.e. from / up to the date on which asset is ready for use / disposed-off.

The useful lives are as follows:

Plant and machinery	10 years
Electrical Installations	10 years
Computers	3 years
Servers & Networks	6 years
Vehicles- Motor car	8 years
Furniture and Fixtures	10 years
Office Equipment	5 years
Building_Commercial	30 Years
Laboratory Equipment	10 Years

The residual values, useful lives and method of depreciation are reviewed at each financial year end and adjusted prospectively, if appropriate.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Group and its cost can be measured reliably. The carrying amount of the replaced part will be derecognized. The costs of repairs and maintenance are recognized in the statement of profit and loss as incurred.

Items of stores and spares that meet the definition of Property, plant and equipment are capitalized at cost, otherwise, such items are classified as inventories.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date is disclosed as capital advances under other assets. The cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress.

2.7 Intangible assets

Research and development expenses:

Expenditure on research activities is recognised in profit or loss as incurred.

Development expenditure is capitalised as part of the cost of the resulting intangible asset only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Group intends to and has sufficient resources to complete development and to use or sell the asset.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Otherwise, it is recognised in profit or loss as incurred.

Subsequent to initial recognition, development expenditure, capitalized if any, is measured at cost less accumulated amortisation and any accumulated impairment losses.

Process Knowhow:

The group continually invests in methods development in the bioanalytical laboratory, essential for supporting the business and enhancing capabilities. These proprietary methods, expected to be utilized over 7 years, are fundamental for bioanalysis in various global clinical studies. Accordingly, the company recognize these expenses as intangible assets and amortise them over a period of 7 years.

2.8 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a. Financial assets

Initial recognition and measurement

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Group commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost.
- Debt instruments at fair value through other comprehensive income (FVTOCI).
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL);
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost, if both of the following conditions are met: (i) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and (ii) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the statement of profit and loss. The losses arising from impairment are recognised in the statement of profit and loss. This category generally applies to trade and other receivables.

Debt instrument at FVTOCI

A 'debt instrument' is classified as FVTOCI, if both of the following criteria are met: (i) The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and (ii) The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in OCI. However, the Group recognizes interest income, impairment losses and foreign exchange gain or loss in the statement of profit and loss. On de-recognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to statement of profit and loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Equity Instruments

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as FVTPL. If the Group decides to classify an equity instrument as FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to statement of profit and loss. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group's balance sheet) when:

- a) The rights to receive cash flows from the asset have expired, or
- b) The Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Group continues to recognize the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Impairment of Financial Assets

The Group assesses at each balance sheet date whether a financial asset or a group of financial assets is impaired.

In accordance with Ind AS 109, the Group uses "Expected Credit Loss" (ECL) model, for evaluating impairment of Financial Assets other than those measured at Fair Value Through Profit and Loss (FVTPL).

Expected credit losses are measured through a loss allowance at an amount equal to:

- The 12 months expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date);
- Full lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument)

The Group follows simplified approach for recognition of impairment loss allowance on trade receivables and under the simplified approach, the Group does not track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECL at each reporting date right from its initial recognition. The Group uses a provision matrix to determine impairment loss allowance on trade receivables. The provision matrix is based on its historically observed default rates over the expected life of trade receivable and is adjusted for forward looking estimates. At every reporting date, the historical observed default rates are updated

For other assets, the Group uses 12-month ECL to provide for impairment loss where there is no significant increase in credit risk. If there is significant increase in credit risk full lifetime ECL is used.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value i.e., loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts.

Subsequent measurement

The measurement of financial liabilities depends on their classification.

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Group that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading, unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the statement of profit and loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/losses attributable to changes in own credit risk are recognized in OCI. These gains/loss are not subsequently transferred to the statement of profit and loss.

However, the Group may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognized in the statement of profit and loss.

Loans and borrowings

Borrowings is the category most relevant to the Group. After initial recognition, interest-bearing borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in the statement of profit and loss when the liabilities are derecognised as well as through the EIR amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

De-recognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Reclassification of financial assets and liabilities

The Group determines classification of financial assets and liabilities on initial recognition. After initial recognition, no re-classification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a re-classification is made only if there is a change in the business model for managing those assets. A change in the business model occurs when the Group either begins or ceases to perform an activity that is significant to its operations. If the Group reclassifies financial assets, it applies the re-classification prospectively from the re-classification date, which is the first day of the immediately next reporting period following the change in business model. The Group does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet, if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

2.9 Derivative financial instruments and hedge accounting

The Group currently does not use derivative financial instruments, such as forward currency contracts, currency and interest rate swaps, to hedge its foreign currency risks and interest rate risks. If and when the company uses such derivative financial instruments, they will be initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Any gains or losses arising from changes in the fair value of derivatives are taken directly to the statement of profit and loss.

2.10 Cash & Cash Equivalents

Cash and bank balances comprise of cash balance in hand, in current accounts with banks, and other short-term deposits. For this purpose, "short-term" means investments having maturity of three months or less from the date of investment, and which are subject to an insignificant risk of change in value. Bank overdrafts that are repayable on demand and form an integral part of our cash management are included as a component of cash and cash equivalents for the purpose of the statement of cash flows.

2.11 Inventories

Inventories are valued at the lower of cost and net realizable value.

Inventories consisting of materials, stores and spares and loose tools are valued at cost or net realizable value by using weighted average method.

Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The net realizable value of work-in-progress is determined with reference to the selling prices of related finished products.

2.12 Impairment of non-financial assets

The carrying amounts of the Group's non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment.

If any such indication exists, then the asset's recoverable amount is estimated.

For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March 31.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit.

For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflow of other assets or groups of assets (the "cash-generating unit").

The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to project future cash flows after the fifth year. To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, the Group extrapolates cash

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth rate does not exceed the long-term average growth rate for the products, industries, or country in which the entity operates, or for the market in which the asset is used.

An impairment loss is recognized in the statement of profit and loss if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.

Reversal of Impairment of Assets

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

2.13 Employee benefits

Short term employee benefits

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

The Group's contributions to defined contribution plans are charged to the statement of profit and loss as and when the services are received from the employees.

Defined benefit plans

The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the advice of qualified actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market interest rates on government bonds are used. The current service cost of the defined benefit plan, recognized in the statement of profit and loss in employee benefit expense, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognized immediately in the statement of profit and loss.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions for defined benefit obligation and plan assets are recognized in OCI in the period in which they arise. When the benefits under a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in the statement of profit and loss. The Group recognizes gains or losses on the settlement of a defined benefit plan obligation when the settlement occurs.

Termination benefits

Termination benefits are recognized as an expense in the statement of profit and loss when the Group is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense in the statement of profit and loss if the Group has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Other long-term employee benefits

The Group's net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognised in the statement of profit and loss in the period in which they arise.

Compensated absences

The Group's current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilised compensated absences and utilise them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Group measures the expected cost of accumulating compensated absences as the additional amount that the Group incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary.

Share based payments

Employees of the Group receive remuneration in the form of Share-based payments, whereby employees render services as consideration for equity instruments.

Equity-Settled Transactions The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using Black Scholes valuation model.

That cost is recognized, together with a corresponding increase in share-based payment (SBP) reserves in equity, over the period in which the performance and/or service conditions are fulfilled in employee benefits expense. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The Statement of profit and loss expense or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period and is recognized in employee benefits expense.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

2.14 Provisions, contingent liabilities and contingent assets

Provisions

A provision is recognized in the statement of profit and loss if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

Contingent liabilities and contingent assets

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are not recognized in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Onerous contracts

A provision for onerous contracts is recognised in the statement of profit and loss when the expected benefits to be derived by the Group from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Group recognises any impairment loss on the assets associated with that contract.

Reimbursement rights

Expected reimbursements for expenditures required to settle a provision are recognised in the statement of profit and loss only when receipt of such reimbursements is virtually certain. Such reimbursements are recognised as a separate asset in the balance sheet, with a corresponding credit to the specific expense for which the provision has been made.

2.15 Revenue recognition:

Ind AS 115 recognizes revenue on transfer of the control of goods or services, either over a period of time or at a point in time, at an amount that the entity expects to be entitled in exchange for those goods or services. In order to align with Ind AS 115, the Accounting policy on revenue recognition was reviewed and revised.

The Group primarily earns revenue from Contract research and testing services.

Revenue is recognised upon transfer of control of promised services to customers in an amount that reflects the consideration the Group expect to receive in exchange for those services.

Revenue from providing services is recognised in the accounting period in which such services are rendered. At contract inception, the Group assesses its promise to transfer services to a customer to identify separate performance obligations. The Group applies judgment to determine whether each service promised to a customer is capable of being distinct, and are distinct in the context of the contract, if not, the promised services are combined and accounted as a single performance obligation. The Group allocates the arrangement consideration to separately identifiable performance obligation based on their relative stand-alone selling price or residual method.

In case of fixed-price contracts, the customer pays the fixed amount based on a payment schedule.

If the services rendered by the Group exceed the payment, a contract asset is recognised. If the payments exceed the services rendered, a contract liability is recognised.

Revenues in excess/short of invoicing are classified as assets/liabilities, as the case may be.

2.16 Dividend and Interest Income

Dividend income is recognised in profit or loss on the date on which the Group's right to receive payment is established.

Interest Income mainly comprises of interest on Margin money deposit with banks relating to bank guarantee and term deposits.

Interest income or expense is recognised using the effective interest method (EIR).

Interest is recognized using the time-proportion method, based on rates implicit in the transactions.

2.17 Borrowing Costs

Borrowing costs are interest and other costs incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset. Other borrowing costs are recognised as an expense in the period in which they are incurred.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

2.18 Tax expenses

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in Other comprehensive income.

The Group has determined that interest and penalties related to income taxes, including uncertain tax treatments, do not meet the definition of income taxes, and therefore accounted for them under Ind AS 37 Provisions, Contingent Liabilities and Contingent Assets.

Current tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity in correlation to the underlying transaction). Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions, where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities and assets are recognized for all taxable temporary differences and deductible temporary differences.

Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity in correlation to the underlying transaction).

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Minimum alternate tax (MAT) paid in a year is charged to the statement of profit and loss as current tax for the year. The deferred tax asset is recognised for MAT credit available only to the extent that it is probable that the Group will pay normal income tax during the specified year, i.e., the year for which MAT credit is allowed to be carried forward. In the year in which the Group recognizes MAT credit as an asset, it is created by way of credit to the statement of profit and loss and shown as part of deferred tax asset. The Group reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent that it is no longer probable that it will pay normal tax during the specified period.

Goods and Service Tax (GST) paid on acquisition of assets or on incurring expenses.

When the tax incurred on purchase of assets or services is not recoverable from the taxation authority, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable. Otherwise, expenses and assets are recognized net of the amount of taxes paid. The net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

2.19 Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Group as a lessee

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The Group recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities.

The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received.

Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets. If ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

The right-of-use assets are also subject to impairment. Refer to the accounting policies in section of Impairment of non-financial assets.

Lease liabilities

At the commencement date of the lease, the Group recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating the lease, if the lease term reflects the Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. The Group's lease liabilities are included in Borrowings.

Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered to be of low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

2.20 Earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the year.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

Diluted earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect of interest and other financing costs or income (net of attributable taxes) associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

2.21 Segment reporting

The Group is engaged in the in "Clinical "Research Services and the same constitutes a single reportable business segment as per Ind AS 108.

2.22 Share capital

Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

2.23 Significant accounting judgements, estimates, and assumption

The preparation of the financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. These estimates and associated assumptions are based on historical experiences and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, the areas involving critical estimates or Judgment are:

Determining the lease term of contracts with renewal and termination options

The Group determines the lease term as the noncancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Group has several lease contracts that include extension and termination options. The Group applies judgement in evaluating whether it is reasonably certain to exercise the option to renew or terminate the lease. That is, it considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate. Furthermore, the periods covered by termination options are included as part of the lease term only when they are reasonably certain not to be exercised.

Property, plant and equipment

The depreciation of property, plant and equipment is derived on determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The useful lives and residual values of Group's assets are determined by management at the time of acquisition of asset and is reviewed periodically, including at each financial year end. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life.

Impairment of financial and non-financial assets

Significant management judgement is required to determine the amounts of impairment loss on the financial and nonfinancial assets. The calculations of impairment loss are sensitive to underlying assumptions.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Tax provisions and contingencies

Significant management judgement is required to determine the amounts of tax provisions and contingencies. Deferred tax assets are recognised for unused tax losses and MAT credit entitlements to the extent it is probable that taxable profit will be available against which these losses and credit entitlements can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Defined benefit plans

The cost of the defined benefit plan and the present value of the obligation are determined using actuarial valuation. An actuarial valuation involves various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds where remaining maturity of such bond correspond to expected term of defined benefit obligation.

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates.

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using internal valuation techniques. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note No. 3:
Property, plant and equipment

Particulars	Building	Plant & Machinery	Furniture & Fixtures	Motor Vehicles	Office & Laboratory Equipment	Computers	Books	Total
Gross carrying value								
Balance as at 1 April 2024	513.50	253.24	380.55	222.00	2,403.18	263.03	0.90	4,036.40
Additions for the year	1.43	8.87	9.97	222.04	509.19	9.70	-	761.20
Disposals for the year	-	-	-	6.15	-	-	-	6.15
Balance as at 31 March 2025	514.93	262.11	390.52	437.89	2,912.37	272.73	0.90	4,791.45
Gross carrying value								
Balance as at 31 March 2025	514.93	262.11	390.52	437.89	2,912.37	272.73	0.90	4,791.45
Additions for the year	0.62	4.76	9.69	0.81	631.12	8.93	-	655.93
Disposals for the year	-	-	-	0.72	-	-	-	0.72
Balance as at 31 March 2026	515.55	266.87	400.21	437.98	3,543.49	281.66	0.90	5,446.66
Accumulated depreciation								
Balance as at 1 April 2024	105.85	170.44	254.71	103.92	1,291.39	230.42	0.90	2,157.63
Depreciation charge for the year	23.95	20.49	29.46	36.24	245.79	13.52	-	369.45
On Disposals	-	-	-	6.15	-	-	-	6.15
Balance as at 31 March 2025	129.80	190.93	284.17	134.01	1,537.18	243.94	0.90	2,520.93
Accumulated depreciation								
Balance as at 31 March 2025	129.80	190.93	284.17	134.01	1,537.18	243.94	0.90	2,520.93
Depreciation charge for the year	24.05	16.97	25.25	48.47	257.47	10.51	-	382.72
On Disposals	-	-	-	0.63	-	-	-	0.63
Balance as at 31 March 2026	153.85	207.90	309.42	181.85	1,794.65	254.45	0.90	2,903.02
Net carrying value								
As on 31 March 2025	385.13	71.18	106.35	303.88	1,375.19	28.79	-	2,270.50
As on 31 March 2026	361.70	58.97	90.79	256.13	1,748.84	27.21	-	2,543.63

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note No. 3: Intangible Assets

Particulars	Software	Copyrights	Process Know how	Total
Gross carrying value				
Balance as at 1 April 2024	172.50	12.04	1,292.00	1,476.54
Additions for the year	-	-	286.05	286.05
Disposals for the year	-	-	-	-
Balance as at 31 March 2025	172.50	12.04	1,578.05	1,762.59
Gross carrying value				
Balance as at 31 March 2025	172.50	12.04	1,578.05	1,762.59
Additions for the year	-	-	170.41	170.41
Disposals for the year	-	-	-	-
Balance as at 31 March 2026	172.50	12.04	1,748.46	1,933.00
Accumulated depreciation				
Balance as at 1 April 2024	161.70	12.04	749.39	923.13
Amortization charge for the year	5.50	-	147.39	152.89
On Disposals	-	-	-	-
Balance as at 31 March 2025	167.20	12.04	896.78	1,076.02
Accumulated depreciation				
Balance as at 31 March 2025	167.20	12.04	896.78	1,076.02
Amortization charge for the year	2.53	-	148.52	151.05
On Disposals	-	-	-	-
Balance as at 31 March 2026	169.73	12.04	1,045.30	1,227.07
Net carrying value				
As on 31 March 2025	5.30	-	681.27	686.57
As on 31 March 2026	2.77	-	703.16	705.93

3. Capital Work in Progress

Particulars	Lease Hold Improvements	Plant & Machinery	Computers	Furniture & Fixtures	Office & Laboratory Equipment	Total
Gross Carrying Value						
Balance as at 1 April 2024	-	-	-	-	281.17	281.17
Additions for the year	-	-	-	-	189.88	189.88
Reclassification	-	-	-	-	-	-
Disposals for the year	-	-	-	-	-	-
Balance as at 31 March 2025	-	-	-	-	471.05	471.05
Gross Carrying Value						
Balance as at 31 March 2025	-	-	-	-	471.05	471.05
Additions for the year	-	-	-	-	-	-
Reclassification	-	-	-	-	-	-
Disposals for the year	-	-	-	-	-	-
Balance as at 31 March 2026	-	-	-	-	471.05	471.05
Accumulated Depreciation						
Balance as at 1 April 2024	-	-	-	-	-	-
Depreciation charge for the year	-	-	-	-	-	-
On Disposals	-	-	-	-	-	-
Balance as at March 31, 2025	-	-	-	-	-	-
Accumulated Depreciation						
Balance as at March 31, 2025	-	-	-	-	-	-
Depreciation charge for the year	-	-	-	-	-	-
On Disposals	-	-	-	-	-	-
Balance as at March 31, 2026	-	-	-	-	-	-
Net carrying value						
As on 31 March 2025	-	-	-	-	471.05	471.05
As on 31 March 2026	-	-	-	-	471.05	471.05

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Ageing of Capital Work in Progress as at 31 March 2026

CWIP-Tangibles	Amount in CWIP for a period of				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Projects-in-progress	-	189.88	281.17	-	471.05
Projects temporarily suspended	-	189.88	281.17	-	471.05

Ageing of Capital Work in Progress as at 31 March 2025

CWIP-Tangibles	Amount in CWIP for a period of				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Projects-in-progress	189.88	281	-	-	471.05
Projects temporarily suspended	189.88	281.17	-	-	471.05

3. Right-of-use assets

Particulars	Building	Total
Gross Carrying Value		
Balance as at 31 March 2024	507.68	507.68
Additions for the year	423.66	423.66
Disposals for the year	11.30	11.30
Balance as at 31 March 2025	920.04	920.04
Gross Carrying Value		
Balance as at 31 March 2025	920.04	920.04
Additions for the year	26.15	26.15
Disposals for the year	6.72	6.72
Balance as at 31 March 2026	939.47	939.47
Accumulated depreciation		
Balance as at 31 March 2025	422.55	422.55
Depreciation for the year	158.10	158.10
Balance as at 31 March 2026	580.65	580.65
Net carrying Value		
As on 31 March 2025	497.49	497.49
As on 31 March 2026	358.82	358.82

Notes:

- i. The title deeds of all immovable properties are held in the name of the company. The company has not revalued its property plant and equipment.
- ii. Pledge on Property, Plant and Equipment
 Property, Plant and Equipment (Other than Vehicles) with a net carrying amount aggregating Rs.1,490.00 lakhs (March 31, 2025-Rs. 1831.50 Lakhs) are subject to a
 Pari Passu first charge on the company's Term loans. Further, the Property, Plant and Equipment (Other than Vehicles) are subject to Pari Passu second charge on the company's current borrowings.
- III. Hypothecation on Vehicles
 Vehicles with Net Carrying amount aggregating Rs. 206.21 Lakhs (March 31, 2025- Rs. 204.73 Lakhs) are subject to hypothecation.
- IV. During the year Depreciaion on Property, Plant & Equipment Rs.27.61 Lakhs transfer to Process Knowhow.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consolidated Notes to financial statements for the Year Ended 31st March, 2026

4. Non current investments

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Naya Pharma Pvt Ltd (Associate Company with 31.03% of Share Holding)	300.00	-
Less: Share of Profit/ (Loss) from Associate accounted using Equity Method	(1.53)	-
Total	298.47	-

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Investments measured at cost		
In Equity shares of Associated companies(16,50,165 equity shares of Rs.18.18/- each in of Naya Pharma Private Limited) fully paid-up	300.00	-
Total of investments measured at Cost	300.00	-
Foot notes:		
Aggreagate value of quoted investments and market value thereof	-	-
Aggreagate value of unquoted investments	300.00	-

Notes:

The Company has complied with number of layers prescribed under clause 87 of Section 2 of the Companies Act, 2013 read with

the Companies (Restriction on number of layers) Rules, 2017.

5. Other non current Assets

PARTICULARS	As on 31.03.2026	As on 31.03.2025
i) Capital Advances to related Parties	630.54	630.54
ii) Capital Advances to Others	577.00	227.00
Total	1,207.54	857.54

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

6. Deferred Tax Asset (Net)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Deferred Tax Assets	91.89	91.06
Add/Less: Deferred Tax Liabilities	(95.22)	0.84
Total	(3.33)	91.89

7. Inventories

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Consumables, at the lower of cost and net relisable value	302.74	161.82
Total	302.74	161.82

8. Trade receivables (Unsecured)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Considered good	2,091.01	1,594.22
Trade receivables wkich have significant increase in credit risk	-	-
Credit impaired	-	-
	2,091.01	1,594.22
Less: Allowances for expected credit losses	21.70	-
Total	2,069.31	1,594.22

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Ageing schedules

Trade receivables ageing schedule for the year ended 31 March 2026

PARTICULARS	Outstanding for following periods from due date of payment						Total
	Not due	Less than 6 months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	
(i) Undisputed trade receivables- considered good	-	1,656.86	42.84	7.07	36.98	347.26	2,091.01
(ii) Undisputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
(iii) Disputed trade receivables- considered good	-	-	-	-	-	-	-
(iv) Disputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
Less: Allowances for expected credit losses	-	-	-	-	-	(21.70)	(21.70)
Total trade receivables Current	-	1,656.86	42.84	7.07	36.98	325.56	2,069.31

Ageing schedules

Trade receivables ageing schedule for the year ended 31 March 2025

PARTICULARS	Outstanding for following periods from due date of payment						Total
	Not due	Less than 6 months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	
(i) Undisputed trade receivables- considered good	-	1,159.83	134.73	60.58	230.62	8.46	1,594.22
(ii) Undisputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
(iii) Disputed trade receivables- considered good	-	-	-	-	-	-	-
(iv) Disputed trade receivables- considered Doubtful	-	-	-	-	-	-	-
Less: Allowances for expected credit losses	-	-	-	-	-	-	-
Total trade receivables Current	-	1,159.83	134.73	60.58	230.62	8.46	1,594.22

9. Cash and Cash Equivalents

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Balances with Banks in current accounts	7.04	3.45
Cash on hand	40.68	18.11
In term deposits with maturity less than 3 months	902.84	2.67
Total	950.55	24.23

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

10. Other Financial Assets

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Interest Receivable	0.62	-
Rent Receivable	1.00	-
Loan to Associates	57.02	-
Other Receivables	155.00	155.00
Total	213.64	155.00
Non Current Financial Assets		
Security Deposit	85.86	77.84
Bank balances in fixed deposits more than 12 months	0.39	0.39
Total	86.26	78.24

11. Current Tax Assets (Net)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Tax deducted at source	578.37	331.09
MAT Credit Entitlement	45.93	12.02
Total	624.30	343.11

12. Other Current Assets

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Prepaid Expenses	98.90	53.94
Other Receivables	56.25	8.25
Vendor advances	439.06	277.53
Advances to employees	34.10	39.15
Balances with Government authorities- GST	74.31	73.35
Unbilled Revenue (Contract Asset-Note 30)	123.84	145.15
Total	826.47	597.37

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

13. Share capital

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Authorised 2,50,00,000 equity shares of Rs.10/- each (31 March 2026: 2,50,00,000 equity Shares of Rs.10/- each)	2,500.00	2,100.00
Issued, subscribed and paid- up 1,99,18,965 (31 March, 2026) equity Shares of Rs. 10/- each fully paid-up	1,991.90	1,583.40

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

PARTICULARS	As on 31.03.2026		As on 31.03.2025	
	Number	Amount	Number	Amount
At the beginning of the period	1,58,33,965	1,583.40	1,54,80,215	1,548.02
Issued during the period	40,85,000	408.50	3,53,750.00	35.38
Outstanding at the end of the period	1,99,18,965	1,991.90	1,58,33,965	1,583.40

- b. Rights, preferences and restrictions attaching to equity shares The Company has a single class of equity shares having a par value of ₹10 per share. Each holder of equity shares is entitled to one vote per share. Any dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in the case of an interim dividend. In the event of liquidation, the equity shareholders are entitled to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to the number of equity shares held.

c. Details of shareholders holding more than 5% share in the company

PARTICULARS	As on 31.03.2026		As on 31.03.2025	
	Number of Shares	% of Share Holding	Number of Shares	% of Share Holding
Sri K. Krishna Kishore	21,35,113	10.71%	21,35,113	13.48%
Smt. K. Vanaja	15,73,800	7.90%	15,73,800	9.94%
M/s. Padmaja Private Trust	15,00,000	7.53%	-	0

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

d. Details of shares held by promoters

PARTICULARS	As on 31.03.2026		As on 31.03.2025		% Change during the year
	Number of Shares	% of Share Holding	Number of Shares	% of Share Holding	
Sri K. Krishna Kishore	21,35,113	10.71%	21,35,113	13.48%	-2.77%
Smt. K. Vanaja	15,73,800	7.90%	15,73,800	9.94%	-2.04%
K. Gopi Krishna	7,20,000	3.61%	7,20,000	4.55%	-0.94%
K. Jeevan Krishna	9,17,772	4.61%	9,17,772	5.80%	-1.19%
T. Sri Devi	1,21,000	0.61%	1,21,000	0.76%	-0.15%
Jeevan Mitra Chitfund Private Limited	85,200	0.43%	85,200	0.54%	-0.11%
T. Ravi Babu	3,93,200	1.97%	3,93,200	2.48%	-0.51%
Snigdha Mothukuri	78,500	0.39%	78,500	0.50%	-0.11%

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

14. Other equity

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Securities premium reserve		
Opening Balance	2,358.46	2,037.71
Options Exercised	1,225.50	320.75
Closing Balance	3,583.96	2,358.46
Share-based payment reserve		
Opening Balance	282.70	499.36
Addition	71.13	104.09
Options Exercised	-	(320.75)
Closing Balance	353.83	282.70
Shares forfeited reserves		
Opening Balance	20.17	20.17
Closing Balance	20.17	20.17
Retained Earnings		
Opening Balance	727.55	723.02
Profit/Loss adjusted during the year	115.08	4.53
Fair Value loss on Financial instruments at fair value through Profit & Loss	(0.92)	-
On account of Consolidation	-	-
Closing Balance	841.71	727.55
Money received against share warrants		
Opening Balance	0.01	0.01
Current year transfer	350.00	-
Closing Balance	350.01	0.01
Other Comprehensive Income		
Opening Balance	12.90	14.52
Re-measurement gains/ (losses) on defined benefit plans	17.82	(1.62)
Closing Balance	30.72	12.90
Total	5,180.43	3,401.79
Non controlling interest		
Opening Balance	21.91	9.16
Non controlling interest	100.75	12.75
Closing balance	122.66	21.91

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

15. Long term borrowings

PARTICULARS	Non Current portion		Current Portion	
	As on 31.03.2026	As on 31.03.2025	As on 31.03.2026	As on 31.03.2025
Term Loan- secured				
A) From Banks				
i) Vehicle Loans	106.24	147.57	41.30	37.82
ii) Machinery loans	872.94	855.46	218.12	165.54
iii) Covid Loan	15.75	75.00	59.16	53.92
B) Intercompany Loans	15.00	15.00	-	-
C) Loans and advances from related parties	-	80.00	-	-
Total	1,009.92	1,173.03	318.57	257.28

Loan	Sanctioned amount	Rate of interest	Repayment	Commencing
Machinery loan – Karur Vysya Bank	420.00	10.25%	60 monthly instalments	28-Jun-25
Machinery loan – Karur Vysya Bank	255.00	9.25%	85 monthly instalments	30-Jan-26
Covid loan – Karur Vysya Bank	175.00	8.15%	38 monthly instalments	5-Apr-24
Machinery loan – Karur Vysya Bank	640.00	9.00%	69 monthly instalments	24-Jul-24
Car loan – HDFC Bank	30.06	8.80%	48 monthly instalments	7-Sep-23
Car loan – Mercedes-Benz Financial Services	95.15	8.78%	60 monthly instalments	5-Sep-24
Car loan – Mercedes-Benz Financial Services	81.00	8.62%	60 monthly instalments	5-Mar-25

Machinery loans and the Covid loan from Karur Vysya Bank are secured by hypothecation of machinery and assets acquired out of the bank finance, and by a pari passu first charge on plant and equipment other than vehicles. Vehicle loans are secured by hypothecation of the vehicle financed. Refer note 3.

There has been no default in the repayment of principal or interest on any borrowing during the period and no borrowing has been guaranteed by a director except as disclosed in note 18.

16. Lease liabilities

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Non-current lease liabilities	287.21	386.01
Total	287.21	386.01
Current lease liabilities	125.31	157.64
Total	125.31	157.64

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

17. Non Current Provisions

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Provision for Employee benefit- Gratuity	73.88	55.84
Total	73.88	55.84

18. Current Borrowings

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Loan repayable on Demand		
i) Loan From Banks	387.40	84.01
ii) Current Maturity of Longterm Borrowings	318.57	257.28
Total	705.98	341.30

Notes:

The cash credit facility from Karur Vysya Bank is primarily secured by hypothecation of the entire current assets of the Company, present and future, and by a pari passu second charge on property, plant and equipment other than vehicles. It is additionally guaranteed by a director. Working capital limits in excess of Rs. 5 crores have been sanctioned on the security of current assets, and the quarterly returns filed with the bank agree with the books of account.

19. Trade Payables

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Total outstanding dues of micro and small enterprises	222.12	114.88
Total Outstanding dues of creditors other than micro and small enterprises	390.64	202.82
Total	612.76	317.70

Trade payables ageing

Trade payables ageing for the year ended 31 March 2026

PARTICULARS	Outstanding for following periods from due date of payment					Total
	Not due	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	222.12	-	-	-	222.12
(ii) Others	-	377.88	2.25	7.57	2.94	390.64
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
	-	600.00	2.25	7.57	2.94	612.76

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Trade payables ageing Trade payables ageing for the year ended 31 March 2025

PARTICULARS	Outstanding for following periods from due date of payment					Total
	Not due	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	114.88	-	-	-	114.88
(ii) Others	-	185.13	2.25	13.28	2.16	202.82
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
	-	300.01	2.25	13.28	2.16	317.70

Dues to Micro and Small Enterprises

The information as required to be disclosed Micro and Small Enterprises under the Micro, Small and Medium Enterprises Development Act, 2006 (Act) is as given below and the information mentioned in Balance Sheet. Trade Payables dues to Micro and Small Enterprises, has been determined on the basis of information available with the Company and relied on by the auditors:

	As on 31.03.2026	As on 31.03.2025
i) Principal amount remaining unpaid as on 31st March (overdue amounts)	222.12	114.88
ii) Interest due thereon as on 31st March	Nil	Nil
iii) Interest paid by the Company in terms of Section 16 of Micro, Small and Medium Enterprises Development Act, 2006 along with the amount of payment made to the suppliers beyond the appointed day during the year.	Nil	Nil
iv) Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Act.	Nil	Nil
v) Interest accrued and remaining unpaid as at 31st March	Nil	Nil
vi) Further, interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises for the purpose of disallowance as a deductible expenditure under Section 23 of the Act.	Nil	Nil

Amount shown against dues to Micro & Small Enterprises under the head trade payables represents amount outstanding as on 31st March but not due for payment.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

20. Other Financial liabilities (Current)

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Interest Payable	53.21	53.21
Rent Payable	4.69	3.94
Creditors for Capital Assets	0.86	0.86
Other Payables	74.26	55.16
Total	133.02	113.17

21. Other Current Liabilities

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Statutory Dues- TDS	31.89	73.32
Statutory Dues-Professional tax	0.66	0.59
Statutory Dues-GST	16.16	0.23
Statutory Dues- Provident Fund	10.47	8.15
Statutory Dues- ESI	0.82	0.81
Salaries payable	175.05	125.45
Directors Remuneration Payable	9.37	8.87
Provision for expenses	8.28	4.38
Advance received from Customers (Contract Liability- Note 30)	11.14	3.97
Prepaid Revenue (Contract Liability- Note 30)	101.46	37.77
Total	365.31	263.56

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

22. Current Provisions

PARTICULARS	As on 31.03.2026	As on 31.03.2025
Provision for Income Tax	44.56	12.02
Provision for Employee benefit- Gratuity	2.45	1.66
Total	47.01	13.68

23. Revenue from operations

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Clinical Research Services- Domestic	3,085.10	3,627.63
Clinical Research Services- Export	3,068.62	1,056.73
Total	6,153.71	4,684.36

Note: Disaggregation of revenue, contract balances and information about major customers are in note 30.

24. Other Income

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Interest on Income Tax Refund	0.28	16.00
Interest from Fixed Deposits	0.57	2.99
Interest From Unsecured Loans	3.28	22.39
Interest on Lease Deposits measured at amortised cost	4.95	4.83
Miscellaneous Income	23.34	1.69
Dividend Income from Chit Fund	11.56	5.03
Profit on sale of Property, Plant & Equipment	0.14	0.75
Insurance Claims	-	10.33
Net Gain/ (Loss) on Foreign Currency Transactions and Transalation.	48.54	(2.36)
Rent Received	4.60	3.60
Total	97.27	65.26

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

25. Cost of Material Consumed

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Opening Stock	161.82	108.99
Add Purchases	628.62	433.09
	790.44	542.07
Less: Closing Stock	302.74	161.82
Total	487.70	380.25

26. Employees benefit expenses

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Salaries & Allowances	1,746.34	1,328.07
Staff Welfare Expenses	44.27	35.33
Gratuity	41.12	17.78
Leave encashment	11.63	4.90
Director's Remuneration	249.89	215.55
Share Based payments to employees	71.14	104.09
Total	2,164.38	1,705.71

27. Finance Cost

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Interest expense	-	-
on Lease	43.97	43.96
on Vehicle Loans	14.67	7.30
on Cash Credit and Bill Discounting Facilities	42.60	30.24
other borrowing Cost	9.67	77.61
on Term loan from Bank	93.02	16.96
Total	203.94	176.09

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

28. Other expenses

PARTICULARS	For the Year Ended 2025-26	For the Year Ended 2024-25
Rent - Short Term Leases	3.72	2.53
Electricity	148.66	112.71
Licenses & Renewals	169.18	96.92
Repairs & Maintenance	145.68	68.70
Insurance	40.52	43.39
Communication Charges	19.27	16.20
Travelling, Conveyance	86.90	80.25
Printing & Stationery	14.33	12.80
Advertisement, Publicity & Business Promotion	47.17	23.48
Sales Commission	299.48	219.16
Professional Charges	500.66	439.50
Auditors Remuneration		
: For Statutory Audit	2.10	2.10
: For Tax Audit	0.25	0.25
: For Certification	0.25	0.25
General Expenses	59.37	37.03
Office Maintenance	86.36	79.49
Director's Sitting fees	12.05	7.35
Registrar's fee	2.07	1.01
Garden Maintenance	5.20	4.74
Provision for CSR	-	5.50
BSE Listing Fee	4.20	3.25
ROC Filing Fee	3.84	0.31
Volunteer Expenses	794.62	581.85
Water Charges	0.56	0.69
Property Tax Paid	2.05	2.05
Bank charges	8.46	5.82
Loan Processing Charges	10.35	9.44
Loss on Chit	29.00	-
Statutory Fee	1.71	-
Allowances for expected credit losses	21.70	
Interest on Income Tax	0.28	0.57
Total	2,519.98	1,857.34

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2026 | (All amounts in ₹ lakhs, unless otherwise stated)

29. Changes in liabilities arising from financing activities

For the year ended 31 March 2026

PARTICULARS	Current Borrowings	Non-current Borrowings	Lease liabilities	Total
As at 1 April 2025	341.30	1,173.03	543.65	2,057.98
Proceeds from borrowings during the year	570.40	255.00	-	825.40
Repayment of borrowings during the year	(205.72)	(418.11)	-	(623.83)
Interest accretion on Lease Liability	-	-	43.97	43.97
Recognition of right of use liability during the year	-	-	26.15	26.15
Payment of lease liability (Principal & Interest)	-	-	(201.25)	(201.25)
Effect of Changes in Foreign Exchange Rates	-	-	-	-
As at 31 March 2026	705.98	1009.92	412.52	2,128.42

For the year ended 31 March 2025

PARTICULARS	Current Borrowings	Non-current Borrowings	Lease liabilities	Total
As at 1 April 2024	273.29	804.95	262.71	1,340.95
Proceeds from borrowings during the year	125.86	585.99	-	711.85
Repayment of borrowings during the year	(57.85)	(217.91)	-	(275.76)
Interest accretion on lease liabilities	-	-	43.96	43.96
Recognition of right-of-use liability during the year	-	-	423.65	423.65
Payment of lease liability (principal and interest)	-	-	(186.67)	(186.67)
As at 31 March 2025	341.30	1173.03	543.65	2,057.98

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

30. Revenue from contracts with customers

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Clinical research services – domestic	3,085.10	3,627.63
Clinical research services – export	3,068.62	1,056.73
Total revenue from operations	6,153.71	4,684.36

Contract balances

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Trade receivables (gross)	2,091.01	1,594.22
Less: allowance for expected credit losses	(21.70)	–
Contract assets – unbilled revenue (note 12)	123.84	145.15
Contract liabilities – advance from customers (note 21)	11.14	3.97
Contract liabilities – revenue billed in advance (note 21)	101.46	37.77

31. Auditor's remuneration

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
a) Audit fees	2.10	2.10
b) Other charges	-	-
Tax Audit	0.25	0.25
Certification fee	0.25	0.25
TOTAL	2.60	2.60

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

32. Earning Per Share

Particulars	Year ended 31 March 2026	Year ended 31 March 2025
Profit for the year	103.33	5.90
Less: share attributable to non -controlling interests	(11.75)	(7.53)
Profit attributable to the owners of the parent – numerator for EPS	115.08	13.43
Number of equity shares at the beginning of the year	1,58,33,965	1,54,80,215
Add: equity shares issued during the year	40,85,000	3,53,750
Number of equity shares at the end of the year	1,99,18,965	1,58,33,965
Weighted average number of equity shares – basic	1,68,30,033	1,56,19,777
Weighted average number of equity shares – diluted	1,68,30,033	1,56,19,777
Basic earnings per share (Rs.)	0.68	0.08
Diluted earnings per share (Rs.)	0.68	0.08

33. Income Taxes

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Current income tax charge	44.56	12.02
MAT credit (entitlement) / utilisation	(33.91)	(12.02)
Deferred tax – origination and reversal of temporary differences	95.22	(0.84)
Income tax expense reported in the Statement of Profit and Loss	105.87	(0.84)

Reconciliation of tax expense and accounting profit

PARTICULARS	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit before tax as reported (after share of loss of the associate)	209.20	5.07
Tax at India's statutory income tax rate of 26%	54.39	1.32
Effect of expenses not deductible for tax purposes	-	-
Others	--	-
Total tax expense	105.87	(0.84)
Effective income tax rate	50.61%	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

34. Segment information

The Group has only one operating segment, namely clinical research services, which is therefore also the only reportable segment.

Revenue from external customers, by geography	FY 2025-26	FY 2024-25
India (country of domicile)	3,085.10	3,627.63
Outside India	3,068.62	1,056.73
Total	6,153.71	4,684.36

All of the Group's operating facilities and all of its non-current assets other than financial instruments and deferred tax are located in India. Ind AS 108 requires disclosure of reliance on major customers. During the year ended 31 March 2026, revenue from 2 no of customer(s) individually exceeded 10% of total revenue from operations, aggregating ₹1,505.36 lakhs (previous year: 2 no of customer(s), ₹1,481.26 lakhs).

35. Employee benefits

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Salaries, wages and bonus	1746.34	1328.07
Gratuity	41.12	17.78
Staff welfare expenses	44.27	35.22
Share based payments to employees	71.14	104.09
Director's remuneration	249.89	215.55
Leave Encashment	11.63	4.90
Total	2164.38	1705.72

Notes:

- The Group operates defined benefit plan i.e., gratuity for its employees. Under the gratuity plan, every employee who has completed at least five years of service gets a gratuity on departure at 15 days of last drawn salary for each completed year of service.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

During the period the Group has recognized the following amounts in the Statement of profit and loss:

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Employers Contribution to Provident fund	52.94	42.34
Employers Contribution to Employee state insurance	6.68	7.54
Total	59.62	49.88

The components of gratuity cost recognized in the statement of profit and loss for the years ended 31 March 2026 and 31 March 2025 consist of the following.

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Current service cost	20.73	14.89
Interest on net defined benefit liability/(asset)	3.84	2.89
Past Service Cost (Vested / Non Vested Benefits)	16.55	-
Components of defined benefit costs recognized in statement of profit or loss - (A)	41.12	17.78
Actuarial (gain) / loss on plan obligations	(17.82)	1.37
Components of defined benefit costs recognized in other comprehensive income - (B)	(17.82)	1.37
Total (A+B)	23.30	19.15

The amount included in the balance sheet arising from the entity's obligation in respect of defined benefit plan is as follows

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Present value of defined benefit obligation	76.33	57.51
Less: Fair value of plan assets	-	-
Net liability recognized in the balance sheet	76.33	57.51
Current portion of the above	2.45	1.66
Non-current portion of the above	73.88	55.85

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Movement in the present value of the defined benefit obligation is as follows

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Defined benefit obligations at the beginning of the year	57.71	42.03
Benefits Paid	(4.47)	(3.67)
Expenses Recognised in statement of Profit & Loss		
Current service cost	20.73	14.89
Interest on defined obligations	3.84	2.89
Past Service Cost (Vested / Non Vested Benefits)	16.55	-
Expenses Recognised in statement of OCI		
Actuarial loss/(gain) due to change in assumptions	(17.82)	1.30
Actuarial loss/(gain) due to experience changes	-	0.07
Defined benefit obligations at the end of the year	76.34	57.51

Summary of Actuarial Assumptions

The actuarial assumptions used to determine benefit obligations in accounting for the Gratuity Plan are as follows.

PARTICULARS	For the Year ended 31 March 2026	For the Year ended 31 March 2025
Interest/discount rate	7.62%	6.77%
Rate of increase in compensation	4.00%	4.00%
Employee attrition Rate	3%	3%
Expected Average Remaining Service	17.10	17.19

Sensitivity analysis

	DR: Discount Rate		ER: Salary Escalation Rate	
	PVO DR+1%	PVO DR-1%	PVO ER+1%	PVO ER-1%
PVO	68.80	85.19	85.23	68.66

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Expected Payout

Year	Expected Outgo First	Expected Outgo Second	Expected Outgo Third	Expected Outgo Fourth	Expected Outgo Fifth	Expected Outgo Six to Ten Years
Payouts	2.45	2.96	3.33	3.72	4.51	37.75

Asset Liability comparisons

Year	31-03-2022	31-03-2023	31-03-2024	31-03-2025	31-03-2026
PVO at end of period	28.47	31.96	42.03	57.51	76.33
Plan Assets	-	-	-	-	-
Surplus/ (Deficit)	(28.47)	(31.96)	(42.03)	(57.51)	(76.33)
Experience adjustments on plan assets	-	-	-	-	-

36. Related party disclosures

Relationship	Name
Subsidiary (consolidated)	Nayas Laboratories Private Limited, incorporated in India – holding reduced from 88.89% to 59.26% during the year; refer note 46
Associate (equity accounted)	Naya Pharma Private Limited, incorporated in India – 31.03% held
Key management personnel	Mr. K Krishna Kishore, Managing Director; Ms. M Snigdha, Executive Director; Mr. Y Nageswara Rao, Whole-time Director; Mr. Maram Srinivas Reddy, Chief Executive Officer; Mr. Venkateswara Rao Ravipati, Chief Financial Officer; Mr. Krishna Sainadh Kodati, Company Secretary
Non-executive and independent directors	Mr. Jeevan Krishna Kuchipudi; Mr. G Mallikarjuna; Mr. G V Subba Rao; Mr. B Suryaprakasa Rao; Mr. Divakar Atluri; Mr. G Bhanu Prakash retired on 29/09/2025
Enterprises owned or significantly influenced by key management personnel	Jeevana Mitra Finance Corporation; Jeevan Mitra Constructions LLP
Non-controlling shareholders of the subsidiary	Mr. K Krishna Kishore, Mrs. K Vanaja and Mr. K Jeevan Krishna, being promoters or members of the promoter group, who subscribed ₹50.00 lakhs, ₹12.50 lakhs and ₹50.00 lakhs respectively of fresh equity share capital in Nayas Laboratories Private Limited during the year. Refer note 46.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

b) Transactions with related parties during the year

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Compensation of key management personnel		
Short-term employee benefits	386.97	296.99
Post-employment benefits	10.10	6.94
Share-based payments	-	84.82
Total compensation of key management personnel	397.07	388.85
Remuneration – individual break-up		
Mr. K Krishna Kishore	108.00	108.00
Ms. M Snigdha	48.00	48.00
Mr. Y Nageswara Rao	15.00	15.00
Mr. K Jeevan Krishna	60.00	56.38
Mr. Koti Reddy Tiyyagura	39.00	24.00
Mr. Maram Srinivas Reddy	83.75	31.69
Mr. Venkateswara Rao Ravipati	20.48	4.55
Mr. Krishna Sainadh Kodati	12.74	9.37
Sitting fees paid to directors		
Mr. G Bhanu Prakash	0.35	1.05
Mr. B Suryaprakasa Rao	2.65	1.95
Mr. G V Venkata Subba Rao	3.25	1.15
Mr. Divakar Atluri	3.25	1.95
Mr. K Jeevan Krishna	1.90	0.50
Mr. G Mallikarjuna	1.90	-
Transactions with the subsidiary – Nayas Laboratories Private Limited		
Investment in equity shares	-	-
Loans given during the year	481.54	349.37
Loans repaid during the year	(366.54)	-
Interest income on loans (at 7% per annum)	28.47	22.39
Corporate guarantee given / outstanding	740.00	740.00
Transactions with the associate – Naya Pharma Private Limited		
Investment in equity shares	300.00	-
Loans given during the year	57.02	-
Interest income on loans (at 11% per annum)	0.68	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(c) Outstanding balances as at the reporting date

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Rent payable		
Jeevana Mitra Finance Corporation	0.36	0.36
Mr. K Krishna Kishore	0.48	0.48
Mrs. K Vanaja	0.48	0.48
Remuneration payable		
Mr. K Krishna Kishore	3.30	3.30
Ms. M Snigdha	3.98	2.57
Mr. K Jeevan Krishna	—	—
Mr. Y Nageswara Rao	1.22	1.10
Loans receivable		
Nayas Laboratories Private Limited (subsidiary)	599.26	484.26
Naya Pharma Private Limited (associate)	57.02	—
Interest accrued on the above loans	48.77	22.55
Investments		
Nayas Laboratories Private Limited (subsidiary)	200.00	200.00
Naya Pharma Private Limited (associate)	300.00	—
Commitments and guarantees		
Corporate guarantee given to Karur Vysya Bank for facilities availed by Nayas Laboratories Private Limited	740.00	740.00

(d) Terms and conditions

Transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates. Outstanding balances at the year end are unsecured and settlement occurs in cash.

Loans given to Nayas Laboratories Private Limited of ₹599.26 lakhs (previous year ₹484.26 lakhs) and to Naya Pharma Private Limited of ₹57.02 lakhs (previous year: nil) are for business purposes and carry interest at 7% and 11% per annum respectively. The Company has given a corporate guarantee of ₹740.00 lakhs to Karur Vysya Bank in respect of loans obtained by Nayas Laboratories Private Limited. The corporate guarantee is disclosed as a contingent liability in note 45. The loans are repayable on demand.

No amounts due from related parties have been written off or provided for during the year (previous year: nil).

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

37. Transactions and balances in foreign currency

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Earnings in foreign exchange		
Export of services (FOB value)	3,068.62	1,056.73
Expenditure in foreign currency	-	-
Travel	28.26	12.27
Capital goods	604.05	477.51

38. Financial instruments – categories, fair values and fair value hierarchy

(a) Categories of financial instruments

Particulars	31 Mar 2026 Amortised cost	31 Mar 2026 FVTPL / FVTOCI	31 Mar 2025 Amortised cost	31 Mar 2025 FVTPL / FVTOCI
Financial assets				
Cash and cash equivalents	950.55	-	24.23	-
Trade receivables	2,069.31	-	1594.22	-
Other financial assets (current and non-current)	299.89	-	233.23	-
Investments in subsidiary and associate (at cost – Ind AS 27)	500.00	-	200.00	-
Financial liabilities				
Borrowings (current and non-current)	1,715.90	-	1,514.33	-
Lease liabilities	412.52	-	543.65	-
Trade payables	612.76	-	317.70	-
Other financial liabilities	133.02	-	113.17	-

(b) Fair values of financial assets and liabilities

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 – valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable;
- Level 3 – valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Particulars	31 Mar 2026 Carrying value	31 Mar 2026 Fair value	31 Mar 2025 Carrying value	31 Mar 2025 Fair value	Level
Financial assets					
Cash and cash equivalents and other bank balances	950.55	950.55	24.23	24.23	3
Trade and other receivables	2,069.31	2,069.31	1,594.22	1,594.22	3
Other financial assets	299.89	299.89	233.23	233.23	3
Total	3,319.75	3,319.75	1,851.68	1,851.68	
Financial liabilities					
Trade payables	612.76	612.76	317.70	317.70	3
Non-current borrowings	1,009.92	1,009.92	1,173.03	1,173.03	3
Current borrowings	705.98	705.98	341.30	341.30	3
Lease liabilities	412.52	412.52	543.65	543.65	3
Other financial liabilities	133.02	133.02	113.17	113.17	3
Total	2,874.20	2,874.20	2,488.85	2,488.85	

There have been no transfers between levels during the year. Management has assessed that the carrying values of the financial assets and financial liabilities for which fair values are disclosed reasonably approximate their fair values, because these instruments have short-term maturities or carry interest at rates that approximate market rates.

39. Financial risk management objectives and policies

The Company's principal financial liabilities comprise borrowings, lease liabilities, trade payables and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include investments, trade and other receivables, cash and cash equivalents, bank balances and security deposits that arise directly from its operations.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's senior management oversees the management of these risks under policies approved by the Board of Directors. The Board provides written principles for overall risk management, as well as policies covering specific areas such as foreign exchange risk, interest rate risk, credit risk and the investment of excess liquidity.

(a) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises interest rate risk, currency risk and other price risk. Financial instruments affected by market risk include borrowings and trade payables.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the Company's financial instruments will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to its borrowings carrying floating rates of interest. The following table demonstrates the sensitivity to a reasonably possible change in interest rates on the floating rate borrowings, with all other variables held constant.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Particulars	Increase / (decrease) in basis points	Effect on profit before tax
Floating rate borrowings outstanding – 31 March 2026		9.00%
31 March 2026 – INR	+50	(2.37)
31 March 2026 – INR	(50)	2.37
Floating rate borrowings outstanding – 31 March 2025		9.00%
31 March 2025 – INR	+50	(1.68)
31 March 2025 – INR	(50)	1.68

The Company has cash credit facility from Karur Vysya Bank as floating rate borrowings; The vehicle, machinery and COVID term loans are at fixed rates and have been excluded since the fixed rate borrowings are not exposed to cash flow interest rate risk.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to its export receivables. The Company does not use derivative financial instruments to hedge its foreign currency exposures; accordingly the entire exposure set out below is unhedged.

Unhedged foreign currency exposure	31 Mar 2026 USD lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 USD lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	7.66	725.02	4.08	348.90
Trade payables	-	-	-	-

Unhedged foreign currency exposure	31 Mar 2026 EURO lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 EURO lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	1.48	161.23	0.47	43.39
Trade payables	-	-	-	-

Unhedged foreign currency exposure	31 Mar 2026 GBP lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 GBP lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	0.14	17.30	0.06	6.64
Trade payables	-	-	-	-

Unhedged foreign currency exposure	31 Mar 2026 CAD lakhs	31 Mar 2026 Rs. lakhs	31 Mar 2025 CAD lakhs	31 Mar 2025 Rs. lakhs
Trade receivables	1.02	68.65	0.75	44.53
Trade payables	-	-	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The following table demonstrates the sensitivity to a reasonably possible change in the USD / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per USD) [was described as "present average rate"]	92.91	92.91	86.23	86.23
Effect on profit before tax	35.58	(35.58)	17.59	(17.59)

The following table demonstrates the sensitivity to a reasonably possible change in the EURO / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per EURO) [was described as "present average rate"]	107.50	107.50	93.45	93.45
Effect on profit before tax	7.96	(7.96)	2.20	(2.20)

The following table demonstrates the sensitivity to a reasonably possible change in the GBP / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per GBP) [was described as "present average rate"]	123.94	123.94	114.95	114.95
Effect on profit before tax	0.87	(0.87)	0.34	(0.34)

The following table demonstrates the sensitivity to a reasonably possible change in the CAD / INR exchange rate, with all other variables held constant.

Particulars	31 Mar 2026 5% increase	31 Mar 2026 5% decrease	31 Mar 2025 5% increase	31 Mar 2025 5% decrease
Closing exchange rate (Rs. per CAD) [was described as "present average rate"]	67.66	67.66	62.38	62.38
Effect on profit before tax	3.45	(3.45)	2.34	(2.34)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

b) Credit risk

Credit risk is the risk of loss that may arise on outstanding financial instruments if a counterparty defaults on its obligations. The Company's exposure to credit risk arises principally from trade receivables. Other financial assets such as security deposits and bank deposits are held with government authorities and scheduled banks and the Company does not expect any credit risk in respect of these.

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer, including the default risk of the industry and the country in which the customer operates. Credit risk is managed through credit approvals, the establishment of credit limits and continuous monitoring of the creditworthiness of customers to whom the Company grants credit in the normal course of business. The Company's credit period for trade receivables generally ranges from 30 to 90 days.

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Neither past due nor impaired	—	—
Past due but not impaired		
Less than 365 days	1,699.70	1,294.56
More than 365 days	391.31	299.66
Less: allowance for expected credit losses	(21.70)	—
Total	2,069.31	1,594.22

Movement in the allowance for expected credit losses

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Balance at the beginning of the year	—	—
Allowance created during the year	21.70	—
Amounts written off / written back during the year	—	—
Balance at the end of the year	21.70	—

An allowance for expected credit losses of ₹21.70 lakhs has been created for the first time during the year and relates to receivables outstanding for more than three years. The Company applies the simplified approach permitted by Ind AS 109 and recognises lifetime expected credit losses on trade receivables using a provision matrix based on historical default experience adjusted for forward-looking information.

(c) Liquidity risk

The Company's objective is to maintain optimum levels of liquidity to meet its cash and collateral requirements at all times. The Company relies on a mix of borrowings and operating cash flows to meet its funding needs. The Company monitors rolling forecasts of its liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Company does not breach borrowing limits or covenants on any of its facilities.

The table below summarises the maturity profile of the Company's financial liabilities based on carrying amounts by contractual maturity.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The table below summarises the maturity profile of the Company's financial liabilities based on carrying amounts by contractual maturity.

Maturities	Upto 1 year	1-3 Years	3-5 Years	Above 5 Years	Total
As at 31 March 2026					
Non-current borrowings	259.41	629.09	121.42	-	1,009.92
Lease liabilities	125.31	287.21	-	-	412.52
Current borrowings	705.98	-	-	-	705.98
Trade payables	600.00	9.82	2.94	-	612.76
Other financial liabilities	133.02	-	-	-	133.02
Total	1,823.72	926.12	124.36	-	2,874.20
As at 31 March 2025					
Non-current borrowings	252.41	600.57	320.05	-	1,173.03
Lease liabilities	157.64	386.01	-	-	543.65
Current borrowings	341.30	-	-	-	341.30
Trade payables	300.01	15.53	2.16	-	317.70
Other financial liabilities	113.17	-	-	-	113.17
Total	1,164.53	1,002.11	322.21	-	2,488.85

The Company had undrawn committed borrowing facilities of ₹362.60 lakhs as at 31 March 2026 (previous year ₹666.00 lakhs).

40. Corporate social responsibility expenditure

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
(i) Amount required to be spent by the Company during the year	-	5.50
(ii) Amount required to be set off for the financial year, if any	-	-
(iii) Total CSR obligation for the financial year	-	5.50
(iv) Amount of expenditure incurred – (a) construction / acquisition of any asset	-	-
(b) on purposes other than (a) above	-	5.50
(v) Shortfall / (excess spent) at the end of the year	-	-
(vi) Total of previous years' shortfall	-	-
(vii) Reason for shortfall	Not applicable	Not applicable
(viii) Nature of CSR activities	Not applicable	Contribution to Madhavi Konda and Diabetes and You (DAY) Society
(ix) Details of related party transactions in relation to CSR expenditure	Nil	Nil
(x) Movement in any provision made on account of a contractual obligation	Nil	Nil

Section 135 of the Companies Act, 2013 did not apply to the Company for the year ended 31 March 2026.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

41. Analytical ratios

Ratio	31 Mar 2026	31 Mar 2025	Variance %	Reason for variance in excess of 25%
Current ratio (times)	2.51	2.38	5.33	Not applicable
Debt-equity ratio (times)	0.30	0.41	(27.84)	Equity rose on the issue of 40,85,000 shares and the receipt of warrant money, faster than borrowings.
Debt service coverage (times)	0.24	0.12	101.39	Higher earnings before interest, tax, depreciation and amortisation in the current year.
Return on equity (%)	1.72%	0.10%	1,595.54	Group profit rose from ₹5.90 lakhs to ₹103.33 lakhs.
Inventory turnover (times)	26.49	34.60	(23.43)	Not applicable
Trade receivables turnover (times)	3.36	3.32	1.19	Not applicable
Trade payables turnover (times)	1.35	1.63	(17.10)	Not applicable
Net capital turnover (times)	2.05	2.81	(26.94)	Working capital increased following the equity issue, faster than the growth in revenue.
Net profit ratio (%)	1.68%	0.13%	1,868.75	Revenue grew 31.4% while total expenses grew 27.3%, improving the margin.
Return on capital employed (%)	4.85%	3.04%	59.44	Increase in profit before interest and tax.

42. Other statutory information

- (i) The Group has been sanctioned working capital limits in excess of ₹5 crores in aggregate from banks on the basis of security of current assets. The quarterly returns and statements filed with such banks are in agreement with the books of account.
- (ii) No entity in the Group has been declared a wilful defaulter by any bank, financial institution or other lender.
- (iii) The Group has complied with the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013.
- (iv) No scheme of arrangement has been approved by the competent authority under sections 230 to 237 of the Companies Act, 2013 during the year.
- (v) The Group has not revalued any of its property, plant and equipment, right-of-use assets or intangible assets during the year.
- (vi) The title deeds of all immovable properties disclosed as property, plant and equipment are held in the name of the respective Group entity.
- (vii) For loans and advances granted to promoters, directors, key managerial personnel and related parties, refer note 51.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

43. Capital management

PARTICULARS	As at 31 March 2026	As at 31 March 2025
Non-current borrowings	1,009.92	1,173.03
Current borrowings	705.98	341.30
Lease liabilities	412.52	543.65
Less: cash and cash equivalents	(950.55)	(24.23)
Net debt	1,177.87	2,033.75
Equity share capital	1,991.90	1,583.40
Other equity	5,202.34	3,410.97
Total capital	7,194.24	4,994.37
Total capital and net debt	8,372.11	7,028.12
Gearing ratio	0.14	0.29

44. Leases

The Group had total cash outflows for leases of ₹204.13 lakhs (previous year ₹189.20 lakhs), comprising lease payments of ₹201.25 lakhs (previous year ₹186.67 lakhs) and short-term lease payments of ₹2.88 lakhs (previous year ₹2.53 lakhs).

45. Additional information required by Schedule III for consolidated financial statements

Name of the entity	Net assets – % of consolidated net assets	Net assets – amount	Share in profit or loss – %	Share in profit or loss – amount	Share in OCI – % and amount	Share in TCI – % and amount
Parent – Jeevan Scientific Technology Limited	100.48%	7,329.77	159.69%	165.01	100.00% / 17.82	150.91% / 182.83
Subsidiary – Nayas Laboratories Private Limited	2.29%	166.74	(58.21%)	(60.15)	–	(49.65%) / (60.15)
Associate – Naya Pharma Private Limited (share of loss)	–	–	(1.48%)	(1.53)	–	(1.26%) / (1.53)
Non-controlling interests in the subsidiary	1.38%	100.75	(11.37%)	(11.75)	–	(9.70%) / (11.75)
Consolidation adjustments and eliminations	(4.15%)	(302.28)	11.37%	11.75	–	9.70% / 11.75
Total	100.0%	7,294.98	100.0%	103.33	100.0% / 17.82	100.0% / 121.15

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Net assets means total assets less total liabilities. The net assets of the parent and of the subsidiary are those shown in their respective standalone financial statements. The consolidation adjustments of ₹(302.28) lakhs against net assets comprise the elimination of the Holding Company's investment of ₹200.00 lakhs in the subsidiary, the ₹1.53 lakh adjustment on equity accounting of the associate, and ₹100.75 lakhs of non-controlling interests which is presented separately above but is already contained within the subsidiary's net assets. The adjustment of ₹11.75 lakhs against share in profit or loss reverses, for the same reason, the amount shown separately against non-controlling interests.

46. Interests in the subsidiary and the change in ownership during the year

Name of the subsidiary	Principal place of business	Ownership at 31 Mar 2026	Ownership at 31 Mar 2025
Nayas Laboratories Private Limited	India	59.26%	88.89%
Non-controlling interests in the subsidiary	India	40.74%	11.11%

Change in the Group's ownership interest

During the year the issued share capital of Nayas Laboratories Private Limited increased from ₹225.00 lakhs to ₹337.50 lakhs. The whole of the increase of ₹112.50 lakhs was subscribed by the non-controlling shareholders; the Holding Company did not subscribe, its investment remaining at ₹200.00 lakhs. The Group's interest accordingly fell from 88.89% to 59.26% while control was retained.

Under Ind AS 110.23 a change in a parent's ownership interest in a subsidiary that does not result in a loss of control is accounted for as an equity transaction. The carrying amounts of the controlling and non-controlling interests are adjusted to reflect the change in their relative interests, and any difference between the amount by which the non-controlling interests are adjusted and the consideration is recognised directly in equity attributable to the owners of the parent.

The fresh share capital was subscribed by Mr. K Krishna Kishore (₹50.00 lakhs), Mrs. K Vanaja (₹12.50 lakhs) and Mr. K Jeevan Krishna (₹50.00 lakhs), each of whom is a promoter or a member of the promoter group of the Holding Company. The subscription is accordingly a related party transaction and is disclosed in note 36. The effect of the change in ownership interest on the equity attributable to the owners of the parent is set out below.

Effect of the change in ownership interest in the subsidiary	FY 2025-26	FY 2024-25
Consideration received from the non-controlling shareholders	112.50	—
Less: increase in non-controlling interests arising on the transaction	(66.93)	—
Difference recognised directly in equity attributable to the owners of the parent	45.57	—

The increase in non-controlling interests of ₹66.93 lakhs is derived from the reconciliation below. Non-controlling interests of ₹12.75 lakhs brought forward, plus ₹66.93 lakhs arising on the transaction, less their ₹11.75 lakh share of the subsidiary's loss for the year, gives ₹67.93 lakhs. That figure is confirmed independently: the non-controlling interests hold 40.74% of the subsidiary, whose net assets at 31 March 2026 were ₹166.74 lakhs, and 40.74% of ₹166.74 lakhs is ₹67.93 lakhs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Summarised financial information of the subsidiary

Nayas Laboratories Private Limited (before intra-group eliminations)	FY 2025-26	FY 2024-25
Total assets	1589.70	1474.32
Total liabilities	1422.96	1359.03
Revenue	767.52	325.71
Profit / (loss) for the year	(60.14)	(67.66)
Total comprehensive income	(60.14)	(67.66)
Accumulated non-controlling interests	100.75	12.75
Profit / (loss) allocated to non-controlling interests	(11.75)	(7.53)
Net cash inflow / (outflow)	0.92	0.97

The summarised financial information above is presented before intra-group eliminations and is drawn from the audited financial statements of Nayas Laboratories Private Limited. The loss allocated to non-controlling interests has been computed on a time-weighted basis, the non-controlling interest having been 11.11% until the fresh capital was subscribed and 40.74% thereafter.

47. Interest in the associate

Name of the associate	Principal place of business	Ownership at 31 Mar 2026	Ownership at 31 Mar 2025
Naya Pharma Private Limited	India	31.03%	Nil

Carrying amount of the investment in the associate	FY 2025-26	FY 2024-25
Cost of the investment – 16,50,165 equity shares acquired at ₹18.18 per share	300.00	–
Share of loss for the year, accounted under the equity method	(1.53)	–
Carrying amount at the end of the year	298.47	–

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Summarised financial information of the associate (100%)

Particulars	FY 2025-26	FY 2024-25
Total assets	767.38	—
Total liabilities	116.08	—
Net assets	651.30	—
Revenue from operations	Nil	—
Loss for the year	(4.93)	—
Other comprehensive income	—	—
Total comprehensive loss	(4.93)	—
Group's share of net assets at 31.03%	202.13	—
Goodwill included in the carrying amount of the investment	96.34	—
Carrying amount of the investment	298.47	—

The associate is a private company and there is no quoted market price for its shares. The Group's share of the net assets of the associate at the reporting date is ₹202.13 lakhs against a carrying amount of ₹298.47 lakhs; the difference of ₹96.34 lakhs is goodwill, which under the equity method forms part of the carrying amount of the investment and is not tested for impairment separately. The associate had no contingent liabilities or capital commitments at the reporting date.

48. Contingent liabilities and commitments

Particulars	FY 2025-26	FY 2024-25
Claims against the Group not acknowledged as debts – goods and services tax	—	—
Claims against the Group not acknowledged as debts – income tax	—	—
Guarantees given to third parties outside the Group	—	—
Estimated amount of contracts remaining to be executed on capital account, net of advances	—	—

The corporate guarantee of ₹740.00 lakhs given by the Holding Company to Karur Vysya Bank for facilities availed by the subsidiary is an intra-group guarantee. It eliminates on consolidation and is therefore not disclosed as a contingent liability of the Group, although it is disclosed in the standalone financial statements of the Holding Company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

49. Previous period/year figures have been regrouped/re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013.

The accompanying notes are integral part of the financial statements.

As per our report of even date
for PAVULURI & Co
Chartered Accountants
Firm Regn No: 012194S

Sd/-
CA. N. RAJESH
Partner
Membership No: 223169
UDIN: 26223169KNYUII7099

Place: Hyderabad
Date: 29 May 2026

for and on behalf of the Board of Directors
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Sd/-
K. Krishna Kishore
Managing Director
DIN: 00876539

Sd/-
M. Snigdha
Executive Director
DIN: 08934860

Sd/-
R Venkateswara Rao
Chief Financial Officer

Sd/-
Kodati Krishna Sainadh
Company Secretary
M.No: A69904